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ABSTRACT
 
Short tandem repeat typing is the primary method of DNA identification used in the field of 
forensic science.  Over the past several years the need to improve on this method has moved 
to the forefront of research. Due to the increasing number of criminal cases and the 
substantial backlogs most laboratories are facing, it is vital to evaluate methods which can 
produce quality DNA profiles in a fast and reliable manner. Direct amplification, also 
referred to as direct PCR, is one alternative method that has been proposed to address this 
issue.  Direct amplification allows for the generating of DNA profiles without using the DNA 
isolation process.  While direct PCR would reduce processing time and resources, it is 
unknown if this technique would be able to generate a robust full or partial profile from 
samples which could be collected from scenes of crime.  Often crime scene personnel must 
use visualization techniques, either in powder or chemical form, in order to see and collect 
biological evidence for submission to a crime laboratory.   
 
In order to evaluate if direct PCR is a feasible solution a comparative study between a direct 
PCR kit and standard DNA profiling practices was undertaken using mock crime scene type 
samples.  Samples of this nature include surfaces which have been exposed to fingerprint 
powders and whole blood which has been chemically enhanced for visualization.  
PowerPlex
®
 18D, a direct amplification system, and PowerPlex
®
 16HS, an extraction-based 
method, were used to produce the profiles. An assessment of the kits aimed to critically 
evaluate and compare how the direct amplification kit performs on samples which have been 
exposed to powder and chemical processing for visual enhancement.  This will be done by 
reviewing two types of samples; epithelial cells which have been exposed the fingerprint 
powders (black, magnetic and white) and whole blood which has been exposed to chemicals 
(luecocrystal violet, amido black and ninhydrin).     
 
Samples subjected to direct amplification using PowerPlex
®
 18D generated DNA profiles 
with greater peak heights when compared to the extraction-based method.  The peak balances 
for heterozygous loci were also higher and more full profiles were generated with direct 
amplification than with the extraction method. The amount of DNA retrieved from each 
substrate also varied even though the same amounts of starting material were deposited, 
proving that the type of substrate can affect the retrieval of DNA.   
 
 
Epithelial cell samples were most successful when processed with white powder.  Magnetic 
powder samples also yielded a positive result when using direct amplification which was not 
expected as in previous data magnetic powder samples have not been successful. Whole 
blood samples which were processed with amido black produced profiles with lower overall 
peak heights when compared to the two other chemical processes.  This could be attributed to 
the rinse step which is required when working with amido black.  Ninhydrin was the most 
successful of the chemicals in generating full, good quality profiles. 
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Chapter 1: 
  
 Figure 1.1:  Diagram of a DNA molecule (Ingram, 2007). 
 Figure 1.2: A DNA sample taken from a crime scene is compared 
with DNA samples from three different suspects utilizing 
VNTRs to create the bands on the gel. If a suspects DNA 
profile matches the crime scene sample, then the evidence 
recovered from the crime scene came from that suspect. 
Conversely, if the DNA profiles do not match, then the 
evidence cannot have come from the suspect. Suspect 2 
and the crime scene sample match (outlined in yellow); 
therefore, the sample from the crime scene is positively 
identified as coming from Suspect 2 (Leja, 2010). 
 Figure 1.3: Figure 1.3: Examples of a short tandem repeat sequence 
using the CSF1PO [AGAT repeat sequence]. A.) 
Homozygous example with 9 repeating units and B.) 
Heterozygous example with 9 and 6 repeating units.  C.) 
Electropherogram output which would be representative 
of the samples generated from A and B. 
 Figure 1.4:   Microsatellite sequence variation results from the gain and 
loss of single repeat units or a single nucleotide. This 
occurs when there is a brief dissociation of the replicating 
DNA strands followed by misaligned re-association 
(Ellegren, 2004). 
 Figure 1.5: A single nucleotide polymorphism is a change in the 
genetic code of an individual where a single nucleotide (1) 
is replaced by another nucleotide (2) in the DNA sequence 
(Kucukkal et al., 2014). 
 Table 1.1: Components of PCR reaction mix (Butler, 2005). 
 Figure 1.6:   Schematic of the DNA amplification process.  1.) The 
double-stranded DNA molecule is separated into two 
  
 
 
 
single strands using heat. 2.) The temperature is then 
lowered to allow the oligonucleotide primers (shown in 
blue) to anneal to the target areas on the single-stranded 
DNA. 3.) The temperature is increased in order for DNA 
polymerase to produce a complete copy of the target DNA 
region (Reece et al., 2010). 
 Table 1.2: A summary of loci which are available in different 
commercially available kits.  The colour represents the 
dye attached to their respective primer. 
 Figure 1.7:   Configuration of the (A) Promega PowerPlex
©
16HS and 
(B) PowerPlex
©
18D kits demonstrating the fluorescent 
dye colour labels and relative PCR product size ranges for 
each of the loci present. (Source: Promega Corporation) 
 Figure 1.8:   Allelic ladder which represents alleles in PowerPlex
®
18D.  
The same alleles are present in PowerPlex
®
16HS with the 
exception of D21338 and D19S433 which are not present 
in this kit.  Green bars contain the loci names.  The red 
triangles along the baseline represent the size range where 
alleles for a specific locus are called and the boxes below 
the baseline represent the allele call for that specific peak. 
The X-axis numerical values indicate the fragment size in 
base pair number. 
 Figure 1.9:   Electropherogram demonstrating a DNA profile generated 
utilizing PowerPlex
®
18D.  The profile displays positive 
control 2800M.  The grey boxes label each of the loci 
present in the STR kit and the boxes under each of the 
peaks are the allele call(s) for that specific peak with the 
designated locus. The X-axis numerical values indicate the 
base pair number and the Y-axis the RFU (relative 
fluorescent unit) values (Source: Promega Corporation). 
 Table 1.3: Fingerprint powders used for enhancement of nonporous 
and semi-porous surfaces. 
   
  
 
 
 
Table 1.4: Chemical enhancement methods used for visualization of 
blood. 
 Figure 1.10:   The chemical structure of ninhydrin. (The structure was 
generated using eMolecules (Gubernator et al., 2015). 
 Figure 1.11: The chemical structure of amido black. (The structure was 
generated using eMolecules (Gubernator et al., 2015). 
 Figure 1.12: The chemical structure of leucocrystal violet. (The 
structure was generated using eMolecules (Gubernator et 
al., 2015). 
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 Table 2.1:   Chemical enhancement techniques and their 
corresponding substrates. 
 Table 2.2: Promega
®
 PowerPlex
®
 16HS cycling conditions for a 32 
cycle program 
 Table 2.3 Promega
®
 PowerPlex
®
 18D cycling conditions for a 27 
cycle program. 
 Table 2.4: Conditions for the electrophoresis run.  
 Table 2.5: Parameters for the analysis of PCR fragments when 
utilizing the ABI 3500 and GeneMapper ID-X software. 
 Table 2.6: Parameters for the analysis of PCR fragments when 
utilizing the ABI 3130 and GeneMapper v3.2 software for 
analysis. 
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 Table 3.1:   Known genetic profile for 2800M. 
 Table 3.2: Known genetic profile for epithelial cell sample. 
 Table 3.3: Known genetic profile for whole blood sample. 
 Table 3.4 Results showing the minimum, maximum and average 
peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of 2800M amplified 
using whole (25μl) and half (12.5μl) reactions with and 
PowerPlex
® 
16HS. The values are averages of three 
replicates. 
 Table 3.5: Results showing the minimum, maximum and average 
  
 
 
 
peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of 2800M amplified 
using whole (25μl) and half (12.5μl) reactions with and 
PowerPlex
® 
18D. The values are averages of three 
replicates. 
 Figure 3.1:   Charts which depict heterozygous loci ratios at different 
concentrations when amplified at (Top) 25μl and (Bottom) 
12.5μl with PowerPlex® 16HS.  The red line indicates the 
0.70 Hb threshold for the heterozygous peak balance.  
Samples displayed are based on three replicates. 
 Figure 3.2:   Charts which depict heterozygous loci ratios at different 
concentrations when amplified at (Top) 25μl and (Bottom) 
12.5μl with PowerPlex® 18D.  The red line indicates the 
0.70 Hb threshold for the heterozygous peak balance.  
Samples displayed are based on three replicates. 
 Figure 3.3:   Graphs demonstrating the variation in the heterozygous 
peak balance ratio (Hb) for the amplification of the 25μl 
(green circles) and 12.5μl (blue diamonds) reactions for 
PowerPlex
®
 16HS for each individual loci.  The red line 
indicates the 0.70 threshold for the heterozygous peak 
balance. 
 Figure 3.4:   Graphs demonstrating the variation in the heterozygous 
peak balance ratio (Hb) for the amplification of the 25μl 
(green circles) and 12.5μl (blue diamonds) reactions for 
PowerPlex
®
 18D for each individual loci.  The red line 
indicates the 0.70 threshold for the heterozygous peak 
balance. 
 Table 3.6: Results showing the minimum, maximum and average 
peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of epithelial cells 
amplified at 12.5μl with PowerPlex® 16HS and 
PowerPlex
® 
18D. The values are averages of three 
replicates. 
  
 
 
 
 Figure 3.5:   Heterozygous loci peak height ratios for epithelial cells at 
different dilutions when amplified at 12.5μl with (Top) 
PowerPlex
®
 16HS and (Bottom) PowerPlex
®
 18D.  The 
red line indicates the 0.70 Hb threshold for the 
heterozygous peak balance.  Samples displayed are based 
on three replicates. 
 Figure 3.6:   Electropherograms displaying DNA profiles generated 
with epithelial cells at x2 dilution using (1) PowerPlex
®
 
16HS (RFU 20,000) and (2) PowerPlex
®
 18D (RFU 
5,000).  The x-axis represents relative fluorescent units 
(RFU) and the y-axis fragment size in base pairs. 
 Figure 3.7:   Electropherograms displaying DNA profiles generated 
with epithelial cells at x10 dilution using (1) PowerPlex
®
 
16HS (RFU 9,500) and (2) PowerPlex
®
 18D (RFU 5,000).  
The x-axis represents relative fluorescent units (RFU) and 
the y-axis fragment size in base pairs. 
 Table 3.7:   Results showing the minimum, maximum and average 
peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of whole blood 
amplified at 12.5μl with PowerPlex® 16HS and 
PowerPlex
® 
18D. The values are averages of three 
replicates. 
 Figure 3.8: Heterozygous loci peak height ratios for whole blood 
samples at different dilutions when amplified at 12.5μl 
with (Top) PowerPlex
®
 16HS and (Bottom) PowerPlex
®
 
18D.  The red line indicates the 0.70 Hb threshold for the 
heterozygous peak balance.  Samples displayed are based 
on three replicates. 
 Figure 3.9: Electropherograms displaying full profiles generated with 
whole blood cells at a x2 dilution using (1) PowerPlex
®
 
16HS (RFU 20,000) and PowerPlex
® 
18D (RFU 10,000).  
The x-axis represents relative fluorescent units (RFU) and 
the y-axis fragment size in base pairs. 
  
 
 
 
 Figure 3.10: Electropherograms displaying full profiles generated with 
whole blood cells at a x10 dilution using (1) PowerPlex
®
 
16HS (RFU 20,000) and PowerPlex
® 
18D (RFU 2,500).  
The x-axis represents relative fluorescent units (RFU) and 
the y-axis fragment size in base pairs. 
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 Table 4.1:   Loci within Promega
®
 PowerPlex
®
 16HS and Promega
®
 
PowerPlex
®
 18D 
 
kits, their chromosome location, repeat 
category and motif, and primer sequences. 
 Figure 4.1:   Bar graph representation of the average peak heights (in 
RFU) by locus for 150 profiles generated using the 
standard extraction method and profiled using PowerPlex
®
 
16HS. Error bars represent the standard deviation. 
 Figure 4.2:   Bar graph representation of the average peak heights (in 
RFU) by locus for 150 profiles generated using the 
standard extraction method and profiled using PowerPlex
®
 
18D. Error bars represent the standard deviation. 
 Figure 4.3: Bar graph representation of the average heterozygous peak 
height balance ratio by locus for 50 profiles generated for 
the Mexican population using both PowerPlex
®
 16HS and 
PowerPlex
®
 18D.   The red line indicates the 0.70 Hb 
threshold for the heterozygous peak balances.  Error bars 
represent the standard deviation. 
 Figure 4.4: Bar graph representation of the average heterozygous peak 
height balance ratio by locus for 50 profiles generated for 
the Caucasian population using both PowerPlex
®
 16HS 
and PowerPlex
®
 18D.   The red line indicates the 0.70 Hb 
threshold for the heterozygous peak balances.  Error bars 
represent the standard deviation. 
 Figure 4.5: Bar graph representation of the average heterozygous peak 
height balance ratio by locus for 50 profiles generated for 
the African American population using both PowerPlex
®
 
16HS and PowerPlex
®
 18D.   The red line indicates the 
  
 
 
 
0.70 Hb threshold for the heterozygous peak balances.  
Error bars represent the standard deviation. 
 Table 4.2:   Microvariant (MV) and off ladder (OL) alleles produced 
in both PowerPlex
®
 16HS and PowerPlex
®
 18D kits. 
 Table 4.3:   CSF1PO peak balance ratios for profiles containing allele 
9 for PowerPlex
®
 16HS and PowerPlex
® 
18D. 
   
Chapter 5:   
 Figure 5.1:   (A) Example of a fibre-glass brush used for powder 
processing (Evident, 2015). (B) Example of a magnetic 
wand with a ‘bulb’ of powder at the end of the wand 
(Arrowhead Forensics, 2015).  This ‘bulb’ acts as the 
brush when processing a surface. 
 Figure 5.2:   Photographs of white and black laminate which exhibit 
developed epithelial deposits with standard black powder, 
magnetic flake and white powder (left to right, 
respectively) for samples A and B with a x2 dilution.  
Row 1 depicts sample A which was analysed with 
PowerPlex
®
 16HS.  Row 2 depicts sample A which was 
analysed with PowerPlex
®
 18D.  Row 3 depicts sample B 
which was analysed with PowerPlex
®
 16HS.  Row 4 
depicts sample B which was analysed with PowerPlex
®
 
18D. 
 Figure 5.3:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
® 
16HS (left) and 
PowerPlex
® 
18D (right) kits.  Different dilutions (x1, x2, 
x10) of the two DNA samples (A and B) were processed 
in triplicate using standard black powder and amplified 
with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green 
squares indicate that the full correct alleles were observed 
for those loci.  Yellow squares represent one allele drop 
out.  Red squares represent loci where both expected 
alleles are missing. 
  
 
 
 
 Figure 5.4:   
 
A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
® 
16HS (left) and 
PowerPlex
® 
18D (right) kits.  Different dilutions (x1, x2, 
x10) of the two DNA samples (A and B) were processed 
in triplicate using magnetic flake powder and amplified 
with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green 
squares indicate that the full correct alleles were observed 
for those loci.  Yellow squares represent one allele drop 
out.  Red squares represent loci where both expected 
alleles are missing. 
 Figure 5.5: A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
® 
16HS (left) and 
PowerPlex
® 
18D (right) kits.  Different dilutions (x1, x2, 
x10) of the two DNA samples (A and B) were processed 
in triplicate using white powder and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for 
those loci.  Yellow squares represent one allele drop out.  
Red squares represent loci where both expected alleles are 
missing. 
 Table 5.1: Results for profiles generated with PowerPlex
®
 16HS 
showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
with the 3 powders (black, magnetic, and white). The 
values are averages of three replicates. 
 Table 5.2: Table 5.2: Results for profiles generated with PowerPlex
®
 
18D  showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
with the 3 powders (black, magnetic, and white). The 
  
 
 
 
values are averages of three replicates. 
 Figure 5.6:   (1) Electropherogram of sample B processed with black 
powder, x1 dilution and analysed with PowerPlex
®
 16HS 
on a scale of 560 RFU. (2)  Electropherogram of sample B 
processed with black powder, x1 dilution and analysed 
with PowerPlex
®
 18D on a scale of 1050 RFU.  The x-axis 
represents relative fluorescent units (RFU) and the y-axis 
fragment size in base pairs. 
 Figure 5.7:   (1) Electropherogram of sample B processed with 
magnetic flake powder, x2 dilutions and analysed with 
PowerPlex
®
 16HS on a scale of 100 RFU. (2) 
Electropherogram of sample B processed with magnetic 
flake powder, x2 dilution and analysed with PowerPlex
®
 
18D on a scale of 900 RFU. The x-axis represents relative 
fluorescent units (RFU) and the y-axis fragment size in 
base pairs. 
 Figure 5.8:   Variation in the average total PCR product (RFU) between 
the powders and dilutions processed with PowerPlex
®
 
16HS.  Error bars represent the standard deviation.  No 
samples with a x10 dilution produced a profile for any of 
the powders. 
 Figure 5.9:   Variation in the average total PCR product (RFU) between 
the powders and dilutions processed with PowerPlex
®
 
18D. Error bars represent the standard deviation. 
 Figure 5.10:   Variation in the average total PCR product (RFU) between 
the dilutions and kits utilized to process the powder 
samples. Error bars represent the standard deviation. 
 Figure 5.11:   Variation of the average total PCR product (RFU) 
between the powders and kits utilized to process the 
powder samples. Error bar represent the standard 
deviation. 
 Figure 5.12: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with black powder and 
  
 
 
 
analysed with PowerPlex
®
 16HS. The red line indicates 
the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond symbols represent x1 dilutions, green 
diamonds represent x2 dilutions, and orange diamonds 
represent x10 dilution samples. 
 Figure 5.13: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with black powder and 
analysed with PowerPlex
®
 18D. The red line indicates the 
0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds 
represent x2 dilutions and the orange diamonds x10 
dilution samples. 
 Figure 5.14: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with magnetic flake 
and analysed with PowerPlex
®
 16HS. The red line 
indicates the 0.70 Hb threshold for the heterozygous peak 
balances. Blue diamond symbols represent x1 dilutions, 
green diamonds represent x2 dilutions, and orange 
diamonds represent x10 dilution samples. 
 Figure 5.15: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with magnetic flake 
and analysed with PowerPlex
®
 18D. The red line indicates 
the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds 
represent x2 dilutions and the orange diamonds x10 
dilution samples. 
 Figure 5.16: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with white powder and 
analysed with PowerPlex
®
 16HS. The red line indicates 
the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond symbols represent x1 dilution, green 
diamonds represent x2 dilutions, and orange diamonds 
represent x10 dilution samples. 
  
 
 
 
 Figure 5.17: Peak height ratios of the various heterozygous loci present 
in both samples A and B processed with white powder and 
analysed with PowerPlex
®
 18D. The red line indicates the 
0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds 
represent x2 dilutions and the orange diamonds x10 
dilution samples. 
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Figure 6.1:   
 
Graph displaying the average PCR product concentration 
(RFU/µl) for each kit, PowerPlex
®
 16HS and PowerPlex
®
 
18D, for all samples processed using LCV (purple bars) 
and for all samples processed with no chemical 
enhancement (grey bars).  The error bars represent the 
standard deviations for each of the kits. 
 Figure 6.2:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Plastic and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Figure 6.3:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Tile and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
  
 
 
 
squares represent loci where both expected alleles are 
missing. 
 Figure 6.4:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Raw Wood and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Figure 6.5: A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Lead and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are  
missing. 
 Figure 6.6:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Laminate and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
   
  
 
 
 
 
Figure 6.7:   
A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Gypsum and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares specify loci where both expected alleles are 
missing. 
 Figure 6.8:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using LCV on Glass and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Table 6.1: Results for LCV profiles using PowerPlex
®
 16HS showing 
the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for 
the various dilutions of samples A and B, amplified using 
half (12.5μl) reactions, and processed on various 
substrates. The values are averages of three replicates. 
 Table 6.2: Results for LCV profiles using PowerPlex
®
 18D  showing 
the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for 
the various dilutions of samples A and B, amplified using 
half (12.5μl) reactions, and processed on various 
substrates. The values are averages of three replicates. 
 Figure 6.9:   Average PCR product concentration (RFU/µl) for each kit, 
  
 
 
 
PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples 
processed using LCV (purple bars) and for all samples 
processed with no chemical enhancement (grey bars).  The 
error bars represent the standard deviations for each of the 
dilutions. 
 Figure 6.10 
(A-G): 
The average PCR product concentration in (RFU/µl) by 
dilution for samples processed with no chemicals and 
samples processed with LCV on A) glass, B) gypsum, C) 
laminate, D) lead, E) plastic, F) raw wood, and G) tile.  
The error bars represent the standard deviations for each 
of the dilutions and processed/unprocessed sample 
averages. 
 Figure 6.11:   (Top) Peak height ratios for CSF1PO produced for various 
substrates when analysed with PowerPlex
®
 16HS.  
(Bottom)  Peak height ratios for CSF1PO produced for 
various substrates when analysed with PowerPlex
®
 18D.  
All three replicates of each sample (A and B) for each 
dilution are represented. 
 Figure 6.12:   Figure 6.12:  (Top) Peak height ratios for D13S317 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D13S317 produced for various substrates when analysed 
with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
 Figure 6.13:    Figure 6.13:  (Top) Peak height ratios for D18S51 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D18S51 produced for various substrates when analysed 
with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
 Figure 6.14:   Figure 6.14:  (Top) Peak height ratios for D21S11 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
  
 
 
 
D21S11 produced for various substrates when analysed 
with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
 Figure 6.15:    Figure 6.15:  (Top) Peak height ratios for D3S1358 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D3S1358 produced for various substrates when analysed 
with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
 Figure 6.16:    Figure 6.16:  (Top) Peak height ratios for D7S820 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D7S820 produced for various substrates when analysed 
with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
 Figure 6.17:   (Top) Peak height ratios for FGA produced for various 
substrates when analysed with PowerPlex
®
 16HS.  
(Bottom)  Peak height ratios for FGA produced for various 
substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.18:    Figure 6.18:  (Top) Peak height ratios for Penta E 
produced for various substrates when analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for Penta 
E produced for various substrates when analysed with 
PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
 Figure 6.19: Combined dye electropherogram displaying (1) sample A 
(Glass, x1) processed with PowerPlex
®
 16HS displayed at 
500 RFU. Combined dye electropherogram displaying (2) 
sample A (Glass, x1) processed with PowerPlex
®
 18D 
displayed at 15000 RFU. 
 Figure 6.20:   Sample A, x1 dilution (left) and processed with 
  
 
 
 
PowerPlex
®
 16HS. Sample A, x1 dilution (right) 
processed with PowerPlex
®
 18D. 
 Figure 6.21:   Electropherograms demonstrating profiles produced with 
PowerPlex
®
 16HS and 18D.  (1) Sample A, x1 dilution 
and processed with PowerPlex
®
 16HS on lead. (2) Sample 
A, x1 dilution and processed with PowerPlex
®
 18D on 
lead.  The x-axis represents relative fluorescent units 
(RFU) and the y-axis fragment size in base pairs. 
 Figure 6.22:   The average PCR product concentration (RFU/µl) for each 
kit, PowerPlex
®
 16HS and PowerPlex
®
 18D, for all 
samples processed using amido black and for all samples 
processed with no chemical enhancement.  The error bars 
represent the standard deviations for each of the kits. 
 Figure 6.23:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Amido Black on Plastic and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Figure 6.24:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Amido Black on Tile and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
  
 
 
 
 Figure 6.25: A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Amido Black on Lead and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Figure 6.26:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Amido Black on Laminate and amplified 
with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green 
squares indicate that the full correct alleles were observed 
for that locus.  Yellow squares represent one allele drop 
out.  Red squares represent loci where both expected 
alleles are missing. 
 Figure 6.27:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Amido Black on Glass and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Table 6.3: Results for Amido Black profiles using PowerPlex
®
 16HS 
showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
  
 
 
 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
on various substrates. The values are averages of three 
replicates. 
 Table 6.4: Results for Amido Black profiles using PowerPlex
®
 18D 
showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
on various substrates. The values are averages of three 
replicates. 
 Figure 6.28:   The average PCR product concentration (RFU/µl) for each 
kit, PowerPlex
®
 16HS and PowerPlex
®
 18D, for all 
samples processed using amido black (green bars) and for 
all samples processed with no chemical enhancement 
(grey bars).  The error bars represent the standard 
deviations for each of the dilutions.   
 Figure 6.29 
(A-E): 
The average PCR product concentration in (RFU/µl) by 
dilution for samples processed with no chemicals and 
samples processed with amido black on A) Glass, B) 
Laminate, C) Lead, D) Plastic, and E) Tile.  The error bars 
represent the standard deviations for each of the dilutions 
and processed/unprocessed sample averages. 
 Figure 6.30:    (Top) Peak height ratios for CSF1PO produced for 
various substrates processed with amido black and 
analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height 
ratios for CSF1PO produced for various substrates 
processed with amido black and analysed with 
PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
 Figure 6.31:   (Top) Peak height ratios for D13S317 produced for 
various substrates processed with amido black and 
analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height 
  
 
 
 
ratios for D13S317 produced for various substrates 
processed with amido black and analysed with 
PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
 Figure 6.32:   (Top) Peak height ratios for D18S51 produced for various 
substrates processed with amido black and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D18S51 produced for various substrates processed with 
amido black and analysed with PowerPlex
®
 18D. All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.33:   (Top) Peak height ratios for D21S11 produced for various 
substrates processed with amido black and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D21S11 produced for various substrates processed with 
amido black and analysed with PowerPlex
®
 18D.  All 
three replicates of each sample (A and B) for each dilution 
are represented. 
 Figure 6.34:   (Top) Peak height ratios for D3S1358 produced for 
various substrates processed with amido black and 
analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height 
ratios for D3S1358 produced for various substrates 
processed with amido black and analysed with 
PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
 Figure 6.35:    (Top) Peak height ratios for D7S820 produced for various 
substrates processed with amido black and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D7S820 produced for various substrates processed with 
amido black and analysed with PowerPlex
®
 18D.  All 
three replicates of each sample (A and B) for each dilution 
are represented. 
 Figure 6.36:    (Top) Peak height ratios for FGA produced for various 
  
 
 
 
substrates processed with amido black and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for FGA 
produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.37:   (Top) Peak height ratios for Penta E produced for various 
substrates processed with amido black and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for Penta 
E produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.38: Electropherograms of (1) Sample B (x1, Laminate) 
processed with PowerPlex
®
 16HS and displayed at 
2000RFU. (2) Sample B (x1, Laminate) processed with 
PowerPlex
®
 18D and displayed at 20000RFU. The y-axis 
shows the relative fluorescent units (RFU) and x-axis 
numbers indicate the fragment size in base pairs. 
 Figure 6.39:   (Left) Sample A prepared with x1 dilution on lead and 
processed with amido black. This sample was processed 
with PowerPlex
®
 16HS.  (Right) Sample A prepared with 
x2 dilution on lead and processed with amido black. This 
sample was processed with PowerPlex
®
 18D. 
 Figure 6.40:   Graph displaying the average PCR product concentration 
(RFU/µl) for each kit, PowerPlex
®
 16HS and PowerPlex
®
 
18D, for all samples processed using ninhydrin and for all 
samples processed with no chemical enhancement.  The 
error bars represent the standard deviations for each of the 
kits. 
 Figure 6.41:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS  (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
  
 
 
 
and x10) of the two samples (A and B) were processed in 
triplicate using Ninhydrin on Raw Wood and amplified 
with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green 
squares indicate that the full correct alleles were observed 
for that locus.  Yellow squares represent one allele drop 
out.  Red squares represent loci where both expected 
alleles are missing. 
 Figure 6.42:   A diagrammatic representation of the quality of the 
profiles obtained from the PowerPlex
®
 16HS  (left) and 
PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, 
and x10) of the two samples (A and B) were processed in 
triplicate using Ninhydrin on Gypsum and amplified with 
PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares 
indicate that the full correct alleles were observed for that 
locus.  Yellow squares represent one allele drop out.  Red 
squares represent loci where both expected alleles are 
missing. 
 Table 6.5: Results for Ninhydrin profiles using PowerPlex
®
 16HS 
showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
on various substrates. The values are averages of three 
replicates. 
 Table 6.6: Results for Ninhydrin profiles using PowerPlex
®
 18D 
showing the minimum, maximum and average peak 
heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of samples A and 
B, amplified using half (12.5μl) reactions, and processed 
on various substrates. The values are averages of three 
replicates. 
 Figure 6.43:   The average PCR product concentration (RFU/µl) for each 
kit, PowerPlex
®
 16HS and PowerPlex
®
 18D, for all 
  
 
 
 
samples processed using ninhydrin and for all samples 
processed with no chemical enhancement.  The error bars 
represent the standard deviations for each of the dilutions. 
 Figure 6.44:    (Top) Peak height ratios for CSF1PO produced for 
various substrates processed with ninhydrin and analysed 
with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
CSF1PO produced for various substrates processed with 
ninhydrin and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
  
Figure 6.45:   
 
(Top) Peak height ratios for D13S317 produced for 
various substrates processed with ninhydrin and analysed 
with PowerPlex® 16HS.  (Bottom)  Peak height ratios for 
D13S317 produced for various substrates processed with 
ninhydrin and analysed with PowerPlex® 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.46:   (Top) Peak height ratios for D18S51 produced for various 
substrates processed with Ninhydrin and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D18S51 produced for various substrates processed with 
Ninhydrin and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.47:    (Top) Peak height ratios for D21S11 produced for various 
substrates processed with Ninhydrin and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D21S11 produced for various substrates processed with 
Ninhydrin and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
   
  
 
 
 
Figure 6.48:   (Top) Peak height ratios for D3S1358 produced for 
various substrates processed with Ninhydrin and analysed 
with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for 
D3S1358 produced for various substrates processed with 
Ninhydrin and analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are 
represented. 
 Figure 6.49:   (Top) Peak height ratios for FGA produced for various 
substrates processed with Ninhydrin and analysed with 
PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for FGA 
produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates 
of each sample (A and B) for each dilution are 
represented. 
 Figure 6.50:    Figure 6.50:  (Top) Peak height ratios for D7S820 
produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D7S820 produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 
18D.  All three replicates of each sample (A and B) for 
each dilution are represented. 
 Figure 6.51:   Figure 6.51:  (Top) Peak height ratios for Penta E 
produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for Penta E produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 
18D.  All three replicates of each sample (A and B) for 
each dilution are represented. 
 Figure 6.52:   Electropherograms demonstrating the two profiles 
generated from sample A (x1, Gypsum).  (Top) The 
profile generated with PowerPlex
®
 16HS.  (Bottom)  The 
profile generated with PowerPlex
®
 18D. 
   
  
 
 
 
Figure 6.53:   Average of the total PCR products for each of the 
chemicals used as enhancements for the substrates in this 
project. Error bars represent the standard deviations for 
each of the chemicals. 
 Figure 6.54:   Average of the total PCR products for all of the chemicals 
used as enhancements for the substrates without regard to 
kit or specific chemical.  Error bars represent the standard 
deviations for each of the dilutions. 
 Figure 6.55:   The total PCR concentrations for all substrates: glass, 
gypsum, laminate, lead, plastic, raw wood, and tile 
without regard to kit or chemical.  Error bars represent the 
standard deviation. 
 Figure 6.56 
 
Total PCR concentrations for both kits, PowerPlex
®
 16HS 
and PowerPlex
®
18D.  Error bars represent the standard 
deviations for the total PCR concentration. 
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CHAPTER 1. 
INTRODUCTION 
_____________________________ 
 
DNA profiling has attained an important position among the tools used for criminal and 
civil casework since the first ‘DNA fingerprint’ was generated using restriction fragment 
length polymorphisms (RFLPs) by Sir Alec Jeffreys in 1984 (Jeffreys et al., 1985a).  In 
1985, polymerase chain reaction (PCR) was introduced by Kary Mullis and the Cetus 
Corporation (Mullis et al., 1987).  The development of PCR allowed for the enzymatic 
replication of a specific region of DNA using minute amounts of biological sample (Saiki 
et al., 1985; Mullis et al., 1987).  By the early 1990s, short tandem repeats (STRs) 
became the standard genetic markers to generate DNA profiles (Lygo et al., 1994).  STR 
technology is easy to implement, robust, works with trace amounts of DNA and can be 
utilized for different types of casework samples (Butler, 2005).  The evolution of 
multiplex STR kits has been rapid and it continues to evolve and change as new 
methodologies and technologies are introduced. Recently direct PCR has been introduced 
to the field of forensic science (Wang et al., 2009; Yang et al., 2007a; Yang et al., 
2007b).  This means that DNA profiles can be generated directly from the different types 
of samples without the need of DNA extraction. One such kit is Powerplex
®
 18D, which 
has been developed by Promega
®
 Technologies (Oostdik et al., 2013). As all new 
techniques need to be rigorously tested in the forensic sector, this comparative study 
aims to develop DNA profiles from surfaces which have been processed with field 
techniques employing treatments such as fingerprint powders and blood enhancement 
chemicals using a commonly used kit (PowerPlex
®
 16HS) and a direct amplification kit 
(Powerplex
®
 18D). 
1.1 Deoxyribonucleic Acid (DNA) 
Deoxyribonucleic acid (DNA) is found in nucleated cells in the human body.  The DNA 
molecule contains genetic information which is the information needed for the 
development and function of an organism (Butler, 2005; Klug and Cummings, 2003).  
DNA is a polynucleotide meaning it is a nucleic acid built by linking mononucleotides 
(Klug and Cummings, 2003).  A single nucleotide is composed of a phosphate group, 
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nitrogenous base and a ribose pentose sugar (Klug and Cummings, 2003; Watson and 
Crick, 1935).  For the DNA molecules, the C-2′ position of the sugar is occupied by a 
hydrogen atom, hence making up the deoxynucleotide. The phosphate group of one 
nucleotide is found on the C-5′ of the 2′-deoxyribose sugar molecule and this reacts to 
the –OH group on the C-3′ of the neighbouring nucleotide to form a phosphodiester bond 
(Mathews et al., 2000).   The nucleotides are composed of four different nitrogenous 
bases.  Purines, adenine (A) and guanine (G), are nine-member double-rings while 
pyrimidines, cytosine (C) and thymine (T), are six-member single-rings (Mathews et al., 
2000; Watson and Crick, 1935).  The nucleo-bases are bound to the structure at the C-1′ 
position (Klug and Cummings, 2003). This formation differs from ribonucleic acid 
(RNA) which contains a hydroxyl group at the same C-2′ position of the sugar in DNA 
and also replaces thymine (T) with uracil (U) in order to execute the blueprint laid out by 
the DNA molecule (Klug and Cummings, 2003). 
The configuration of a DNA molecule is in the form of a double helix (Watson, 1935). It 
is formed when complementary, anti-parallel chains of nucleotides bond to one another 
and coil around a central axis forming a right-handed double helix (Klug and Cummings, 
2003; Mathews et al., 2000).  Complementary pairing of the nucleo-bases, (A) to (T) and 
(C) to (G) provides the hydrogen bonds necessary for the chemical stability of the 
structure (Klug and Cummings, 2003).  Adenine (A) pairing with thymine (T) produces a 
double hydrogen bond while cytosine (C) pairing with guanine (G) produces a triple 
hydrogen bond.  The sugar-phosphate “backbone” of the helix is hydrophilic allowing 
both parts to interact with water (Klug and Cummings, 2003).  The phosphate group is 
negatively charged giving the overall DNA molecule a negative charge.  The nitrogenous 
base pairs, which are hydrophobic, are layered horizontally within the structure and 
protected from contact with water (Klug and Cummings, 2003).  (Figure 1.1) 
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Figure 1.1: Diagram of a DNA molecule (Ingram, 2007). 
 
1.2 Diversity within the Human Genome 
Diversity within the human genome allows for various techniques to be used in forensic 
and paternity based cases by identifying individuals based on their genetic makeup.  The 
whole human genome is represented by 22 pairs of chromosomes, two sex chromosomes 
and mitochondrial DNA.  Sex is determined by the XY-sex determining system where 
XX is found in females and XY in males, the Y chromosome being dominantly male sex 
determining.  The human gene usually analysed to determine sex of a sample in forensic 
based cases is the amelogenin locus.  During PCR amplification using a single primer 
pair, fragments of different lengths are generated depending on whether the person is 
male or female.  The sequence on the X chromosome is shorter by 6bp when compared 
to the Y chromosome allele; thus a female would produce a single peak on an 
electropherogram while a male would exhibit two peaks (Akane, 1998; Buel et al., 1995).     
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Located on each of the chromosomes are two distinct sequence classes, coding regions 
and non-coding regions. Coding regions are areas which are transcribed, called genes.    
Genes make up approximately 2% of the human genome.  Genes can be classified as 
protein coding and non-protein coding.  Protein coding genes are made up of exons and 
introns.   Exons contain protein coding-regions of the gene and are retained in the final 
mature messenger RNA (mRNA).  Introns are intervening sequences that are removed by 
RNA splicing.   Non-coding regions have an important function as well including 
sequences important for the regulation of the transcription and translation of the protein-
coding sequences.  The regulatory function of a gene is influenced by multiple stretches 
of DNA located both in close proximity and far from the actual gene and translated 
region of mRNA.  Just as protein-coding genes can contain genetic variation, non-coding 
regions can also show variability.  They include differences in VNTRs, variable number 
tandem repeats; STRs, short tandem repeats; and SNPs, single nucleotide 
polymorphisms. 
Tandem repeats occur in DNA sequences when two or more nucleotides are repeated 
directly next to each other for a number of times. Variable number tandem repeats 
(VNTRs), also referred to as minisatellites, can be seen as variable number sequences of 
tandem repeats within the human genome.  VNTR individual repeat units range from 10-
100bp long. In 1985, Alec Jeffreys developed the first DNA profile by understanding and 
utilizing the sequences and patterns of VNTRs that are specific to an individual’s 
genomic profile (Jeffreys et al., 1985b; Jeffreys et al., 1985c).  A match probability is 
determined by the rarity of the alleles presented in the profile.  Each allelic marker within 
a specific locus has a frequency with which is occurs in the population and by evaluating 
the combined frequency a match probability can then be generated.  The VNTR markers 
were found to be highly discriminating, giving a match probability lower than 3x10
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(Jeffreys et al., 1985c).  The visualization of these VNTRs required the use of restriction 
enzymes which cleaved the regions of DNA surrounding the VNTRs.  This technique 
was termed restriction fragment length polymorphism (RFLP).  Gel electrophoresis was 
used to separate the DNA fragments by molecular weight and the gel fragments were 
transferred to a nitrocellulose membrane using Southern blotting and identified via a 
radio-labelled DNA probe.  Multi-locus DNA probes detect sets of 15-20 variable 
fragments per individual ranging from 3.5 to 20kb in size and single locus probe detects 
a single hypervariable locus using high stringency hybridization (Roewer, 2013).  The 
4
 
 
various sizes of bands located on the gel represent the varying fragment sizes obtained 
from one individual making them unique identifiers (Figure 1.2).  While this 
methodology was promising, it required a large amount of DNA (>100ng), was labour 
intensive and required a large amount of time to conduct (Meyers 1995).   
 
 
 
 
 
 
 
 
Figure 1.2:  A DNA sample taken from a crime scene is compared with DNA 
samples from three different suspects utilizing VNTRs to create the bands on the 
gel. If a suspects DNA profile matches the crime scene sample, then the evidence 
recovered from the crime scene came from that suspect. Conversely, if the DNA 
profiles do not match, then the evidence cannot have come from the suspect. 
Suspect 2 and the crime scene sample match (outlined in yellow); therefore, the 
sample from the crime scene is positively identified as coming from Suspect 2 (Leja, 
2010). 
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C. Electropherogram Output 
 
 
 
 
 
Figure 1.3: Examples of a short tandem repeat sequence using the CSF1PO [AGAT 
repeat sequence]. A.) Homozygous example with 9 repeating units and B.) 
Heterozygous example with 9 and 6 repeating units.  C.) Electropherogram output 
which would be representative of the samples generated from A and B. 
STRs, short tandem repeats, are microsatellites which usually contain 2 to 6bp repeat 
sequences (Figure 1.3) (Kotte-Marchant and Davis, 2012).  Like VNTRs, they are highly 
discriminating and have a low mutation rate (10
-3 
per generation) (Brinkmann et al., 
1998; Shriver et al., 1995; Weber and Wong, 1993; Butler, 2005). Mutations within STR 
loci occur slowly over time (rates are in the order of 1-5 mutations per 1,000 allele 
transfers) and are thought to occur because of replication slippage or defective DNA 
replication repair (Figure 1.4) (Nadir, 1996; Ellegren, 2004; Butler, 2005). STRs were 
targeted to build commercial DNA kits due to their ability to be multiplexed and their 
utility in amplifying small amounts of biological samples (Lander et al., 2001).  Studies 
to use STRs as genetic markers began with the UK Forensic Science Service (FSS) in the 
early 1990s (Butler, 2005).  The United States’ Federal Bureau of Investigation, Royal 
Canadian Mounted Police, and other European laboratories also contributed to the early 
efforts to develop a multiplex kit for forensic purposes (Butler, 2005).  During the efforts 
to develop kits for forensic use, a number of loci were identified. Initially kits could 
amplify three to four loci used with silver staining methods and, in a matter of a couple 
of years, expanded to over fifteen STRs which use multi-coloured fluorescent tags 
(Butler, 2005). Most of the loci used for forensic testing are tetranucleotide repeats, 
meaning they contain a four-base repeating sequence.  Tetranucleotides are used more 
often as the four-base spread in the alleles makes closely spaced heterozygotes easier to 
resolve during capillary electrophoresis.  Tetranucleotides are also more common than 
penta- and hexanucleotides in the human genome; however, these are still considered for 
possible implementation into commercial STR kits.  Di- and trinucleotides are not used 
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as the stutter peak, a peak which appears one or more repeat unit less than the true allele 
due to strand slippage during PCR, may present exhibit itself with a peak height 30% or 
higher when compared to the true peak and would make it difficult to determine if it is in 
fact a true allele or stutter product.  Displaying peaks of this nature would make it 
difficult to interpret sample mixtures.  Characteristics of these loci include amplifiability 
using polymerase chain reaction (PCR); high heterozygosity; predictable length of alleles 
(Ruitberg et al., 2001); and the ability to multiplex the loci in one reaction.  To date, 
there are more than 20,000 tetranucleotide STR loci which have been characterized in the 
human genome and there may be more than one million depending on the method used to 
count the loci (Collins et al., 2003).  
 
 
 
 
 
 
 
Figure 1.4: Microsatellite sequence variation results from the gain and loss of single 
repeat units or a single nucleotide. This occurs when there is a brief dissociation of 
the replicating DNA strands followed by misaligned re-association (Ellegren, 2004). 
SNPs, single nucleotide polymorphisms, are single base variants between individuals at a 
specific point in the human genome (Figure 1.5) (Morin et al., 2004).  Between any two 
individuals there are likely to be millions of SNPs which become yet another tool one 
could use to differentiate between individuals (Divne et al., 2005).  Because SNPs are 
single nucleotides they have been targeted in the use of highly degraded samples where 
long flanking regions for primers used in standard amplification may not exist or be 
degraded so the extent that adhering to the region is not possible (Budowle and Van 
Daal, 2008).  However, due to the loci being bi-allelic, 50-80 SNPs are required to obtain 
the discriminating power of a typical STR-based system (Budowle and Van Daal, 2008; 
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Chakraborty et al., 1999; Divne and Allen 2005; Morin et al., 2004).  The mutation rate 
of SNPs, on average 1 in 10
-8
 per nucleotide per generation, is much lower than those of 
STRs (Durrett and Limic, 2001; Nachman and Crowell, 2000).  This makes them 
particularly useful when complex kinship analysis or parentage testing is required.    
 
 
 
 
 
Figure 1.5:  A single nucleotide polymorphism is a change in the genetic code of an 
individual where a single nucleotide (1) is replaced by another nucleotide (2) in the 
DNA sequence (Kucukkal et al., 2014). 
Another type of DNA which exists in a cell is mitochondrial DNA, mtDNA. 
Mitochondria is found in abundance in the human body and are predominately known for 
their production of adenosine triphosphate (ATP) which is the energy currency cells need 
to function.  Unlike nuclear DNA, mtDNA comes from the cytoplasm of an oocyte that 
contributes to the formation of the zygote, and thus it is of maternal origin. It is found in 
abundance within cells (>1000 copies) which makes mtDNA a viable option when 
dealing with highly degraded samples and when standard STR analysis fails.  
Mitochondrial DNA is a circular molecule that is 16,569bp long and does not contain 
intron sequences (Anderson et al., 1981; Levin et al., 1999).  Mitochondrial DNA is 
passed through the maternal line and may not be able to individualize persons but can 
provide a family association.  For forensic purposes, the focus is on two hypervariable 
regions that are specifically targeted in the mtDNA molecule, HV1 and HV2, as they are 
highly polymorphic noncoding regions (Budowle et al., 2003; Holland and Parsons, 
1999; Wilson et al., 1995). While mtDNA does not produce an individualized profile, it 
can establish familial linkage which can be useful in missing and unidentified person’s 
cases. Once these regions have been sequenced, the data are compared to the Cambridge 
Reference Sequence (CRS), the variants reported and then an association may be made 
(Bandelt et al., 2014). 
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1.3 DNA Isolation 
DNA isolation, also referred to as extraction, is the process of separating genomic DNA 
from cellular proteins and other molecules (Butler, 2005).  Failure to remove other 
cellular debris can inhibit the PCR and data analysis.  Numerous kits are available on the 
market for genomic DNA extraction.   
Organic extraction, also referred to as phenol-chloroform extraction, involves the serial 
addition of several chemicals in order to recover high-molecular-weight double-stranded 
DNA (Butler, 2005).  To begin the process sodium dodecylsulfate (SDS) and Proteinase 
K are added to a tube containing the biological sample in order to break down the 
proteins that protect the DNA molecule (Vandenberg et al., 1997).  Then phenol-
chloroform and isoamyl alcohol are added to the sample in order to separate the proteins 
from the DNA.  The sample is then placed in a centrifuge to separate the unwanted 
proteins and cellular debris from the DNA (Mason, 2015; Vandenberg et al., 1997).  The 
resulting product is double-stranded DNA molecules which can then be used for further 
analysis.  This process was primarily used during RFLP analysis as it is the most 
effective way to obtain high molecular weight DNA (Comey et al., 1994).  However, it is 
time-consuming, especially when dealing with a large number of samples, involves 
hazardous chemicals (phenol is highly corrosive and can cause severe chemical burns), 
involves transferring the sample between multiple tubes which elevates the risk of error 
or contamination, and could aid in the loss of overall DNA sample quantity (Butler, 
2005; Montpetit et al., 2005). 
FTA cards (formerly Whatman, now part of the GE Healthcare Life Sciences, Pittsburgh, 
PA) are commonly used today to isolate DNA (FTA/FTA Elute Sample Collection Cards 
and Kits: Product Information,  2011).  The cards work by having the biological material 
spotted onto the chemically coated paper where the cells are lysed and protected from 
degradation and bacterial growth (Vandenberg et al., 1997; Wang et al., 2009).  A small 
punch can be utilized to extract the stain from the paper and placed into a tube for 
washing.  The bound DNA is then released using a FTA Purification Reagent to remove 
the haem and other inhibitors.  The cleaned punch can then be added to the PCR mix for 
amplification (Vandenberg et al., 1997; Wang et al., 2009). This type of method is 
primarily used for its ease of collection, ability to be shipped without coolant/ refrigerant 
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shipping containers, and its ability to be placed in long-term storage at room temperature 
when used with blood and saliva samples (Butler, 2005). 
Another approach commonly used today is solid-phase extraction.  There are various 
methods which utilize a substrate such as silica particles to bind DNA in an automated 
process (Montpetit et al., 2005; Shewale and Liu 2014).  Solid-phase extraction kits 
allow for rapid and efficient purification of nuclear DNA located within the sample (Tan 
et al., 2009).  They are designed to isolate genomic DNA from blood samples, buccal 
swabs and several other sample medium types after exposure to a lysate solution using 
selective binding to silica-based membranes in the presence of chaotropic salts (Shewale 
and Liu, 2014).  Through a series of washes and spins, the nuclear DNA is purified and 
eluted in a low salt elution buffer until further processing.  There are several 
commercially available products for this purpose. QIAGEN
®
, Inc. developed QIAmp
®
 
spin columns to isolate the DNA (Greenspoon et al., 1998; Scherczinger et al., 1997), 
while DNA IQ, marketed by Promega
®
, utilizes the same silica-based DNA binding and 
elution chemistries but uses silica-coated paramagnetic resin (Bowden et al., 2011; 
Frégeau et al., 2010). 
The techniques for DNA isolation have progressed over the years to compensate for need 
to increase throughput and efficiency in casework laboratories (Montpetit et al., 2005).  
Many of these processes can be aided with liquid handling systems (such as TECAN 
liquid handling robotics, Männedorf, Switzerland) or automated DNA extraction 
machines (such as the Promega Maxwell
®
16 and Qiagen BioRobotEZ1), but the 
extraction step still takes time to process (Davis et al., 2012; Frégeau et al., 2010; 
Lindner et al., 2011; Morf et al., 2011; Silva et al., 2013; Stangegaard et al., 2009).  
While these processes have assisted in helping to reduce backlogs, the maintenance and 
overall purchase costs of the robotics are a concern when considering the budgets of 
some laboratories.   
1.4 Amplification 
The process of amplification is the act of replicating or copying a target portion of the 
DNA sequence until the desired concentration is achieved for analysis.  Polymerase 
chain reaction allows such amplification (Nishimura et al., 2000).  This replication is 
achieved by preparing PCR reaction mix and combining it with a sample of the DNA.  
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The PCR reaction contains several components which aid in the amplification process 
(Table 1.1).  
Table 1.1:  Components of PCR reaction mix (Butler, 2005).   
Reagent Typical Concentration 
Tris-HCL, pH 8.3 10 mM 
Magnesium chloride 1.2-2.5mM 
Potassium chloride 50mM 
Deoxynucleotide triphosphate (dNTPs) 200μM each dATP, dTTP, dCTP, dGTP 
DNA Polymerase, thermal stable (Taq and TaqGold- most common) 0.5-2.5U 
Bovine serum albumin (BSA) 100μg/mL 
Primers 0.1-1.0μM 
Template DNA 1-10ng genomic DNA 
 
Each component of the PCR reaction mix plays an important role in the replication 
process.     
The ‘reaction buffer’ generally comes as a single commercially produced solution which 
provides the optimal pH and monovalent salt environment for the target reaction.  Each 
individual component can also be purchased which allows the user to have more control 
over the conditions present in specific reactions.  The ‘reaction buffer’ usually contains 
Tris-HCL, potassium chloride and sometimes magnesium chloride (MgCl2) (Integrated 
DNA Technologies, 2011; Butler, 2005). Depending on the product purchased, 
magnesium chloride may be separate from the ‘reaction buffer’.  Magnesium chloride, 
additionally, influences the interaction between the primers and the DNA template and is 
essential for polymerase action to occur.  Low concentrations of MgCl2 may help to 
stabilize interaction of the primers and their intended primer binding site on the DNA 
template; however, too low of a concentration may yield a low PCR product since 
magnesium chloride is need in order for polymerase reactions to occur.  High 
concentrations of MgCl2 may yield nonspecific binding and/or erroneous PCR product 
formation (Butler, 2005; Shewale and Liu, 2014).   
Bovine serum albumin (BSA) is a PCR additive which can help to increase the yield of 
the PCR products produced.  BSA is believed to aid in the relief of inhibition effects seen 
in the replication process (Department of Environmental Sciences, 2004; Ralser et al., 
2006).  It is an optional component and not included in all reaction mixes. 
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Deoxynucleotide triphosphates (dNTPs) are the building blocks of the DNA template 
which is being replicated (Butler, 2005; Department of Environmental Sciences, 2004).  
The addition of dNTPs allows for the synthesizing of DNA for the polymerase enzyme 
(Shewale and Liu, 2014).  An equal concentration of dATP, dTTP, dGTP, and dCTPs are 
necessary to ensure accuracy during the replication process. 
DNA polymerase is used to build the complementary strand to the single-stranded DNA 
template by using the nucleotides present in the reaction.  Almost all PCR reactions 
employ a heat-stable polymerase which is derived from heat-loving organisms referred to 
as thermophiles (ABI Life Technologies, 2011; Butler, 2005; Shewale and Liu, 2014). 
TaqDNA Polymerase was originally isolated from the bacterium Thermus aquaticus and 
is commonly used in commercial DNA kits (Gelfand et al., 1989; Tindall and Kunkel, 
1988). 
DNA primers, oligonucleotides, are short single-stranded DNA molecules that flank the 
target region to be repeated during the amplification process (Mitsuhashi et al., 1996; 
Ralser et al., 2006; Robertson and Walsh-Weller, 1998).  They can be used in a single 
capacity where a forward and reverse primer targets a single location on the DNA strand; 
however, advances in the amplification technique allow for ‘multiplexing’.  Multiplex 
PCR uses multiple sets of forward and reverse primers to target multiple locations along 
the DNA strand in a single PCR reaction.  They are generally 15-30 nucleotides in length 
and are not complementary to themselves or to any other primers in the multiplex (Gill et 
al., 1997).  This helps to avoid primer dimers and hairpin formations during the 
amplification process (Vallone and Butler, 2004). 
PCR products are a vital component in developing a DNA profile from a small sample 
using capillary electrophoresis (Yang et al., 2007; Saferstein, 2005).  The development of 
commercialized STR multiplex kits and automated machines has made the process 
easier.  
1.4.1 Amplification Process 
Amplification is enzymatic process by which the target regions within the DNA 
molecule are replicated repeatedly in order to increase the amount of a specific DNA 
sequence (Butler, 2005).  It is carried out using thermal cycling which is a series of 
heating and cooling cycles conducted on a thermo cycler machine (Mullis, 1987; Mullis 
and Faloona, 1987).  Generally, there are three steps in the cycling process - 
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denaturation, annealing, and elongation (Figure 1.6).  Denaturation completely denatures 
the target DNA making it single stranded and opening it up for the complementary 
sequences of the primers (Integrated DNA Technologies, 2011; Robertson and Walsh-
Weller, 1998).  This is generally conducted at around 94
○
-95
○
C for 30 seconds to one 
minute.  Annealing allows the primers to adhere to the target areas that are being 
replicated.  Annealing temperatures fluctuate based on the composition of the primers 
(Integrated DNA Technologies, 2011; Department of Environmental Sciences, 2004).  
For the purposes of this project, 60
○
C was optimal.  Elongation occurs in the last step of 
the process where the temperature is elevated to approximately 70-72
○
C (Integrated 
DNA Technologies, 2011; Department of Environmental Sciences, 2004).  At this point 
DNA polymerase is at its optimal temperature and it extends the primers using dNTPs to 
create a complementary strand.  The cycles are then repeated.  The number of cycles is 
dependent on the type of samples being processed and the optimal cycling parameters for 
the kit being used.  With each heating cycle, the number of copies of the target DNA 
theoretically doubles thus exponentially growing the amount of target DNA. 
 
 
 
 
 
 
 
 
Figure 1.6:  Schematic of the DNA amplification process.  1.) The double-stranded 
DNA molecule is separated into two single strands using heat. 2.) The temperature 
is then lowered to allow the oligonucleotide primers (shown in blue) to anneal to the 
target areas on the single-stranded DNA. 3.) The temperature is increased in order 
for DNA polymerase to produce a complete copy of the target DNA region (Reece et 
al., 2010). 
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1.4.2 Direct Amplification 
Over the past several years, scientists have been working to eliminate the DNA isolation 
step which was once thought absolutely necessary for profile development (Morata et al., 
1998; Akane et al., 1994; Park et al., 2008).  New developments in direct amplification 
technology suggest that the step may not be as important as once conceived (Mercier et 
al., 1990).   
The concept of eliminating the DNA isolation step is not new; however, it really became 
an area of focus in the field of forensic science in the early 2000s.  While the theory of 
direct amplification is relatively sound, blood samples in low quantity seem to be highly 
problematic.  Blood contains numerous inhibitors which must be taken into account such 
as haem (Akane et al., 1994), and immunoglobulin in human plasma (Al-Soud and 
Radstrom, 2001).  Denaturing reagents and detergents previously used in the isolation 
step also yield a number of problems during the amplification process (Burckhardt, 
1994).  In the early 1990s Mercier et al.(1990), reported that whole blood samples, both 
fresh and frozen, could be amplified without extraction, or any other alternate form of 
purification, by heating and cooling the sample three times prior to beginning the 
replication process. In 1994, a technique using a microwave treatment successfully 
amplified non-purified whole blood and hair shaft samples.   In 2007, BioQuest Inc. from 
Seoul, South Korea, released a novel buffer system which not only eliminated the 
extraction process but using a patented buffer, AnyDirect, also improved PCR replication 
and overall profile quality (Yang et al., 2007).  The AnyDirect buffer system was the first 
of its kind to be placed on the market for consumers.  Successful direct amplification 
using the AnyDirect Buffer was not limited to whole blood but also included obtaining 
profiles from Arabidopsis leaves (Yang et al., 2007) and chicken DNA (Bailes et al., 
2006).  In the fall of 2009, Applied Biosystems released its first direct amplification kit 
internationally, Identifiler
®
 Direct (ABI Product Overview, 2010).  In May of 2010, the 
FBI approved this application as the first direct amplification system for database and 
paternity testing laboratories (Genomeweb, 2010).  In June of 2011, PowerPlex
® 
18D, 
Promega’s direct amplification system, was approved by NIST for database and familial 
relationship testing.  To date, neither kit has been approved for casework samples. 
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1.4.3 Components of a Direct Amplification  
While the exact components of the newly optimized commercial kits for extracted 
samples and direct PCR are unknown, there are publications which may offer insight into 
the possible elements of their composition. 
In March of 2010, DNA Polymerase Technology Inc. published a paper regarding novel 
mutants of Taq polymerase (Zhang et al., 2010).  OmniTaq (Taq-22), a double mutant of 
Taq polymerase, is an enzyme which is resistant to the inhibitory effects of blood, soil, 
crude soil extracts, and some food media (Zhange et al., 2010).  It is extremely sensitive 
and able to amplify trace amounts of DNA very quickly.  Omni Klentaq LA (Klen-taq-
10) is a triple mutant of the Klentaq polymerase which makes the enzyme resistant to the 
same inhibitory effects as OmniTaq with the inclusion of fluorescent dyes (Kermekchiev 
et al., 2009).  The ‘long accurate’ option of the Omni Klentaq LA is also available and 
allows for amplification of longer products with higher fidelity and accuracy 
(Kermekchiev et al., 2009).  Clontech Laboratories, part of Takara Biotech Company, 
has also released ‘Terra™ PCR direct polymerase’ which is a novel enzyme developed 
for direct amplification from tissue samples, crude extracts, and dirty templates.  The 
utility of these novel alterations to Taq polymerase are especially notable in regards to 
whole blood samples which have often been a source of contention for the DNA analyst 
because of the inhibition displayed due to haemoglobin which can copurify with DNA 
(Akane et al., 1994). This ultimately leads to the inactivation of the DNA polymerase, 
nonbinding primers, and/or degradation of the target DNA rendering these samples non-
viable for development of a partial or full profile (Al-Soud and Radstrom, 2001).  As 
blood is a common biological fluid found in scenes of crime, this is an area of weakness 
within older multiplex kits. 
PCR enhancers may also aid in the robustness of the newly configured kits.  Dimethyl 
sulfoxide, tetramethylxene, betaine, and homoectoine have all been documented as 
chemicals which can have positive effects on PCR (Bachman et al., 1990; Schnoor et al., 
2004; Zhang et al., 2010).   Also, an increase in magnesium chloride and bovine serum 
albumin (BSA) concentration have been suggested as other alternatives for the increase 
in strong profiles generated from the new kits (vanOorschot et al., 2010). 
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1.5 STR Analysis 
1.5.1 Current Technologies used for STR-based DNA Profiling 
The development of commercial multiplex kits for human identification involves the 
amplification of several STR loci within one reaction tube also referred to as 
multiplexing.  This allows for gathering maximum information from the small amount of 
DNA and reduces processing times.  The STR loci within the commercial kits range in 
size from 100-600 base pairs depending on the specific loci contained in the kit.  Loci 
with alleles that fall in similar base pair size ranges have been given a different dye 
colour in order to avoid overlapping.   
Several multiplex STR kits have been validated for forensic and DNA databasing such as  
Applied Biosystems
® 
AmpFℓSTR® SGM Plus®(Cotton, 2000), Applied Biosystems® 
AmpFℓSTR® Profiler Plus® (Frank et al., 2001; Frégeau et al., 2003; Holt et al., 2002), 
Applied Biosystems
® 
AmpFℓSTR® Cofiler® (Holt et al., 2002; LaFountain et al., 2001; 
Moretti et al., 2001), Applied Biosystems
® 
AmpFℓSTR® Identifiler® (Boon et al., 2006; 
Collins et al., 2004), Promega
® 
PowerPlex
®
16 System (Krenke et al., 2002).  While these 
kits are the foundation of forensic and databasing work, advancements in STR 
technology have recently introduced several new kits.  The new kits involve new 
optimized master mixes to help overcome inhibition, direct amplification for increased 
efficiency and an increased number of loci in order to harmonize loci across multiple 
jurisdictions as well as increase discrimination capacity when loci drop-out occurs such 
as in degraded samples or when analysing mixtures (Gill et al., 2006). These kits include, 
but are not limited to, Promega
®
 PowerPlex
®
18D (Myers et al., 2012; Vallone et al., 
2011), Applied Biosystems
® AmpFℓSTR® IdentifilerDirect™ (Mulero et al., 2008), 
Applied Biosystems
® AmpFℓSTR® NGM™ (ABI: Life Technologies, 2011; Barbaro et 
al., 2011a, Barbaro et al., 2011b).  Table 1.2 displays loci information for the kits as well 
as dye colours. 
DNA amplification using commercial multiplex kits contains primers which are labelled 
with different fluorophores, allowing the sample to be reproduced while distinguishing 
between different loci. Again, a table depicting various kits with their corresponding loci 
and dye colours are located in Table 1.2.  After amplification, a small portion of the 
amplicon is mixed with an internal lane standard, or ILS.  The ILS is a solution 
consisting of different known fragment sizes which is tagged with its own dye, different 
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from any used during PCR. Internal lane standards which are commonly used by Applied 
Biosystems™ are GeneScan™ 500 which is labelled with ROX™ and is red in colour 
and GeneScan™ 600 which is labelled with LIZ, generally orange in colour from 
Applies Biosystems.  Promega
®
 kits generally contain ILS600 which is red in colour and 
CC5 ILS500 which is orange.  The fragments are then separated by size and colour by 
capillary electrophoresis, CE, and detected by laser-induced fluorescence (Applied 
Biosystems, 2005; Beale, 1998; Budowle et al., 1997; Butler, 2004; Landers et al., 1996; 
Lazaruk et al., 1998; Slater et al., 2003). 
Promega PowerPlex
®
 16HS and PowerPlex
®
 18D were used throughout the course of 
this work.  PowerPlex
®
 16HS contains 15 loci plus amelogenin, and detects using four 
fluorescent dyes (Figure 1.7A). The internal lane standard for this kit is ILS600 which is 
displayed in red. PowerPlex
®
 18D contains 17 loci plus amelogenin, and detects using 
four fluorescent dyes (Figure 1.7B). The internal lane standard for this kit is CC5 ILS500 
which is displayed in orange.  A full list of the loci, size range of the allelic ladder and 
the number of repeats for each locus used in the two kits (Promega
®
 PowerPlex
®
16HS 
and Promega
®
 PowerPlex
®
18D) are located in Appendix 8. 
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Table 1.2: A summary of loci which are available in different commercially available kits.  
The colour represents the dye attached to their respective primer. 
 Applied Biosystems
®
 (Life Technologies) Promega
®
 Corporation 
STR Loci 
AmpFℓSTR® 
Identifiler
®
 
AmpFℓSTR® 
Identifiler
®
 Direct 
AmpFℓSTR® 
NGM
®
 
PowerPlex
® 
16HS 
System 
PowerPlex
® 
18D 
System 
# of Loci 16 16 16 16 18 
D1S1656   ♥   
D2S1338 ◙ ▲ ●  ♦ 
D2441   ♥   
D3S1358 ◙ ▲ ♥ ■ ■ 
D5S818 ♥   ♣ ♣ 
D7S820 ●   ♣ ♣ 
D8S1178 ● ♣ ▲ ☼ ☼ 
D10S1248   ●   
D12S391   ♥   
D13S317 ◙   ♣ ♣ 
D16S539 ◙ ▲ ● ♣ ♣ 
D18S51 █ ♣ ◙ ■ ■ 
D19S433 █ █ █  ♦ 
D21S11 ● ♣ ◙ ■ ■ 
D22S1045   █   
FGA ♥ █ █ ☼ ☼ 
TH01 ◙ █ █ ■ ■ 
AMEL ♥ ♣ ◙ ☼ ☼ 
vWA █ ▲ ● ☼ ☼ 
Penta E    ■ ■ 
Penta D    ♣ ♣ 
TPOX █   ☼ ☼ 
CSF1PO ●   ♣ ♣ 
Legend: 
♦= CXR ♣= JOE: 6-Carboxyl-2’,7’-dimethoxy-4’,5’-dichlorofluorescein 
▲= 5- FAM: 5-Carboxyl Fluorescein █ = NED 
●= 6-FAM: 6-Carboxyl Fluorescein ♥= PET 
■= FL: Fluorescein ☼= TMR: N’N’N’N’-tetramethyl-6-carboxyrhodamine 
◙= Vic  
18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2 Development of Electropherograms by Capillary Electrophoresis 
During the migration of the sample through the capillary, the fluorophore attached to the 
5′ end of the amplified fragment is excited and light of a particular wavelength is 
emitted.  This emitted wave is separated by colour by the prism and a multi-coloured 
electropherogram is then generated for analysis.  Software, generally GeneMapper
®
 ID 
or IDx, is used to analyse the raw data generated from the genetic analyser. 
Fragments are compared to an allelic ladder which is run in conjunction with the 
samples.  Figure 1.8 shows the allelic ladder for PowerPlex
®
 18D.  The ladder is the 
same for PowerPlex
®
 16HS except loci D21338 and D19S433 are not present. All 
common alleles for each locus are present in the allelic ladder.  The sample fragments in 
combination with the allelic ladder peaks allow for the assignment of alleles for each 
Figure 1.7: Configuration of the (A) Promega PowerPlex
©
16HS and (B) 
PowerPlex
©
18D kits demonstrating the fluorescent dye colour labels and 
relative PCR product size ranges for each of the loci present. (Source: Promega 
Corporation) 
A 
B 
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peak present in the profile (Butler, 2005).  A typical electropherogram showing a DNA 
profile generated using Promega’s PowerPlex®16HS is demonstrated in Figure 1.9. 
 
Figure 1.8:  Allelic ladder which represents alleles in PowerPlex
®
18D.  The same 
alleles are present in PowerPlex
®
16HS with the exception of D21338 and D19S433 
which are not present in this kit.  Green bars contain the loci names.  The red 
triangles along the baseline represent the size range where alleles for a specific locus 
are called and the boxes below the baseline represent the allele call for that specific 
peak. The X-axis numerical values indicate the fragment size in base pair number. 
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Figure 1.9:  Electropherogram demonstrating a DNA profile generated utilizing 
PowerPlex
®
18D.  The profile displays positive control 2800M.  The grey boxes label 
each of the loci present in the STR kit and the boxes under each of the peaks are the 
allele call(s) for that specific peak with the designated locus. The X-axis numerical 
values indicate the base pair number and the Y-axis the RFU (relative fluorescent 
unit) values (Source: Promega Corporation). 
1.6 Forensic Type Samples 
A DNA profile can be generated using almost any biological material containing 
nucleated cells.  These can vary from bodily fluids, to soft tissue, to bone.  A reference 
profile allows for the comparison of such samples and enables statistical evaluation of 
the forensic sample’s source of origin.  
1.6.1 Factors Affecting the Development of a DNA Profile 
There are many external aspects to take into consideration when developing a viable 
DNA profile for comparison.  Environmental considerations such as ultraviolet light, 
extreme temperatures, humidity, bacterial growth, and acidity can cause the sample to 
degrade and therefore limit the chance of obtaining a profile (McNally et al., 1989). 
Crimes which involve more than one person such as sexual assaults can also complicate 
the evaluation of the DNA provided.  Also, first responders and investigators may 
compromise and contaminate biological evidence if proper safety precautions are not 
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observed. This may lead to more complex samples which may not be resolved down to 
the original, or single, source of the DNA. 
When working scenes of crime, techniques to process biological samples may also be 
required.  The use of powders for latent fingerprints or enhancement chemicals for blood, 
semen, saliva, etc. is common practice to further visualize the evidence which can then 
be collected for analysis and identification.  It is important to understand how these 
powders and chemicals can affect the production of a DNA profile further downstream 
from the crime scene collection. 
1.6.2 Contact Surfaces 
Surface characteristics pay an important part in determining the processing or 
enhancement technique needed within a specific scene of a crime.  The basic types of 
surfaces encountered at a scene are: 
 Porous (Gardner, 2012): paper, cardboard, raw wood 
 Semi Porous (Lennard, 2007): glossy paper, wax paper, plasticized cardboard 
 Nonporous Smooth (Gardner,  2012): painted/varnished wood, plastics, glass, metal 
 Nonporous Rough (Gardner, 2012): leather, vinyl, textured surfaces such as 
countertops 
 Special Conditions (Gardner,  2012): adhesive tapes, human skin, latent blood prints 
 
Other factors which must be considered are temperature of the substrate, electrostatic 
forces on the receptive surfaces, and the degree of wetness on the surface (Gardner, 
2012; Lennard, 2007).  When possible the entire item should be collected for processing 
in a sterile laboratory environment. 
1.6.3 Biological Samples 
Biological evidence consists of samples recovered from scenes of crime that are of 
unknown origin.  They may be in the form of hair, tissue, bones, teeth, and blood or other 
bodily fluids. Although this type of evidence is not always visible, almost all scenes do 
contain biological evidence. Locard’s Exchange Principle first stated in 1910 by 
criminologist Edmond Locard, states that when an object contacts another object, there is 
an exchange of material between the two objects. This is the foundation of the transfer of 
evidentiary material within a crime scene or whilst in the act of committing a crime.  The 
four most common types of samples recovered from a crime scene and received by 
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forensic laboratories for the development of DNA profiles are blood, semen, epithelial 
cells and hair follicles (Goodwin et al., 2007). 
1.6.3.1  Skin Epithelial Cells  
Dermal epithelial cells account for approximately 16% of a person’s total body weight  
(Camden, 2009). These are shed constantly and can also be deposited through skin 
surface/item interaction. Epithelial cell samples are generally collected from surface 
swabbing in crime scenes, suspects or as reference samples through the use of swabs.  
Fingerprints are also a good source of epithelial cells.  When a person touches an object 
during a crime, fingerprint patterns consisting of amino acids, proteins, salts, and 
epithelial cells can be transferred to the surface and left behind at the scene.  While 
fingerprints are common at scenes, it may be difficult to develop a DNA profile from the 
trace amount of cells deposited and this is dependent upon the perpetrator’s ability to 
‘shed’ cells from their body. 
The determination of a person’s ability to ‘shed’ has been heavily debated and reported 
within scientific articles.  The varied quantities of DNA collected from individuals from 
touched objects could be due to the different amounts of DNA shed from each 
individuals (vanOorschot and Jones, 1997). The first thorough investigation of this 
concept came from Lowe et al who defined the level of shedders as ‘good’ and ‘poor’ 
based on the number of alleles recovered after a plastic tube was held at various time 
intervals and after hand washing (Lowe et al., 2002).  It has been indicated that that there 
is more variation in the amount of DNA deposited between individuals than the variation 
of deposit between the same individuals’ left and right hands (Meakin and Jamieson, 
2013; Bright and Petricevic, 2004). Further studies have revealed that individuals and 
their respective hands could exhibit different ‘shedder’ types on different days thus 
leading to the belief that the label of shedder type may be too narrow and does not take 
into account other factors which may affect the deposition of DNA (Meakin and 
Jamieson, 2013). The complexity of the shedding process and the differences in the 
interaction between the dermal surfaces and the touched surfaces has also cast doubts on 
consistent shedder status of individuals (Quinones and Daniel, 2012).  
 
 
 
23
 
 
1.6.3.1.1 Fingerprint Enhancement Techniques 
Fingerprint enhancement techniques are routinely used at crime scenes.  Powder 
processing or chemical enhancements may be utilized to better visualize or increase the 
detail of latent or blood evidence that is faintly visible, or latent. Enhancement can 
increase the value of evidence when bloodstain patterns, finger and palm prints, footwear 
impressions, tool/weapon impressions, etc. are suspected at the scene of crime. 
1.6.3.1.2 Powder Processing 
The utilization of powder to develop latent friction ridge impressions dates back to the 
late 19
th
 century.  Friction ridge skin can be found on the palms of hands, fingers, and the 
soles of feet.  The purpose of the powder is to enhance the ridges of the friction ridge 
skin deposit which is unique to each individual and can be used for identification.   
The adhesion of powders to fingerprint residue is accomplished by a pressure deficit 
mechanism (Thomas, 1978).  When a powder particle is moist only on its lower side 
during the sweat deposit, the bottom of the curvature of the meniscus then causes a 
pressure deficit inside the droplet, causing the particulate to adhere (Sodhi and Kaur, 
2001; Thomas, 1978). The electrostatic attraction between the sweat residue and the 
powder particles, resulting due to frictional charges, also plays a small role in adhesion 
(Thomas, 1978). 
The adherence of the processing powder to the ridges depends on the size and shape of 
the particles that compose the formulation. Small, fine particles adhere more easily than 
large, coarse ones. Generally powders are formulated with either very fine, rounded 
particles (about 1 μm in diameter) or of fine flake particles (about 10 μm in diameter) 
(Wilshire, 1996). 
Powder processing is conducted on nonporous surfaces where the moisture and oil, 
residual from the sweat and natural secretion of a depositor, is located.  Once a latent 
print surface has been identified the powder is applied mechanically using a glass-fibre 
or camel hair brush.  The powder binds to the ridge pattern of the fingerprint and is 
collected through photography and/or lifting with an adhesive medium such as tape. 
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Fingerprint powder composition has varied greatly since its first use.  These powders can 
be broken down into three broad categories: standard, metallic, and luminescent.  
Standard powder is composed of a resinous polymer and a colorant which yields contrast 
to the surface for visualization.  Metallic powders contain a resinous polymer, pulverized 
metal and a colorant. These are less messy than the standard powders but their use is 
limited due to their metallic property which enables them to bind to metal surfaces, 
coating the fingerprint pattern.  Luminescent powder is composed of natural or synthetic 
organic compound derivatives which when exposed to ultraviolet or laser light illuminate 
the print with fluorescence or phosphorescence.  The advantage of luminescent powders 
is their ability to be viewed under alternative wavelengths of light which helps to 
neutralize multi-coloured backgrounds. 
Table 1.3 lists the powders used during the course of this project.  Luminescent powders 
were not used due to the need of an alternative light source and barrier filters for viewing 
and a single-reflex camera to document the developed fingerprint. 
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* Can include filler material, which is commonly fine to medium mesh pumice; volcanic rock rich in silica and is 
lightweight.  
** Other ingredients include: Lycopodium powder, Lead, Mercury, Copper, Cadmium, Silicon, Titanium and Bismuth  
*** Dragon’s Blood is powered rosin from the Daemonorops draco plant.  
Table 1.3:  Fingerprint powders used for enhancement of nonporous and semi-porous 
surfaces. 
 Name Chemical Components* Shape / Size 
White Powder 
Formulations 
   
 Haddonite White 
Titanium Dioxide 67% 
Kaolin 16.5% 
French Chalk 16.5% 
OR 
Titanium Dioxide 33.3% 
Basic Lead Carbonate 33.3% 
Gum Arabic 33.3% 
Granular Shape 
 
 Lanconide 
Zinc Sulfide 
Zinc Oxide 
Barium Sulfate 
Titanium Dioxide 
Bismuth Oxychloride 
Calcium Carbonate 
 White Tempera Titanium Dioxide Starch 
Black Powder 
Formulations 
   
 Black Powder 
Graphite 
Charcoal 
Lamp Black 
Photocopier Toners 
Anthocene 
 
Other Ingredients** 
Granular Shape 
 
Dactyl Black 
and 
Haddonite Black 
Lamp Black 70% 
Graphite 20% 
Gum Acacia 10% 
  
 
 
Dragon’s Blood 
Variation*** 
Lamp Black 25% 
Rosin 25% 
Oxide 50% 
 Grey 
Mercury 25% 
Chalk 50% 
Gum Acacia 25% 
OR 
Lead carbonate 87.5% 
Gum Acacia 12.5% 
Metallic Powder 
Formulation 
   
 
Dual Component: 
1. Magnetic Iron 
Carrier 
2. Non-Magnetic Flake 
Developer 
Chalk or Talc 
Bronze 
Gold 
Aluminum Metal 
Stearic Acid 
1. Spherical Iron Carrier: 
50µm diameter 
2. Granular Flake 
Developer: 10µm-20 µm 
diameter 
2
5
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1.6.3.2  Blood 
Blood is the most common biological fluid found at scenes of crimes (Virkler and 
Lednev, 2009). Blood is a complex fluid which consists of plasma, which is 
proteinaceous solution containing proteins, amino acids, salts, and different cells.  These 
are red blood cells (erythrocytes), white blood cells (leukocytes), and platelets 
(thrombocytes) (Bleay et al., 2012; Bossers et al., 2011). Erythrocytes and thrombocytes 
lack a nucleus, leaving the leukocytes as the only source of nuclear DNA in the blood 
(Bleay et al., 2012). 
Detection of blood at a crime scene can vary from visualization through the human eye to 
using a chemical enhancement which may or may not need an alternative light source.  
Over the past few decades a variety of chemicals have been made available for forensic 
use.  Each chemical is advantageous for a variety of reasons.  Whether by substrate, 
reaction colour, reaction mechanism or ability to fluoresce, there should be an optimum 
chemical for one to select when processing any substrate found or submitted as evidence 
to a laboratory for processing.  Table 1.4 lists the most commonly reported chemical 
enhancement methods, mechanisms for development, preferred surface type, reaction 
colour and fluorescence details. 
1.6.3.2.1 Chemical Enhancement 
Chemical enhancement is a reaction of compounds to various components of a stain 
which is indicative of the presence of a biological secretion.  These chemicals generally 
fall into one of the following categories: amino-reactive compounds, protein dyes, or 
haem-reactive chemicals.  
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Table 1.4:  Chemical enhancement methods used for visualization of blood. 
Chemical Common Name Sensitivity 
Reaction 
Colour 
Fluorescence Wavelength/ 
Lenses-Glasses 
Surface 
Type 
Reference 
Acid Violet 17 
Coomassie 
Violet 
Proteins Purple No N/A Porous and 
Nonporous 
(Champod  et al., 2004; Sears  et 
al., 2001) 
Acid Yellow 7 
Brilliant 
Sulfoflavin 
Proteins Yellow Yes 
400-490/ 
yellow or orange 
Nonporous 
(Marchant and Tague, 2007; 
Stoilovic and Lennard, 2010) 
Acid Black 1 Amido Black Proteins Dark blue No N/A Porous and 
Nonporous 
(Bevel and Gardner, 2008; 
Bossers  et al., 2011; Cullen  et 
al., 2010;  Farrugia  et al., 2010; 
Sears and Prizeman,  2000) 
Acid Blue 83 Coomassie Blue Proteins Dark blue No N/A Porous and 
Nonporous 
(Blakesley and Boezi, 1977;  
Volker  et al., 1985) 
Multiple Chemicals:  
Crocein scarlet 7B, 
Coomassie brilliant 
blue, Glacial acetic 
acid, Trichloroacetic 
acid 
Crowl’s Double 
Stain 
Proteins Red No N/A Nonporous 
(Bossers et al., 2011; Frégeau et 
al., 2000) 
Acid Violet 19 
Hungarian Red 
(Acid Fuchsin) 
Proteins Red Yes 515-560/ red Nonporous 
(Bossers et al., 2011; Frégeau et 
al., 2000) 
1,8-diazafluoren-9-one DFO Amino Acids Purple Yes 
495-550/ red or 
orange 
Porous and 
Nonporous 
(Lennard,  2001;  Sears  et al., 
2005;  Theeuwen et al., 1998) 
 
1,2-indanedione 
 
IND Amino Acids Yellow Yes 
515-570/ red or 
orange 
Porous 
(Hauze  et al., 1998 ; Wallace-
Kunkel  et al., 2007; Weisner et 
al., 2001) 
Ninhydrin Nin Amino Acids Purple No N/A Porous 
(Bossers et al., 2011; Cullen et 
al., 2010; Frégeau  et al., 2000; 
Grubwieser et al., 2008) 
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Multiple Chemicals 
**Luminol based 
Bluestar® Haem Dark blue Yes Chemiluminescent Nonporous 
(Dilbeck, 2006;  Cullen  et al., 
2010;  Farrugia  et al., 2010;  
Tobe et al., 2007) 
Diaminobenzidine DAB Haem Brown No N/A 
Porous and 
Nonporous 
( Lennard, 2001; 2007) 
Fluorescein None Haem Yellow Yes 
420-485/ orange 
and yellow 
Nonporous 
(Sears and Prizeman, 2000;  
Barni  et al., 2007) 
4,4′,4′′-
Methylidynetris(N,N-
dimethylaniline 
Leucocrystal 
Violet 
(LCV) 
Haem Purple No N/A 
Porous and 
Nonporous 
(Cullen et al., 2010;  Farrugia et 
al., 2010) 
3-
Aminophthalhydrazide 
Luminol Haem Blue/Green Yes Chemiluminescent Nonporous 
(Barni  et al., 2007;  Tobe  et al., 
2007) 
 
Ortho-toluidine O-tol Haem Blue No N/A Nonporous (Frégeau  et al., 2000) 
Tetramethlylbenzidine TMB Haem Blue/Green No N/A Nonporous (Garner et al., 1976) 
Titanium dioxide TiO2 Haem White No N/A Nonporous (Bergeron, 2003;  Wade,  2002) 
Table continued….. 
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1.6.3.2.1.1 Amino-reactive Dyes   
Amino acids are an abundant class of chemical compounds found in latent finger and 
blood prints (James et al., 2005).  The substrates which react with amino-reactive 
chemicals may be reacting to the terminal amino acid groups on proteins and peptides, as 
well as the free amino acids found in plasma (Bossers et al., 2011; Farrugia et al., 2013; 
Lee and Gaensslen, 2001).  Human sweat has been widely reported in scientific literature 
as containing a large amount of amino acids, varying in type and concentration (Jelly et 
al., 2009).  Since the concentration and profile of amino acids fluctuate, it is important 
that the chemicals used to enhance these types of evidentiary items be non-specific 
amino-sensitive reagents (James et al., 2005).  This allows for greater availability and a 
higher probability of enhancement.  Amino-reactive chemicals can be used on porous 
surfaces, raw wood and as an enhancement for latent blood prints (Bleay et al., 2012; 
IAI, 2012).  A wide range of chemicals has been proposed with the most conventional 
ones being ninhydrin (Figure 1.10), 1,8-diazafluoren-9-one (DFO), and 1,2-indanedione 
(IND).  DFO and IND are fluorescent chemicals and require the use of an alternative 
light source for visualization (Bleay et al., 2012; IAI, 2012).   
 
 
 
 
 
Figure 1.10:  The chemical structure of ninhydrin. (The structure was generated 
using eMolecules (Gubernator et al., 2015). 
1.6.3.2.1.2 Protein Dyes 
Dyes that bind to the cationic groups of proteins are referred to as “protein reactive dyes” 
(Bossers et al., 2011; Farrugia et al., 2011; James et al., 2005).  The negative charge of 
the sulfonate group within the dye is attracted to the positive charge of the proteins found 
within blood under moderately acidic conditions (Bossers et al., 2011).  Thus, most 
formulations of these chemicals often contain an acidic component, such as citric acid, 
acetic acid, or sulfosalicylic acid (SSA).  Acid Yellow 7, coomassie blue, hungarian red 
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(acid fuchsin), and amido black are among the most popular dyes used in forensic 
laboratories (Bleay et al., 2012; Praska and Langenburg, 2013).  Amido black is the most 
versatile of the protein dye chemicals as it can be dissolved in a number of solvents 
including water and citric acid; water, ethanol, and acetic acid; and acetic acid and 
methanol (Figure 1.11).  It also performs well on nonporous surfaces. 
 
 
 
 
 
 
 
Figure 1.11:  The chemical structure of amido black. (The structure was generated 
using eMolecules (Gubernator et al., 2015). 
1.6.3.2.1.3 Haem-reactive Dyes 
Haemoglobin is an oxygen-transporting protein with a molecule size of about 65,000 
daltons (Cotter, 2001).  Haemoglobin make up about 95% of the dry weight (mass) of the 
red blood cell (Scott and White Hospital, 2013; Cotter, 2001).  The active site on the 
haemoglobin structure is an iron atom which is coordinated in a porphyrin macrocycle 
(Wirstam et al., 1999).  Haem catalyses oxidation reactions; the chemicals within this 
category begin as colourless and convert to colour once the reaction has taken place.  
These chemicals do have a limitation in that they are not human specific and will react to 
the blood of any species.  Leucocrystal violet (Figure 1.12) is one of the more popular 
chemicals used in the class of solutions (Bossers et al., 2011; Praska and Langenburg,  
2013).  It yields a purple/blue reaction when it encounters the haemoglobin in blood.   
 
 
 
31
 
 
 
 
 
 
 
 
Figure 1.12:  The chemical structure of leucocrystal violet. (The structure was 
generated using eMolecules (Gubernator et al., 2015). 
1.7 The Project 
The aim of this project is the evaluation of a direct amplification system (PowerPlex
®
 
18D) in forensic samples, specifically blood and epithelial cells, which have been 
exposed enhancement techniques.  These techniques include powder enhancement for 
epithelial cell samples and chemical processing for whole blood samples. 
1.7.1 Working hypothesis: 
 Direct amplification systems will be accurate and surpass the efficiency of the 
current DNA profiling methods. 
 The direct amplification system will be effective in providing accurate DNA 
profiles when used on evidentiary samples which have been processed using 
other forensic processing techniques (i.e. Powder Processing, Amido Black, 
Leucocrystal Violet, and Ninhydrin). 
 
1.7.2 Project Objectives  
1. To process and evaluate epithelial cell samples and whole blood samples at 
various dilutions in order to determine the limit-of-detection for the enhanced 
samples used during this project. 
2. To conduct a concordance study with 150 samples to show that both PowerPlex® 
16HS and PowerPlex
®
 18D produce concordant alleles for all 150 samples. 
3. To process and comparatively analyse epithelial cell samples under various 
dilutions which have been placed on a nonporous laminate surface and exposed to 
one of three powder types- black powder, magnetic flake, or white powder.  
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These samples will be processed with both PowerPlex
®
 16HS and PowerPlex
®
 
18D. 
4. To process and comparatively analyse whole blood samples under various 
dilutions which have been placed on one of seven substrates (gypsum, glass, tile, 
lead, plastic, raw wood or laminate) and enhanced with one of three chemicals 
(leucocrystal violet, amido black or ninhydrin). 
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CHAPTER 2.                                                                      
MATERIALS AND METHODS 
 
 
The following section describes the methodologies used during this project. It also 
details the experiments which were carried out. A list of materials and equipment 
employed during this project is given in Appendix 1. 
2.1 Quality Management 
Good laboratory practices were employed throughout the course of this project to ensure 
the reliability, consistency, and quality of the samples and the integrity of chemicals 
used. Lab coats and disposable gloves were worn throughout the procedure in order to 
reduce the chance of contamination. Surfaces and equipment were thoroughly cleaned 
with 2% (v/v) bleach solution and lightly rinsed with deionized water before preparing 
the samples. All samples were prepared using dedicated pipettes with sterile filter tips to 
prevent cross-contamination. For each PCR run, both positive and negative controls 
were conducted to ensure success of the PCR run and to check for possible 
contamination issues.   
Prior to collecting any samples this project was approved through the Institutional 
Review Board at St. Edward’s University and received ethical approval through the 
University of Central Lancashire.  A risk assessment is also on file at the University of 
Central Lancashire.  All samples obtained from individuals during the course of this 
research were collected following a written consent which was approved by both 
universities.  A copy of both consent forms can be found in Appendix 6. 
2.2 Enhancement Products  
2.2.1 Latent Fingerprint Powders 
Latent fingerprint powders were purchased from an approved forensic vendor as 
indicated in the Appendix 1.  The powders used for this experiment were standard black 
powder, magnetic flake, and standard white powder.  These powders were selected due 
to their availability and widespread usage in the field of latent fingerprint processing. 
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2.2.2 Chemical Enhancement Techniques 
Amido black (acid black 1), leucocrystal violet (LCV), and ninhydrin were purchased 
from approved forensic vendors as indicated in Appendix 1.  The recipes for each 
prepared solution can be found in Appendix 2. 
2.3 Substrates for Forensic Samples 
White and black laminate were chosen for the powder-based samples in order to show 
maximum contrast with the powder colour which was being used for that specific 
sample and dilution. 
The substrates used for the chemical processes were white laminate (12in x 12in carrara 
marble), tile (Value White Wall Tile 150mm x 150mm), glass (Microscope slide), metal 
(lead), plastic (acetate sheets), gypsum board and raw wood.   These substrates were 
selected based on their usage as substrates in other publications regarding DNA 
analysis.  Metal (lead), gypsum board and raw wood have also been noted as samples 
which have produced little to no profile when using standard DNA analysis techniques 
(Spear et al., 2002). 
Each substrate was cleaned with a 2% (v/v) bleach solution and placed in the cross-
linker for 30 minutes. 
 
2.4 Collection and preparation of samples 
2.4.1 Collection of Buccal Swabs  
Fifty buccal swab samples from each population (Caucasian, Black, and Mexican-
American), were collected using sterile OmniSwabs (Whatman
®
).  Each unrelated 
person submitted two samples, one for each kit used during the concordance study.  The 
swabs were placed in a 2.25 inch x 3.5 inch coin envelope (Quality Parks Products) to 
dry and were stored at 4°C until used.  Both samples were consumed during the 
experiment. 
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2.4.2 Population Selection 
The populations selected for this study were Mexican, African American and U.S. 
Caucasian.  The Mexican population was to be the primary focus while the African 
American and U.S. Caucasian populations were used as a base population for the study. 
The Mexican population has a huge impact on the state of Texas.  While generally 
accepted as part of the Hispanic population, the Mexican population is largely from the 
northern part of Mexico which, as history indicates, was occupied by the Olmec, Maya, 
Teotihuacan, Toltec, and Aztec Indians prior to Spanish conquest in the mid-1500s 
(Philip, 2010).  With a shared border and growing instability in the Mexican 
government, migration to the US from Mexico is a common occurrence.  According to 
the Census Bureau’s American Community Survey, approximately 29.2 million, or 
13.7% of the US population, is Mexican American and lives in the United States as 
legal US citizens (Farley and Alba, 2002).  It is estimated that there are an additional 
12-20 million undocumented immigrants currently living in the US (Farley and Alba, 
2002; History of Illegal Immigration in the U.S., 2009).  There are roughly 24 million 
people living in the state of Texas as of 2009; 36.9% of these are Mexican Americans 
(Pew Hispanic Center, 2009).  A comparative look at the allelic frequencies, the power 
of discrimination (PD), and power of exclusion (PE) between the Hispanic database and 
Native American database initially was to be reviewed with regard to the Mexican 
samples which would traditionally be reported using the Hispanic database. However, 
due to the limited amount of reagents allotted for this thesis, the original population 
study was not carried out.  The samples were used as concordance between the two 
commercial DNA kits used during the course of this work for the mock crime scene 
samples.  
2.4.3 Collection of Buccal cells from Saliva for Powder Study 
In order to eliminate the inconsistency between fingerprint deposits left by individuals 
on surfaces, either by depletion or shedder status, a decision was made to use ‘cleaned’ 
epithelial cells obtained from cheek swabs in order to provide a consistent deposit of 
cells for powder development.   Buccal swabs were collected from two unrelated 
individuals using sterile OmniSwabs (Whatman
®
).  These swabs are in addition to the 
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concordance study samples discussed in 2.4.1..  Each swab was placed into a 1.5ml tube 
containing 200μl of PBS 1X solution and vortexed vigorously for 1 minute.  The swab 
was removed from the tube and spun at 12,000rpm for 1 minute.  The supernatant was 
removed from the tube leaving the remaining buccal “pellet” which was suspended 
again in 200μl of PBS solution by vortexing vigorously. This process was repeated 
twice to remove the amylase from the saliva leaving the buccal cells (McClintock 
2014). 
 
2.4.3.1 Epithelial Cell Dilutions (Limit of Detection) 
A buccal swab was taken from an individual in accordance with the protocol outlined in 
Section 2.4.2.  The sample was diluted using the following ratios: x2, x10, x50, x100, 
x150 and x200 with amplification grade water (Frégeau et al., 2000).  DNA was 
extracted using the QIAamp
®
 DNA Mini extraction kit.  A second set of samples was 
prepared for direct amplification with the same dilutions and pre-treated with Swab 
Solution™.  They were then amplified in triplicate using the half-reaction protocols for 
Promega
®
 PowerPlex
®
 16HS
 
and Promega
®
 PowerPlex
®
 18D, respectively (Section 
2.5.5). 
 
2.4.3.2 Preparation of Epithelial Cells Recovered from Substrates 
Laminate flooring tiles were obtained in two colours, black and white.  These were used 
as the substrates for this experiment.   Each flooring tile was cut into roughly 1.5-2 inch 
squares and cleaned with deionized water and 2% (v/v) bleach solution then UV 
irradiated in a cross-linker for 30 minutes before use.  Once the substrates were 
prepared, 3 samples were created for each individual utilizing 20µl of the x10 epithelial 
cell dilution: small stains were created on the laminate flooring tiles and the area that 
the stain encompassed was circled with a black permanent marker.  The samples were 
allowed to dry for 24 hours in a dry secure area.  After the stains dried, standard black 
powder and magnetic black powder were applied to the white laminate squares and the 
white standard powder was applied to the black laminate squares.  Each of the squares 
was photographed and labelled.  Once the photographs were complete, each square was 
swabbed individually using the dual swab technique. The samples were amplified in 
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triplicate for the autosomal STR kits being tested, Promega
®
 PowerPlex
®
 16HS
 
and 
Promega
®
 PowerPlex
®
 18D. 
 
2.4.4 Collection of Blood Samples for Simulated Forensic Samples 
Two samples of human blood were collected from 2 unrelated individuals using 
Vacuette
®
 EDTA tubes by a licensed registered nurse.  The samples were labelled 
“BIOHAZARD” and stored at 4°C.   
 
2.4.4.1 Blood Dilutions (Limit of Detection) 
A whole blood sample was drawn from an individual in accordance with the protocol 
outlined in Section 2.4.4.  The blood was then diluted with distilled water at the 
following ratios: x2, x10, x50, x100, x150 and x200 (Frégeau et al., 2000). The DNA 
was then extracted from the blood samples using the Qiagen DNA extraction method as 
described in Section 2.5.1. Samples were then amplified in triplicate using the 
Promega
®
 PowerPlex
®
 16HS kit. 
A second set of samples was prepared with the same dilutions and pre-treated with 
Swab Solution (Section 2.5.2).  They were then subjected to amplification using the 
Promega
®
 PowerPlex
®
 18D. Each sample was amplified in triplicate. 
2.4.4.2 Preparation of Human Blood Samples on Substrates 
Approximately 20μl of x1 blood was applied to various substrates and lightly spread 
using a thin glass spatula.  The substrates listed in Section 2.3 were selected based on 
their common occurrence at crime scenes, and as substrates which had been previously 
processed without enhancement chemicals using a direct amplification system (Frégeau 
et al., 2000; Swaran and Welch, 2012).  All were prepared in triplicate.  The x1 blood 
samples were then diluted to x2 and x10, respectively.  The substrate preparation 
process was repeated for the x2 and x10 dilutions.  All surfaces were photographed 
prior to exposure to blood enhancement chemicals.  All samples were allowed to dry for 
24 hours prior to processing.   
After the 24 hour period, samples to be enhanced with amido black (acid black 1) were 
sprayed with the chemical and allowed to process for 1 minute.  Once the processing 
was complete, the substrates were then rinsed with amplification grade water and 
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allowed to dry at room temperature.   Gypsum wood and raw wood were not used with 
this chemical as amido black is not suitable for porous substrates due to the rinse step. 
All selected samples developed with leucocrystal violet (LCV) were exposed to the 
chemical via spray.  Once a reaction was visualized as the stain turned purple, no further 
chemical was deposited.  Since LCV does not have a rinse step, all substrates selected 
for this study were processed. 
Samples to be processed with ninhydrin were sprayed with the chemical and left to dry 
overnight.  No heat was applied to the sample.  ninhydrin is only used on porous 
surfaces; therefore, only gypsum wood and raw wood were processed using the 
chemical. 
Table 2.1 details each chemical and the substrates which were processed.  All developed 
blood enhanced stains were then photographed again to document the reaction of the 
chemical and swabbed using the double swab method (Sweet et al., 1997). 
Table 2.1:  Chemical enhancement techniques and their corresponding substrates. 
Chemical (Name Abbreviation) Substrates 
Leucocrystal Violet (LCV) Tile, Plastic, Lead, Glass, Laminate, Gypsum Board, Raw Wood 
Amido Black (AB) Tile, Plastic, Lead, Glass, Laminate 
Ninhydrin (NIN) Gypsum Board, Raw Wood 
 
2.5 Profiling of Human DNA  
2.5.1 Extraction of human DNA  
2.5.1.1 DNA extraction of Omni Swabs 
Extraction of buccal swabs was conducted using the QIAamp
®
 DNA Mini kit in 
accordance with the manufacturer’s recommended procedure and utilizing all solutions 
supplied with the kit (Qiagen, 2011).  Each swab was placed into a sterile, 2ml micro 
centrifuge tube and 600μl of 1X PBS was added.  Samples were then briefly mixed by 
vortexing and quickly centrifuged.  The swabs were then removed and discarded.  20μl 
of Proteinase K and 600μl of Buffer AL were added to each of the tubes.  The samples 
were mixed by vortexing and briefly centrifuged.  The samples were allowed to 
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incubate at 56°C for 10 minutes.  Following incubation, 600µl of 100% (v/v) ethanol 
was added to each of the tubes, which were mixed again and quickly centrifuged to 
remove any droplets which may be present in the cap of the tube.  
A QIAGEN
®
 Spin Column was placed in a correspondingly labelled collection tube and 
approximately 700μl of the sample mixture was added to the spin column.  Each sample 
was centrifuged at 8,000rpm for 1 min and the contents located at the bottom of the 
collection tube were discarded. This step was repeated until the entire sample mixture 
had been filtered.  Each QIAGEN
®
 Spin Column was then transferred to a clean 2ml 
tube and 500μl of Wash Buffer AW1 was then added to the column. The column was 
centrifuged at 8,000rpm for 1 min. The contents in the collection tube were discarded.  
The column was placed into a clean collection tube.  500μl of Wash Buffer AW2 was 
added to the column and centrifuged at 8,000rpm for 1 minute at room temperature. 
Each of the sample columns was finally placed in a sterile labelled 1.5 ml 
microcentrifuge tube.  100μl of Buffer AE was added to the column.  The sample was 
allowed to incubate at room temperature for 1 minute and then centrifuged at 8,000rpm 
for 1 minute.  All samples were stored at 4°C until use. 
2.5.1.2 DNA extraction from Cotton Swabs 
Extraction from cotton swabs was carried out as described in section 2.5.1.1 with the 
following modification: Buffer AL and Ethanol were both reduced to 400μl (Qiagen,  
2011). 
 
2.5.1.3 DNA extraction of Blood Samples 
Extraction of buccal swabs was conducted using the QIAamp
®
 DNA Mini kit (Qiagen) 
in accordance with the manufacturer’s recommended procedure (Qiagen, 2011).  For 
each sample, 20μl of Proteinase K was added to a sterile labelled 2ml microcentrifuge 
tube.  200μl of each whole blood sample was then added to each tube.  Where the 
sample was less than 200µl, PBS was added to the sample for a final volume of 200µl.    
Again, the extraction procedure was carried out as described in section 2.5.1.1 with the 
following modification: Buffer AL and Ethanol were both reduced to 200μl. 
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2.5.2 Pre-treatment of Direct Amplification Samples 
Samples which were processed using the direct amplification protocol were pre-treated 
with Swab Solution™ (Promega® 2013) according to the manufacturer’s 
recommendations (Promega Corporation, 2015).  Each swab was placed in a 1.5ml tube 
with 500ml of Swab Solution™ (Promega® 2013).  The tubes were then incubated at 70 
°C for 30 min.  Samples were stored at 4 °C. 
 
2.5.3 Quantification of DNA using NanoDrop 2000  
 Extracted human biological samples were quantified using the NanoDrop 2000 
(Thermo Fisher Scientific).  The NanoDrop 2000 is a spectrophotometer which 
measures the absorbption of light at specific wavelengths by biological molecules; 
absorption is expressed in nanometres (Thermo Fisher Scientific, 2009).  Purification of 
the samples through DNA extraction is a necessity when working with nucleic acid 
samples in order to ensure accurate results.  Generally, nucleic acids have absorbance 
maxima at 260 nm and proteins at 280 nm, and absorbance is proportional to the total 
concentration of the molecule. 1μl of extracted DNA solution was placed on the 
receptor and the concentration and quality of the sample assessed using the nucleic acid 
concentration (derived from the absorbance at 260 nm) and the 260/280 ratio (Thermo 
Fisher Scientific, 2010). A ratio of 1.8 is generally accepted as ‘pure’ DNA (Thermo 
Fisher Scientific, 2007; Thermo Fisher Scientific, 2009).  Ratios significantly higher or 
lower could indicate the presence of phenol, proteins, or other contaminants.  A blank 
was run after every ten samples to ensure a proper reading but this is not reflected in the 
list of data.    
 
2.5.4 Haematocrit Counts 
For the mock forensic samples that were not extracted, the two blood samples and two 
epithelial samples were quantified using haematocrit counts.  Haematocrit counts were 
necessary in order to approximate the amount of DNA in each sample.  As the samples 
were amplified in their raw state, i.e. not extracted and purified, the use of the 
NanoDrop 2000 (Thermo Fisher Scientific) was not possible. A microscope slide 
specifically designed for haematocrit counting was cleaned with 97% (v/v) ethanol and 
rinsed with deionized water.  The slide was then allowed to dry at room temperature.  
Both epithelial cell samples were then diluted x10, placed on the slide and stained using 
41
 
 
 
 
 
hematoxylin and eosin for visualization.  A cell count was then conducted.  Each sample 
was counted in triplicate and the average of the cells taken in order to quantify each 
sample.  
 
2.5.4.1 Staining of Epithelial Cells 
Ehrlich’s haematoxylin and eosin (H&E) was used to stain the epithelial cells in order 
for them to be counted.  This method was used to stain the nuclei within cells blue. The 
red blood cells, cytoplasm, and connective tissue which were also present were stained 
red/pink.  The protocol and staining supplies were obtained from the University of 
Central Lancashire laboratory technician. The recipes for the solutions as dictated in the 
instruction sheet can be found in Appendix 2 (Avwioro, 2011).  As described in section 
2.5.4, the slides were allowed to dry and Ehrlich’s haematoxylin was applied and the 
sample exposed for 15 minutes.  After 15 minutes, the slide was gently rinsed with 
distilled water then again with Scott’s tap water for 3 minutes. (Scott’s tap water is a 
blueing reagent designed for histology and cytology.) The slide was then stained with 
alcoholic eosin for 3 minutes.  After 3 minutes, an absolute alcohol rinse was applied to 
dehydrate the sample.  The stain was mounted by placing a small drop of  a glue-like 
substance (histomount) to the stain and then a clear cover slide was placed over the 
stain. 
 
2.5.5 Controls 
Negative control samples were conducted using PBS 1X, blank swabs, and the Swab 
Solution.  Extraction negatives were conducted with each set of extracted samples.  
Positive controls were conducted and analysed with each amplification run using 
Promega
®
 2800M positive control for both direct amplification and extracted samples. 
For all substrates processed with chemicals (i.e. tile, plastic, lead, glass, laminate, 
gypsum board, raw wood), a positive control was conducted by placing each of the 
samples on the substrate and swabbing without any chemical processing. 
Commercial internal lane standards with known fragment sizes were used with all 
samples analysed for this project.  Internal lane standard ILS600, was run with all 
samples analysed with PowerPlex
®
 16HS.  CC5 ILS500, internal lane standard, was run 
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with every sample analysed with PowerPlex
®
 18D.  Multiple allelic ladders were run 
with each plate of samples placed on the genetic analyser.  A ladder correctly 
identifying all alleles above the minimum threshold was used for analysis and 
identification of alleles.  All samples were analysed at a 50 RFU threshold.  
2.5.6 Amplification using Promega
®
 PowerPlex
®
 16HS and PowerPlex
®
 18D
 
Throughout the project, human DNA was amplified using the human identification kits 
Promega
®
 PowerPlex
®
 16HS and Promega
®
 PowerPlex
®
 18D. 
 
2.5.6.1 Amplification with Promega
®
 PowerPlex
®
 16HS 
2.5.6.1.1 Amplification at full volume reactions (25μl) 
Full volume reactions were run at 25µl. Samples were prepared as described by the 
manufacturer, with 5µl of the Promega
®
 PowerPlex
®
 16HS Master Mix, 2.5µl 
Promega
®
 PowerPlex
®
 16HS Primer Mix, 15.5µl nuclease-free water and 2µl of DNA. 
 
2.5.6.1.2 Amplification at reduced reaction volume (12.5μl) 
Reduced volume reactions were run at 12.5µl. Samples were prepared as described by 
the manufacturer using half of the stated volumes, i.e. 2.5µl of the Promega
®
 
PowerPlex
®
 16HS Master Mix, 1.25µl Promega
®
 PowerPlex
®
 16HS Primer Mix, 8.25µl 
nuclease-free water and 1µl of DNA.   The following table (Table 2.2) describes of the 
cycling parameters used.  
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Table 2.2: Promega
®
 PowerPlex
®
 16HS cycling conditions for a 32 cycle program. 
PCR Stages Temperature Time  
 
Initial Incubation 
 
96 °C 
 
2 min 
 
Denaturation 94 °C 30 sec 
10 Cycles Amplification 60 °C 30 sec 
Extension 70 °C 45 sec 
Denaturation 90 °C 30 sec  
Amplification 60 °C 30 sec 22 Cycles 
Extension 70 °C 45 sec  
Final Incubation 60 °C 30 min  
Hold 4 °C ∞  
 
2.5.6.2 Amplification with Promega
®
 Powerplex
®
 18D 
Promega
®
 PowerPlex
®
 18D is a direct amplification system which is being tested for its 
concordance against an already used kit as well as its robustness when using forensic 
based samples. 
 
2.5.6.2.1 Amplification at full reaction volume (25μl) 
Amplification of human DNA with the Promega
®
 PowerPlex
®
 18D human 
identification kit was carried out as described by the manufacturer. For each reaction, 
5μl of Promega® PowerPlex® 18D Master Mix 5X (the Master Mix included AmpliTaq 
Gold), 5μl of Promega® PowerPlex 18d® 5X Primer Mix and 13μl of Promega® 
PowerPlex
®
 18D nuclease-free water were mixed with 2μl of human DNA. Together 
with the DNA samples, the appropriate positive and negative controls were prepared.  
 
2.5.6.2.2 Amplification at reduced reaction volume (12.5μl) 
Half volume, 12.5µl amplification reaction with Promega
®
 PowerPlex
®
 18D human 
identification kit was carried out using 2.5μl of Promega® PowerPlex® 18D Master Mix 
5X (the Master Mix included AmpliTaq Gold), 2.5μl of Promega® PowerPlex® 18D 5X 
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Primer Mix and 6.5μl of Promega® PowerPlex® 18D nuclease-free water, mixed with 
1μl of human DNA for a final volume of 12.5μl. Together with the DNA samples, the 
appropriate positive and negative controls were prepared. Samples were then vortexed, 
spun down and amplified using the conditions outlined in Table 2.3. 
 
2.5.7 Fragment analysis by capillary electrophoresis  
This section describes the analysis of PCR products by capillary electrophoresis (CE) 
with the ABI Prism
®
 3130 and 3500.   
 
2.5.7.1 Preparation of samples for CE 
Amplified PCR products, allelic ladders and CE blanks were prepared in tubes by 
mixing 1µl of the sample with 9.5µl of Hi-Di formamide and 0.5µl of either ILS 600™ 
for Promega
®
 PowerPlex
®
 16HS
 
or CC5 ILS 500 for Promega
®
 PowerPlex
®
 18D to 
give a total volume of 11.0µl. Tubes were then vortexed, centrifuged, covered with 
septa, and denatured at 94 °C for 2 min. After denaturation, tubes were immediately 
transferred onto ice and allowed to stand for 5 min before being loaded onto the 
instrument.  
2.5.7.2 Sample analysis using the Genetic Analyser  
Electrophoresis was performed on the ABI Prism
®
 3130 or 3500 machine through POP-
6
™
 polymer using a 50 cm capillary and Running Buffer (1X). The position of each 
sample was entered onto the sample sheet and the appropriate dye for the internal 
standard was selected.  
Table 2.3 Promega
®
 PowerPlex
®
 18D cycling conditions for a 27 cycle program. 
PCR Stages Temperature Time  
 
Initial Incubation 
 
96 °C 
 
2 min 
 
Denaturation 94 °C 10 secs 
27 Cycles 
Amplification 60 °C 1 min 
Final Incubation 60 °C 20 min  
Hold 4 °C ∞  
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2.5.7.3 Analysis of DNA profiles 
Results were analysed using GeneMapper
®
 ID v3.2 or ID-X. Parameters for the analysis 
of the PCR products were those described in Table 2.4. The analysis range and the size 
call range were defined for each run. All other factors were kept constant. The CE blank 
was used to define the internal standard for each run.  
 
Table 2.4: Conditions for the electrophoresis run.  
 
Parameters Value  
Injection time  5 s 
Injection voltage 15 kV 
Run Voltage 15 kV 
Temperature  60 °C 
Run Time  30 min 
 
Table 2.5: Parameters for the analysis of PCR fragments when utilizing the ABI 
3500 and GeneMapper ID-X software. 
Parameter Value 
Analysis Range Variable 
Size Call Range Variable 
Data Processing None 
Size Calling Method Local Southern 
Peak Detection 50 RFU 
Baselining 251 pts 
Min Peak Half Width 2 pts 
Polynomial Degree 3 pts 
Peak Window Size 19 pts 
Peak Window Size Slope Threshold for peak start / end 0-0 
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Table 2.6: Parameters for the analysis of PCR fragments when utilizing the ABI 
3130 and GeneMapper v3.2 software for analysis. 
Parameter Value 
Analysis Range Variable 
Size Call Range Variable 
Data Processing None 
Size Calling Method Local Southern 
Peak Detection 30 RFU 
Baselining 251 pts 
Min Peak Half Width 2 pts 
Polynomial Degree 3 pts 
Peak Window Size 19 pts 
Peak Window Size Slope Threshold for peak start / end 0-0 
2.6 Analysis of results 
All the data presented are summaries of the raw data obtained. The raw data are 
referenced in the Appendix 3, while the actual values can be found on the 
complementary CD attached to this report in the folder called Data. The genotypes of 
the human DNA that were used throughout the various studies can be found in Appendix 
4.  
Tables of results represent a summary of raw data, and in most cases DNA profiles are 
expressed in terms of minimum, maximum and average peak heights and profile type. 
Minimum peak height is the peak height of the allele showing the lowest RFU which 
meets the analysis parameters; maximum peak height is the peak height of the allele 
showing the highest RFU which meets the analysis parameters; average peak height is 
the average RFU of all the alleles in a profile. Peak height ratios express the balance of 
the heterozygous peaks which are present at a specific locus in a percentage. 
The profile types describe the type of profile obtained i.e. full profile (FP), partial 
profile (PP) and no profile (NP). In case of PP, the number of loci completely 
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genotyped is indicated utilizing replicates and the “2 of 3” system to determine each of 
the called loci. A locus was considered complete if all the expected alleles in the loci 
were identified.  
2.7 Statistical analysis  
In order to investigate differences between the samples, statistical analysis was done on 
peak heights (RFU) of replicates. Calculation of averages and standard deviation (s.d.) 
were carried out using Excel 2010. MiniTab v17 was used to perform statistical analysis 
such as one-way ANOVA with α=0.05. Table of results for the statistical analyses are 
referenced in the relevant chapters and in Appendix 3. Minitab projects were created for 
each area where statistical analysis occurred.  The actual outputs of the calculations can 
be found in the complementary CD attached to the report under the folder Data. Each 
area of analysis has a dedicated folder. For example, data for the chemicals is referenced 
under the folder labelled (Data Chemicals). 
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CHAPTER 3. 
SENSITIVITY STUDY 
-REDUCED VOLUME AND DILUTION DETERMINATION- 
 
3.1 Overview 
Human identification kits such as Promega’s PowerPlex® 16 have been optimized for 
forensic use. This type of kit allows for the amplification of a small amount DNA to be 
replicated with multiple loci that contain fluorescently labeled primers.  PCR products 
can then be processed on an automated generic analyzer which provides a faster 
development of DNA profiles (Krenke et al., 2002; Spathis and Lum, 2008). Further 
research and development of the components within human identification kits have led 
to the production of products which are even more tolerant to PCR inhibitors and some 
can even be used in a ‘direct’ manner which skips the extraction and quantitation steps 
previously needed for development of DNA profiles (Oostdik et al., 2013; Ensenberger 
et al., 2013). 
Promega’s PowerPlex® 16HS was the first in the list of Promega’s products to contain 
the improved master mix.  The kit still contains Taq DNA polymerase and the same 
primers and dyes as the previous version of PowerPlex
®
 16 (Ensenberger et al., 2010)  
The optimized mater mix allows for the kit to overcome common PCR inhibitors seen 
in forensic type samples.  PowerPlex
®
 18D followed in 2010 as a human identification 
system specifically designed for direct amplification. PowerPlex
®
 18D can be used with 
extracted samples; however, the validation confirms the optimization of the kit was 
based direct sample and utilizing extracted samples is not recommended (Oostdik et al., 
2011 and 2013).  The validation also discusses the components of the kit which contain 
primers from two kits currently on the market (discussed further in Chapter 4), DNA 
polymerase and optimized magnesium concentrations within the reaction mix.  
The manufacturer recommendations for full volume reactions with both Promega’s 
PowerPlex
® 
16HS and PowerPlex
® 
18D were to utilize 25μl for a final DNA 
concentration of 0.5-1.0 ng/μl.   Lower DNA concentrations have been noted to develop 
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full profiles but the frequency of imbalanced peaks and allele drop also increased.  The 
utilization of a 25μl reaction is not cost effective for this work; therefore, in order to 
maximize resources available, the PCR reaction mix was reduced by half, 12.5μl.  
Published data for both kits indicate that reduced volume reactions are achievable and 
produce reliable results (Oostdik et al., 2013; Hoffman and Fenger, 2010).  The first 
part of this chapter aims to confirm the published information regarding the effects of 
reducing the PCR volume.   
This project aims to conduct a comparative preliminary evaluation of Promega’s 
PowerPlex
®
 16HS and PowerPlex
® 
18D in order to determine if direct amplification 
was a viable option for forensic samples which have been exposed to various processing 
techniques.  While these samples are usually found in very minute concentrations, it 
was the goal to evaluate the products with an adequate amount of DNA to determine if 
inhibition of the enhancement materials were apparent.  During the course of this 
project two sample types were used, epithelial cells and whole blood.  The amount of 
DNA which can be yielded from each of these sample types differs based in the 
individual (Raymond et al., 2009; Sewell et al., 2008; Compté et al., 2015).  It was 
imperative to find dilutions which gave a full genetic profile above the 50 RFU 
threshold in order to move forward with the enhancement of the substrates.       
The primary goals for this chapter were to, 
1. Determine if half reaction volumes are a viable option for this work; 
2. Identify the dilutions which produce a full profile above the 50 RFU threshold 
when processing samples composed of epithelial cells; 
3. Identify the dilutions which produce a full profile above the 50 RFU threshold 
when processing samples composed of whole blood. 
3.2 Experimental Design 
3.2.1 Evaluation of Full (25 µl) and Half (12.5 µl) Reactions using Decreasing 
         Amounts of DNA Template 
Amplification of human control DNA 2800M was carried out utilizing both kits at full 
(25µl) and half (12.5µl) reactions to explore the effect of reducing the PCR volume on 
the quality of DNA profiles generated and on the sensitivity of the assay. Different 
amounts of standard human DNA (0.06 ng, 0.13 ng, 0.25 ng, 0.5 ng, 1 ng and 2 ng) 
were amplified in (standard) 25μl reactions and (reduced) 12.5μl reactions and analyzed 
on ABI 3500 as described in Chapter 2, Section 2.5.7.3. Each sample type was prepared 
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in triplicate.  The raw data can be found in Output Data.  ANOVA statistical analysis 
was conducted to evaluate the difference between volume groups as well as the two 
kits. 
The amplification of the standard human DNA 2800M with PowerPlex
®
 16HS gave a 
profile with twelve heterozygous and three homozygous loci and an XY for 
amelogenin. PowerPlex
®
 18D gave the same profile with an additional two 
heterozygous loci, D19 and D2, respectively.  The allele calls for each locus can be seen 
in Table 3.1  The effect on the amplification efficiency and assay sensitivity were 
evaluated using peak heights and /allele drop-out. These were used to monitor the 
variation in amplification efficiencies between the different PCR volumes at constant 
DNA concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 Sensitivity of Epithelial Cell Samples 
One sample containing epithelial cells was prepared using the procedure outlined in 
section 2.4.3.1 for amplification.  A comparative analysis using both kits in a series of 
sample dilutions was used to aid in determining the amount of retrievable DNA from 
Table 3.1:  Known genetic profile for 2800M. 
Locus Allele Call  
D3S1358 17,18  
TH01 6, 9.3  
D21S11 29, 31.2  
D18S51 16, 18  
Penta E 7, 14  
D5S818 12  
D13S317 9, 11  
D7S820 8,11  
D16S539 9, 13  
CSF1PO 12  
Penta D 12, 13  
Amel X, Y  
vWA 16, 19  
D8S1179 14,15  
TPOX 11  
FGA 20,23  
D19S433 13,14  
D2S1338 22,25  
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the epithelial cell samples. Dilutions were carried out at x2, x10, x50, x100, x150 and 
x200.  Half volume reactions of 12.5μl were used for all samples.  The sample was 
quantified using a cell count described in 2.5.4. Each sample type was prepared in 
triplicate.   
The amplification of the sample with PowerPlex
®
 16HS gave a profile with eight 
heterozygous and six homozygous loci and an XX for amelogenin. PowerPlex
®
 18D 
gave the same profile with additional homozygous and heterozygous loci, D19 and D2, 
respectively.  The allele calls for each locus can be seen in Table 3.2.  The effect on the 
amplification efficiency and assay sensitivity were evaluated using peak heights and 
allele drop-out. These were used to monitor the variation in amplification between the 
different PCR volumes. 
Table 3.2:  Known genetic profile for epithelial cell sample. 
Locus Allele Call  
D3S1358 17, 18  
TH01 7  
D21S11 30.2, 32.2  
D18S51 14, 19  
Penta E 7, 17  
D5S818 11  
D13S317 11, 13  
D7S820 8, 10  
D16S539 11  
CSF1PO 10, 11  
Penta D 12  
Amel X  
vWA 14  
D8S1179 12  
TPOX 11  
FGA 22, 24  
D19S433 15  
D2S1338 17, 25  
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3.2.3 Sensitivity of Blood Samples 
One sample which contained whole blood in an EDTA tube was prepared using the 
procedure outline in 2.4.4.1. A comparative analysis using both kits in a series of 
sample dilutions was used, as in the epithelial cell samples, to aid in determining the 
amount of retrievable DNA from the whole blood samples. Dilutions were carried out at 
x2, x10, x50, x100, x150 and x200. 
The amplification of the single sample with PowerPlex
®
 16HS gave a profile with eight 
heterozygous and six homozygous loci and an XX for amelogenin. PowerPlex
®
 18D 
gave the same profile with two additional heterozygous loci, D19 and D2, respectively.  
The allele calls for each locus can be seen in Table 3.3.  The effect on the amplification 
efficiency and assay sensitivity were evaluated in the same manner as the epithelial 
cells in section 3.2.2. These were used to monitor the variation in the amplification 
between the different PCR volumes. 
Table 3.3:  Known genetic profile for whole blood sample. 
Locus Allele Call  
D3S1358 17, 18  
TH01 7  
D21S11 30.2, 32.2  
D18S51 14, 19  
Penta E 7, 17  
D5S818 11  
D13S317 11, 13  
D7S820 8, 10  
D16S539 11  
CSF1PO 10, 11  
Penta D 12  
Amel X  
vWA 14  
D8S1179 12  
TPOX 11  
FGA 22, 24  
D19S433 15  
D2S1338 17, 25  
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3.3 Results 
3.3.1 Results of Reduced Volume on PCR Product 
Using both PowerPlex
®
 16HS and PowerPlex
® 
18D, amplification of human DNA 
(2800M) was carried out in decreasing reaction volumes to examine the effects of 
reducing the PCR volume on the quality of the DNA profiles which were generated.  
Reactions were carried out for both kits using 25μl and 12.5μl total reaction volumes for 
varying amount of DNA input; 0.06 ng, 0.13 ng, 0.25 ng, 0.5 ng, 1 ng, and 2 ng.  All 
samples were run in triplicate.  The raw data can be found in Output Data.  ANOVA 
statistical analysis was conducted to evaluate the difference between volume groups as 
well as the two kits. 
The PCR product concentration and total PCR product were used to evaluate the 
efficiency of the amplifications at lower volumes for both kits.  The total PCR product 
(in RFU) is calculated by summing the peak heights for all alleles for each of the 
samples at a specific volume.  The total PCR product is then divided by the final 
volume in order to obtain the PCR product concentration (in RFU/μl) (Gaines et al., 
2002). The total PCR product and PCR product concentration can be seen in Tables 3.4 
for PowerPlex
®
 16HS and 3.5 for PowerPlex
®
 18D. 
It was observed that as the final DNA concentration was lowered the peak height 
averages and maxima were also decreased for both kits.  This was to be expected as the 
concentration of target DNA was being reduced. The difference in concentration of the 
total PCR for both kits was not statistically significant when evaluating full versus half 
reactions [F(1, 10)= 2.53, p-value= 0.143].  The half volume reactions in most cases 
gave a higher final PCR product concentration.  Tables 3.4 and 3.5 reflect the data 
generated from PowerPlex
®
 16HS and PowerPlex
®
 18D in regards to full versus half 
reactions. The quality of a DNA profile is assessed a number of ways including the 
evaluation of heterozygous peak height balance (peak height ratio or heterozygote 
balance (Hb) calculation), level of stutter, and other artefacts such as spikes, dye blobs, 
and pull-ups which can all interfere with the interpretation of the profile.  Overall, the 
peaks which were generated with the amplification standard (2800M) were of good 
quality.  Split peaks were noted in profiles generated with 2.0 ng of DNA at the 12.5μl 
reaction volume and 2.0 ng at the 25μl reaction volume.  On occasion spikes, sharp 
peaks which are very intense and appear equally in all dye channels, were also seen in 
the data; however, upon reinjection these peaks were no longer visible. 
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A key factor in assessing the effect of profile quality is determining the heterozygous 
peak balance (Hb), which is the ratio of the two peaks in each heterozygous locus. This 
is calculated by dividing the allele with the lower peak height by the allele with the 
higher peak height (Fourney et al., 2004; Kelly et al., 2012).  For the purpose of this 
project, peak height was assessed since single-source samples were used and ˃0.70 set 
as the threshold for acceptable heterozygous peak balance (Hb) (Gill et al., 1997).  
 This gives a value ranging from 0 to 1 with 1 representing peaks of equal height 
(Fourney et al., 2004; Gill et al., 1997).  Hb values which are lower than 0.70 indicate 
peak imbalance.  Figure 3.4 depicts heterozygous loci which were processed with 
PowerPlex
®
 16HS in full and half reaction volumes.  Figure 3.5 depicts heterozygous 
loci which were processed with PowerPlex
®
 18D in both full and half reactions.  Figure 
3.3 compares the peak height ratios from each of the volumes for individual 
heterozygous loci processed with PowerPlex
®
 16HS.  Figure 3.4 compares the peak 
height ratios from each of the volumes for individual heterozygous loci processed with 
PowerPlex
®
 18D. 
Overall the samples with the lowest DNA concentrations, ones which fell below 0.01 
ng, were below the 0.70 Hb limit more often than samples with higher concentrations.  
When comparing the two kits, PowerPlex
®
 16HS gave a larger number of peak 
imbalances than PowerPlex
®
 18D (Figures 3.1 and 3.2).  PowerPlex
®
 18D when 
processed with a total volume reaction of 25μl failed to produce any samples over the 
Hb limit of 0.70 when using DNA concentrations of 0.01 ng and 0.005 ng.  The 12.5μl 
samples were slightly more successful with several samples processed with 0.01 ng 
were observed above the limit.  The correct allele calls for the known profile (2800M) 
were produced for all developed samples. 
55
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4:   Results showing the minimum, maximum and average peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of 2800M amplified using whole (25μl) and half (12.5μl) reactions with and PowerPlex® 16HS. 
The values are averages of three replicates. 
Volume 
(in μl) 
DNA added 
(in ng) 
Final 
[DNA] 
(in ng/μl) 
Profile Properties Total PCR product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH Average PH Profile Type 
12.5 
0.06 0.0025 -- --  -- NP  -- --  
0.13 0.005 977 (s.d. 134.1)  64 (s.d. 4.04) 243.9 FP 19509 (s.d. 1375.0)  1560.72 (s.d. 125.0)  
0.25 0.01  1313 (s.d. 161.1) 66 (s.d. 37.0) 403.1 FP 34667 (s.d. 1125.7) 2773.4 (s.d. 102.3) 
0.5 0.02  4540 (s.d. 802.4) 287 (s.d. 91.3) 1065.3 FP 92681 (s.d. 9951.6) 7414.5 (s.d. 1065.3) 
1.0 0.04 3428 (s.d. 1200.8)  152 (s.d. 110.7) 1205.7 FP 104910 (s.d. 12014.2)  8392.8 (s.d. 1092.2) 
2.0 0.08  12591 (s.d. 1593.4) 1254 (s.d. 739) 5416.8 FP 471258 (s.d. 31314.2) 37700.6 (s.d. 2846.7) 
25 
0.06 0.005 113 (s.d. 40.3)  50 (s.d. 4.6) 80.0  PP1 1921 (s.d. 410.6) 76.8 (s.d. 37.3) 
0.13 0.01 461 (s.d. 129)  50 (s.d. 5.5) 119.0  PP13 8808 (s.d. 392.3) 325.3 (s.d. 35.7) 
0.25 0.02 1019 (s.d. 261.6)  50 (s.d. 1.5) 200.1  FP 17411 (s.d. 492.8) 696.4(s.d. 44.8) 
0.5 0.04  1365 (s.d. 147.6) 109 (s.d. 36.3) 407.6  FP 35464 (s.d. 1145) 1418.6 (s.d. 104.1) 
1.0 0.08  3069 (s.d. 218.3) 293 (s.d. 82.1) 886.2  FP 77103 (s.d. 1147.0) 3084.1 (s.d. 104.1) 
2.0 0.16  8010 (s.d. 898.8) 955 (s.d. 377.7) 3157.3  FP 274688 (s.d. 8948.3) 10987.52 (s.d. 1047.8) 
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Table 3.5:  Results showing the minimum, maximum and average peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of 2800M amplified using whole (25μl) and half (12.5μl) reactions with and PowerPlex® 18D. 
The values are averages of three replicates.  
Volume 
(in μl) 
DNA 
added 
(in ng) 
Final 
[DNA] 
(in ng/μl) 
Profile Properties Total PCR product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH Average PH Profile Type 
12.5 
0.06 0.0025 105 (s.d. 60.6) 105 (s.d. 60.2) 105 NP 105 (s.d. 0) 8.4 (s.d. 5.5) 
0.13 0.005 338 (s.d. 54.2) 100 (s.d. 4.93) 150.5 PP5 1425 (s.d. 231.5) 114 (s.d. 45.4) 
0.25 0.01 559 (s.d.91) 102 (s.d. 1.15) 205.25 PP8 14208 (s.d. 845.9) 1136.6 (s.d. 55.4) 
0.5 0.02 1035 (s.d. 89.2) 102 (s.d. 8.4) 293.93 PP16 37238 (s.d. 3035.2) 2979.0 (s.d. 152.9) 
1.0 0.04 2902 (s.d. 441.1) 110 (s.d. 19.5) 638.35 FP 86728 (s.d. 4099.9) 6938.2 (s.d. 247.1) 
2.0 0.08 4473 (s.d. 873.4) 108 (s.d. 45.3) 1112.64 FP 110151 (s.d. 8725.4) 8812 (s.d. 793.2) 
25 
0.06 0.005 218 (s.d. 109.1) 102 (s.d. 63.7) 144 PP1 688 (s.d. 301.6) 27.52 (s.d. 27.4) 
0.13 0.01 213 (s.d. 48.5) 100 (s.d. 19.2) 127.44 PP2 1147 (s.d. 350.9) 45.9 (s.d. 31.9) 
0.25 0.02 550 (s.d. 141.0) 105 (s.d. 1.5) 186.2 PP2 4097 (1365.7) 163.9  (s.d. 86) 
0.5 0.04 439 (s.d. 64.8) 102 (s.d. 11) 180.12 PP10 8465 (s.d. 495.8) 338.6  (s.d. 45.7) 
1.0 0.08 1794 (s.d. 396.3) 101 (s.d. 11.9) 405.05 PP16 35239 (s.d. 2360.2) 1409.6 (214.6) 
2.0 0.16 3612 (s.d. 1012.5) 111 (s.d. 6.2) 718.14 FP 71096 (s.d. 12632.1) 2843.8  (s.d. 774.6) 
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Figure 3.1:  Charts which depict heterozygous loci ratios at different 
concentrations when amplified at (Top) 25μl and (Bottom) 12.5μl with PowerPlex® 
16HS.  The red line indicates the 0.70 Hb threshold for the heterozygous peak 
balance.  Samples displayed are based on three replicates.  
           D3           D7          D8           D13        D16        D18         D21        FGA      Penta D   Penta E   TH01     vWA 
           D3           D7          D8           D13        D16          D18       D21           FGA     Penta D   Penta E    TH01       vWA 
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Figure 3.2:  Charts which depict heterozygous loci ratios at different 
concentrations when amplified at (Top) 25μl and (Bottom) 12.5μl with PowerPlex® 
18D.  The red line indicates the 0.70 Hb threshold for the heterozygous peak 
balance.  Samples displayed are based on three replicates.  
           D2          D3           D7           D8        D13        D1         D18          D19       D21       FGA         Penta D   Penta E    TH01     vWA 
             D2          D3           D7        D8           D13        D16        D18         D19       D21         FGA      Penta D   Penta E   TH01     vWA 
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Figure 3.3:  Graphs demonstrating the variation in the heterozygous peak balance 
ratio (Hb) for the amplification of the 25μl (green circles) and 12.5μl (blue 
diamonds) reactions for PowerPlex
®
 16HS for each individual loci.  The red line 
indicates the 0.70 threshold for the heterozygous peak balance. 
For PowerPlex
®
 16HS, D3S1358, Penta D, Penta E and TH01 were observed to have 
the most imbalanced peaks when analysed with a total volume of 25μl.  D2 and Penta D 
also struggled to maintain peak height balances above the threshold when processed 
with 12.5μl reactions (Figure 3.3).  In PowerPlex® 18D, D2S1338 was observed to go 
below the threshold more often than any other locus (Figure 3.4).  This trend was 
observed in both reaction volumes.   
Peak height ratios for 12.5μl reactions were more variable than those observed with the 
full volume.  DNA concentrations which were above 0.04 ng reflected good peak 
balance for both volumes tested.  Lowering the concentrations adversely affected the 
quality of the peak balance. 
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Figure 3.4:  Graphs demonstrating the variation in the heterozygous peak balance 
ratio (Hb) for the amplification of the 25μl (green circles) and 12.5μl (blue 
diamonds) reactions for PowerPlex
®
 18D for each individual loci.  The red line 
indicates the 0.70 threshold for the heterozygous peak balance. 
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3.3.2 Results of Epithelial Based Samples 
Epithelial cell samples were produced in triplicate in order to determine the dilutions to 
be used for the powder enhancement study (Chapter 5).  Samples were evaluated based 
on a 50 RFU threshold and dilutions which produced a low but consistent result for both 
kits were selected for use in further studies.  Low but consistent means the peak heights 
for the samples were close or at 50 RFU but not below this threshold for the triplicate 
sample.  For the samples in Table 3.6, dilutions x2 and x10 were observed to give full 
profiles above the threshold for PowerPlex
®
 16HS.  PowerPlex
®
 18D was more 
successful in that it was able to generate a full profile for samples x2, x10, and x50.  
However, since the x50 dilutions in the PowerPlex
®
 16HS samples only produced a 
partial profile, the dilutions used for the powder study were the x2 and x10 dilutions 
only. 
While full profiles were generated for the x2 and x10 dilutions, overall peak height 
balance was observed more in PowerPlex
®
 18D and of the 18 samples ran 12 displayed 
loci which were above the 0.70 Hb threshold (Figure 3.5 (Bottom)).  PowerPlex
®
 16HS 
showed strong homozygous peaks which elevated the peak height totals and overall 
PCR product concentration date, however, of the 18 samples only 9 displayed loci 
which were above the 0.70 Hb threshold (Figure 3.5 (Top)).  Figure 3.6 displays 
electropherograms generated from both PowerPlex
®
 16HS and PowerPlex
®
 18D using 
x2 dilutions.   Figure 3.7 displays electropherograms generated from both PowerPlex
®
 
16HS and PowerPlex
®
 18D using x10 dilutions. When evaluating these numbers 
statistically, there was not found be a significant difference between the dilutions or the 
kits (p-values below 0.05) (Output Data).   The correct allele calls for the known 
epithelial cell sample were produced for all developed samples. 
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Table 3.6:  Results showing the minimum, maximum and average peak heights, the profile type, total PCR product and 
PCR concentration for the various dilutions of epithelial cells amplified at 12.5μl with PowerPlex® 16HS and PowerPlex® 
18D. The values are averages of three replicates. 
Kit Dilution 
Profile Properties Total PCR product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH Average PH Profile Type 
PP16HS 
x2 29725 (s.d. 10605.2) 71 (s.d. 665.4) 4976.1 FP 358283 (s.d. 23589.0) 28662 (s.d. 2144.5) 
x10 4522 (s.d. 753.4) 146 (s.d. 104) 1263.7 FP 90986 (s.d. 4409.7) 7278.9 (s.d. 400.9) 
x50 1179 (s.d. 401.9) 50 (s.d. 4.9) 242.6 PP12 12856 (s.d. 2685.4) 1028.3 (s.d. 244.1) 
x100 1150 (s.d. 133.7) 50 (s.d. 15.4) 240.1 PP8 10563 (s.d. 602.9) 845.0 (s.d. 54.8) 
x150 277 (s.d. 93.8) 50 (s.d. 7.1) 116.4 PP3 2794 (s.d. 468.2) 223.5 (s.d. 42.6) 
x200 245 (s.d. 92.0) 50 (s.d. 7.5) 114.8 PP2 1607 (s.d. 362.5) 128.6 (s.d. 33.0) 
PP18D 
x2 3988 (s.d. 619.1) 676 (s.d. 142.2) 1632.8 FP 132253 (s.d. 6773.8) 10580.2 (s.d. 615.8) 
x10 1654 (s.d. 335.9) 120 (s.d. 113.9) 542.5 FP 43946 (s.d. 3785.6) 3515.7 (s.d. 344.1) 
x50 409 (s.d. 193.3) 52 (s.d. 11.0) 169.6 FP 13567 (s.d. 1351.1) 1085.4 (s.d. 11.0) 
x100 256 (s.d. 28.3) 50 (s.d. 9) 110.8 PP16 6867 (s.d. 411.4) 549.4 (s.d. 37.4) 
x150 296 (s.d. 20.0) 52 (s.d. 3.5) 135.0 PP17 10123 (s.d. 472.0) 809.8 (s.d. 42.9) 
x200 160 (s.d. 28.4) 50 (s.d. 7.2) 76.0 PP6 2432 (s.d. 403.0) 194.6 (s.d. 36.6) 
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Figure 3.5:  Heterozygous loci peak height ratios for epithelial cells at different 
dilutions when amplified at 12.5μl with (Top) PowerPlex® 16HS and (Bottom) 
PowerPlex
®
 18D.  The red line indicates the 0.70 Hb threshold for the heterozygous 
peak balance.  Samples displayed are based on three replicates. 
                CSF               D13               D18                D21                 D3                  D7                FGA             Penta E 
                CSF               D13               D18                D21                 D3                  D7                FGA             Penta E 
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Figure 3.6:  Electropherograms displaying DNA profiles generated with epithelial 
cells at x2 dilution using (1) PowerPlex
®
 16HS (RFU 20,000) and (2) PowerPlex
®
 18D 
(RFU 5,000).  The x-axis represents relative fluorescent units (RFU) and the y-axis 
fragment size in base pairs. 
 
   D3S1358         TH01            D21S11                                     D18S51            Penta E 
D5S818     D13S317         D7S820            D16S539             CSF1PO   Penta D 
               Amel                 vWA                            D8S1179                     TPOX                         FGA 
D3S1358    TH01         D21S11                                 D18S51         Penta E 
          D5S818               D13S317         D7S820                  D16S539 CSF1PO                 Penta D 
                        Amel             vWA       D8S1179                       TPOX     FGA 
      D19S433                 D2S1338 
1 
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Figure 3.7:  Electropherograms displaying DNA profiles generated with epithelial 
cells at x10 dilution using (1) PowerPlex
®
 16HS (RFU 9,500) and (2) PowerPlex
®
 18D 
(RFU 5,000).  The x-axis represents relative fluorescent units (RFU) and the y-axis 
fragment size in base pairs. 
 
       D3S1358      TH01             D21S11                                         D18S539                   Penta E 
D5S818          D13S317         D7S820                D16S539             CSF1PO         Penta D 
 Amel               vWA                  D8S1179                     TPOX                 FGA 
D3S1358      TH01   D21S11                       D18S51                   Penta E 
   D5S818         D13S317     D7S820       D16S539        CSF1PO                        Penta D 
            Amel         vWA                 D8S1179                       TPOX              FGA 
      D19S433                 D2S1338 
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3.3.3 Results for Whole Blood Samples 
Whole blood samples were produced in triplicate in order to determine the dilutions to be 
used for the chemical enhancement study (Chapter 6).  Samples were evaluated based on a 
50 RFU threshold and dilutions which produced a low but consistent result for both kits 
were selected for use in further studies.  Low but consistent means the peak heights for the 
samples were close or at 50 RFU but not below this threshold for the triplicate sample.  For 
the samples in Table 3.7, all dilutions were observed to give full profiles above the 
threshold for PowerPlex
®
 16HS.  PowerPlex
®
 18D was not as successful in that it was only 
able to generate a full profile for samples x2 and x10.   
While full profiles were generated on for the  x2 and x10 dilutions using PowerPlex
®
 18D , 
overall peak height balance was observed more in PowerPlex
®
 18D and of the 9 samples 
displaying profiles, the majority of the heterozygous loci showed alleles above the 0.70 Hb 
threshold(Figure 3.8 (Bottom)).  PowerPlex
®
 16HS showed strong homozygous peaks 
which elevated the peak height totals and overall PCR product concentration date, however, 
of the 18 samples only 9 displayed loci which were above the 0.70 Hb threshold (Figure 3.8 
(Top)).  Figure 3.9 displays electropherograms generated from both PowerPlex
®
 16HS and 
PowerPlex
®
 18D using x2 dilutions.   Figure 3.10 displays electropherograms generated 
from both PowerPlex
®
 16HS and PowerPlex
®
 18D using x10 dilutions. When evaluating 
these numbers statistically, there was not found be a significant difference between the 
dilutions or the kits (p-values below 0.05) (Output Data).  The correct allele calls for the 
known whole blood sample were produced for all developed samples. 
69
 
 
 
Table 3.7: Results showing the minimum, maximum and average peak heights, the profile type, total PCR product and PCR 
concentration for the various dilutions of whole blood amplified at 12.5μl with PowerPlex® 16HS and PowerPlex® 18D. The 
values are averages of three replicates.  
Kit Dilution 
Profile Properties Total PCR product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH Average PH Profile Type 
PP16HS 
x2 32293 (s.d. 1818.1) 244 (s.d. 490.1) 6761.6 FP 567977 (s.d. 19716.1) 45438.2 (s.d. 1792.4) 
x10 17664 (s.d. 1043.0) 901 (s.d. 204.6) 4907.0 FP 412187 (s.d.137395.7) 32975.0 (s.d. 194.8) 
x50 11740 (s.d. 1270.2) 794 (s.d. 181.2) 3395.7 FP 285241 (s.d. 12898.4) 22819.3 (s.d. 1172.6) 
x100 5709 (s.d. 713.9) 334 (s.d. 145.2) 2068.0 FP 173710 (s.d. 9437.0) 13896.8 (s.d. 857.9) 
x150 9599 (s.d. 1644.7) 628 (s.d. 108.1) 2851.1 FP 239491 (s.d. 7728.4) 19159.3 (s.d. 702.6) 
x200 7063 (s.d. 860.2) 345 (s.d. 156.8) 2147.5 FP 180392 (s.d. 4392.4) 14431.4 (s.d. 399.3) 
PP18D 
x2 440 (s.d. 40.2) 51 (s.d. 4.7) 152.1 FP 12320 (s.d. 336.7) 328.5 (s.d. 26.9) 
x10 1449 (s.d. 222.5) 158 (s.d. 98.7) 543.0 FP 29323 (s.d. 4580.1) 7819 (s.d. 366.4) 
x50 2365 (s.d. 132.1) 56 (s.d.516.8) 1230.3 PP6 54133 (s.d. 9170.4) 4330.6 (s.d. 733.6) 
x100 -- -- -- NP -- -- 
x150 -- -- -- NP -- -- 
x200 -- -- -- NP -- -- 
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Figure 3.8:  Heterozygous loci peak height ratios for whole blood samples at 
different dilutions when amplified at 12.5μl with (Top) PowerPlex® 16HS and 
(Bottom) PowerPlex
®
 18D.  The red line indicates the 0.70 Hb threshold for the 
heterozygous peak balance.  Samples displayed are based on three replicates.  
                            CSF               D13               D18                  D21                 D3                  D7                FGA             Penta E 
                            CSF               D13               D18                  D21                 D3                  D7                FGA             Penta E 
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Figure 3.9:  Electropherograms displaying full profiles generated with whole blood 
cells at a x2 dilution using (1) PowerPlex
®
 16HS (RFU 20,000) and PowerPlex
® 
18D 
(RFU 10,000).  The x-axis represents relative fluorescent units (RFU) and the y-axis 
fragment size in base pairs. 
           D3S1358             TH01             D21S11                                D18S539                        Penta E 
         D5S818          D13S317         D7S820          D16S539            CSF1PO                Penta D 
 Amel               vWA      D8S1179               TPOX                 FGA 
                    D3S1358      TH01                     D21S11             D18S51                                  Penta E 
                        D5S818              D13S317     D7S820              D16S539          CSF1PO                Penta D 
            Amel         vWA              D8S1179                        
      D19S433                 D2S1338 
TPOX                        FGA                     
1 
2 
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Figure 3.10:  Electropherograms displaying full profiles generated with whole blood 
cells at a x10 dilution using (1) PowerPlex
®
 16HS (RFU 20,000) and PowerPlex
® 
18D 
(RFU 2,500).  The x-axis represents relative fluorescent units (RFU) and the y-axis 
fragment size in base pairs. 
1 2           D3S1358               TH01                    D21S11                      D18S539                        Penta E 
         D5S818              D13S317         D7S820                      D16S539                CSF1PO              Penta D 
 Amel                        vWA                       D8S1179                     TPOX                    FGA 
                    D3S1358                TH01        D21S11                                 D18S51                                         Penta E 
            D5S818                    D13S317         D7S820                 D16S539               CSF1PO                            Penta D 
            Amel                      vWA                                  D8S1179                 TPOX                                 FGA 
      D19S433                 D2S1338 
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3.3.4 Controls 
Commercial internal lane standards with known peak sizes were used with all samples 
processed for this project.  Internal lane standard, ILS600, was run with all samples 
analysed with PowerPlex
®
 16HS.  CC5 ILS500, internal lane standard, was run with every 
sample analysed with PowerPlex
®
 18D.  Multiple allelic ladders were run with each plate 
of samples placed on the genetic analyser.  A ladder correctly identifying all alleles above 
the minimum threshold was used for analyse and identification of alleles.  All samples were 
analysed at a 50 RFU threshold.  
3.4 Discussion 
3.4.1 Reduced Volume Reactions (12.5μl) 
The amplification of DNA with PowerPlex
®
 16HS and 18D at a reduced volume was found 
to have a positive effect on the sensitivity and cost efficiency of the amplifications.   
PowerPlex
®
 16HS yielded full profiles for all DNA input above 0.13 ng at a 12.5μl 
reaction.  Reaction volumes of 25μl produced full profiles in samples above 0.25 ng and a 
partial profile with 0.13 ng (PP13) and 0.06 ng (PP1) of DNA.  No profiles were generated 
for samples with 0.06 ng of DNA for reactions with a total volume of 12.5μl.  PCR product 
concentrations (RFU/μl) and the average peak heights for the profiles generated were 
higher when evaluating 12.5μl reactions than with 25μl.  These results are consistent with 
the data generated by Hoffman and Fenger (2010) for PowerPlex
®
 16 which reported ideal 
half reaction input DNA to be between 0.25-1 ng.  The half reactions were slightly more 
successful with PowerPlex
®
 16HS then were reflected in the PowerPlex
®
 16 as input DNA 
at 0.13 ng produced a full profile.  This could be due in part to the enhanced buffer system 
included in PowerPlex
®
 16HS (Ensenberger et al., 2010; Hoffman and Fenger, 2010). 
Heterozygous peak balance (Hb) for samples generated with PowerPlex
®
 16HS proved to 
be almost equal when looking at full (45% below threshold) versus half reactions (50%) 
across all dilutions and heterozygous loci.  This was slightly lower than values presented in 
the validation studies; however, decreasing amounts of DNA were not evaluated in this 
study (Ensenberger et al., 2010). 
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PowerPlex
®
 18D yielded full profiles for DNA input at 2.0 ng and 1 ng with a 12.5μl 
reaction.  Reaction volumes of 25μl produced only full profiles in samples with 2.0 ng of 
DNA.  Partial profiles were generated at all other input DNA volumes, except for 0.06 ng 
where no profile was generated.  PCR product concentrations (RFU/μl) were higher when 
evaluating 12.5μl reactions than with 25μl.  While PowerPlex® 18D was not as successful 
in producing full profiles; however, higher peak heights and more loci were present in the 
12.5μl reactions than with the 25μl.  This is possibly due to the direct amplification 
materials which are typically cruder than purified samples and often include inhibitors from 
the raw DNA sample (Oostdik et al., 2013).  It has been noted that adding the same amount 
of direct amplification material recommended for a full reaction into a reduced reaction 
volume can negatively impact performance; however, the developmental validation showed 
reaction volumes ≥12.5 μl produced reliable full profiles (Oostdik et al., 2013). 
Heterozygous peak balance (Hb) for samples generated with PowerPlex
®
 18D proved to be 
almost equal when looking at full (45% below threshold) versus half reactions (50%) across 
all dilutions and heterozygous loci.  This was slightly lower than values presented in the 
validation studies; however, decreasing amounts of DNA were not evaluated in this study 
(Ensenberger et al., 2010). 
Across both kits, the amplification products produced exceeds those reported in the 
validation studies of both kits (Ensenberger et al., 2010; Hoffman and Fenger, 2010; 
Oostdik et al., 2013). For the purpose of this project, the study showed the validity of the 
12.5 μl volumes for the amplification of human DNA and properly characterise the profiles.  
For studies in this thesis, all amplifications were carried out at 12.5µl. 
3.4.2 Epithelial Cell Samples 
Epithelial cell samples produced full profiles with PowerPlex
®
 16HS using the x2 and x10 
dilutions.  Partial profiles were produced with the remaining dilutions tested.  The x200 
dilution contained the lowest total PCR product (1607 RFU) and provided a partial profile 
containing 2 loci. 
PowerPlex
®
 18D produced profiles for dilutions x2, x10 and x50.  Partial profiles which 
contained all but one and two loci, respectively, were obtained for x100 and x150 dilutions.  
Profiles at the x200 dilution again gave the lowest total PCR product peak heights (2432 
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RFU) and a partial profile of 6 loci.  The ability of PowerPlex
®
 18D to perform better than 
PowerPlex
®
 16HS could be due in part to the enhanced buffer system included in 
PowerPlex
®
 18D (Ensenberger et al., 2010; Hoffman and Fenger, 2010).  The PowerPlex
®
 
18D system was also optimized for direct amplification and contains components that can 
overcome inhabitation without the washing or purification step generally needed for STR 
profiling.  The elimination of this step also allows for the retention of more of the deposited 
sample. 
Dilutions x2 and x10 were consistent in both kits and the x10 dilution yielded a profile with 
low RFUs and fairly balanced peaks. These dilutions were utilized on the laminate substrate 
for exposure to powder processing.  
3.4.3 Whole Blood Samples 
For the whole blood samples, PowerPlex
®
 16HS was more successful than PowerPlex
®
 
18D.  PowerPlex
®
 16HS produced full profiles at all dilutions.  This result is consistent 
with what one would expect to see as the PowerPlex
®
 16HS samples are extracted, 
removing inhibitors and other components which may interfere with the STR profiling 
process. The total PCR product (in RFU) and total PCR concentration (in RFU/μl) 
exhibited a decreasing pattern of numerical values as the sample became more diluted and 
less DNA template was present in the sample.  This was to be expected as the amount of 
biological material is reducing the higher the dilution goes. 
The whole blood samples processed with PowerPlex
®
 18D were not treated except with the 
SwabSolution™ prior to amplification; therefore, all the components of the whole blood 
were still present in the sample. Again, the total PCR product (in RFU) and total PCR 
concentration (in RFU/μl) exhibited a decreasing pattern of numerical values as the sample 
became more diluted and less DNA template was present in the sample. 
PowerPlex
®
 18D produced profiles for dilutions x2 and x10.  A partial profile which 
contained 6 loci was produced at the x50 dilution.  Profiles at the x100, x150, and x200 
dilutions produced no profile.  The highest value of PCR concentration was also observed 
at the x10 dilution (7819 RFU/μl).   
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The whole blood samples were much stronger than the epithelial cell samples generated in 
section 3.4.2.  This is possibly due to the blood samples containing >2ng/µl for each sample 
which is greater than the epithelial cell samples which contained <1ng/ µl for each sample 
generated. 
Dilutions x2 and x10 were consistent in both kits and the x10 dilution yielded a profile with 
low RFUs and fairly balanced peaks.  These dilutions were utilized on all substrates for 
exposure to chemical enhancements. 
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CHAPTER 4.                                                                     
CONCORDANCE STUDY 
 
The following section describes the evaluation of the concordance of Promega
®
 
PowerPlex
®
 16HS and Promega
®
 PowerPlex
®
 18D human identification systems.   
4.1 Overview 
As DNA databases and crime laboratories expand their use of multiplex human 
identification kits, evaluation of concordance regarding specific autosomal STR 
products can help identify incorrect or null alleles present in a dataset due to primer 
binding site mutations. Since these multiplex kits can be composed of different primer 
sequences, such examination may identify problems regarding discordant alleles.   
A significant degree of confidence was placed on the two kits used for this study as 
both kits are products of Promega
®
 Corporation and have been tested repeatedly for 
concordance (Budowle et al., 2011).  PowerPlex
®
 16HS contains the same unchanged 
primer pairs included in PowerPlex
®
 16 (Ensenberger et al. 2010).  PowerPlex
®
 18D is 
composed of primers from PowerPlex
®
 16 which include amelogenin, Penta D, Penta E, 
and the 13 core CODIS loci and D2S1338 and D19S433 from the PowerPlex
®
 ESI 
System (Hill et al.l 2011; Oostdik et al., 2013).   
Table 4.1 lists all of the loci from PowerPlex
®
 16HS and PowerPlex
®
 18D, their 
chromosome locations, repeat category and motif, as well as the published forward and 
reverse primers.  Further details of each of the loci can be found in Appendix 8. 
The purpose of this experiment is to 
1.   Demonstrate the profiles generated with Promega® PowerPlex® 16HS and 
  Promega
®
 PowerPlex
®
 18D human identification systems are concordant;  
2.   Identify any discordance if reflected in the data; 
3.   Discuss any microvariants/off-ladder alleles which may be present in samples; 
4.     Create allele frequency and comparison charts from samples used in this study
 
and produced with both Promega
®
 PowerPlex
®
 16HS and Promega
®
 
PowerPlex
® 
18D .
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1 D2S1338 and D19S433 are in bold to represent the 2 additional loci in PowerPlex® 18D. 
2 Applied Biosystems is now Life Technologies. 
3 Red ‘G’ represents the C→T single nucleotide polymorphism (SNP) at the end of the CSF1PO reverse 
primer which could result in the drop/imbalance of allele 9. 
Table 4.1:  Loci within Promega
®
 PowerPlex
®
 16HS and Promega
®
 PowerPlex
®
 18D 
 
kits, their 
chromosome location, repeat category and motif, and primer sequences. 
STR Loci
1
 
Chromosomal 
Location 
Category; 
Repeat Motif 
Primer Sequences 
(F) Forward, (R) Reverse 
D2S1338 2q35 
Compound; 
TGCC/TTCC 
Primer sequences proprietary to Applied Biosystems®2. 
D3S1358 3p21.31 Compound; 
TCTA/TCTG 
(F) ACTGCAGTCCAATCTGGGT 
(R) ATGAAATCAACAGAGGCTTGC 
D5S818 5q23.2 Simple; AGAT 
(F) GGTGATTTTCCTCTTTGGTATCC 
(R) AGCCACAGTTTACAACATTTGTATCT 
D7S820 7q21.11 Simple; GATA 
(F) ATGTTGGTCAGGCTGACTATG 
(R) GATTCCACATTTATCCTCATTGAC 
D8S1179 8q24.13 Compound; 
TCTA/TCTG 
(F) ATTGCAACTTATATGTATTTTTGTATTTCATG 
(R) ACCAAATTGTGTTCATGAGTATAGTTTC 
D13S317 13q31.1 Simple; TATC 
(F) ATTACAGAAGTCTGGGATGTGGAGGA 
(R) GGCAGCCCAAAAAGACAGA 
D16S539 16q24.1 Simple; GATA 
(F) GGGGGTCTAAGAGCTTGTAAAAAG 
(R) GTTTGTGTGTGCATCTGTAAGCATGTATC 
D18S51 18q21.33 Simple; AGAA 
(F) TTCTTGAGCCCAGAAGGTTA 
(R) ATTCTACCAGCAACAACACAAATAAAC 
D19S433 19q12 
Compound; 
AAGG/TAGG 
Primer sequences proprietary to Applied Biosystems®. 
D21S11 21q21.1 Complex; 
TCTA/TCTG 
(F) ATATGTGAGTCAATTCCCCAAG 
(R) TGTATTAGTCAATGTTCTCCAGAGAC 
FGA 
4q31.3;  
Alpha fibrinogen,  
3rd Intron 
Compound; 
CTTT/TTCC 
(F) GGCTGCAGGGCATAACATTA 
(R) ATTCTATGACTTTGCGCTTCAGGA 
TH01 
11p15.5; 
Tyrosine Hydroxylase, 
 1st Intron 
Simple; TCAT 
(F) GTGATTCCCATTGGCCTGTTC 
(R) ATTCCTGTGGGCTGAAAAGCTC 
vWA 
12p13.31; 
vonWillebrand Factor, 
40th Intron 
Compound; 
TCTA/TCTG 
(F) GCCCTAGTGGATGATAAGAATAATCAGTATGTG 
(R) GGACAGATGATAAATACATAGGATGGATGG 
Penta E 15q26.2 Simple; AAAGA 
(F) ATTACCAACATGAAAGGGTACCAATA 
(R) TGGGTTATTAATTGAGAAAACTCCTTACAATTT 
Penta D 21q22.3 Simple; AAAGA 
(F) GAAGGTCGAAGCTGAAGTG 
(R) ATTAGAATTCTTTAATCTGGACACAAG 
TPOX 
2p25.3; 
Thyroid peroxidase, 
10th Intron 
Simple; AATG (F) GCACAGAACAGGCACTTAGG 
(R) CGCTCAAACGTGAGGTTG 
CSF1PO 5q33.1; c-fms proto-
oncogene, 6th Intron 
Simple; AGAT (F) CCGGAGGTAAAGGTGTCTTAAAGT 
(R) ATTTCCTGTGTCAGACCCTGTT3 
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4.2 Experimental Design  
150 buccal swabs were collected using sterile OmniSwabs (Whatman
®
) from unrelated 
individuals from three different populations as detailed in Section 2.4.2. Each person 
sampled supplied two swabs, one for analysis using standard extraction procedures and 
the other for direct amplification. The samples were processed once with Promega
®
 
PowerPlex
®
 16HS and once with Promega
®
 PowerPlex
®
 18D (no replicates). All 
extracted samples were quantitated using the NanoDrop 2000.  The data can be seen in 
Appendix 7. Cell counts were not conducted for the direct amplification samples for this 
portion of the project. 
4.3 Results  
4.3.1 Evaluation of Concordance 
Concordance evaluations for Promega
®
 PowerPlex
®
 16HS and Promega
®
 PowerPlex 
18D were performed by comparing the two sets of typing results with each other. Since 
these multiplex kits are composed of the same primer sequences, it is expected to yield 
comparable results with the absence of null and discordant alleles.   Of the 150 samples 
profiled with 16HS, 110 produced full profiles, 28 partial profiles and 12 exhibited no 
profiles.  PowerPlex
®
 18D produced full profiles for all 150 samples.  Of the full and 
partial profiles detected, all allele calls were harmonious between the two kits. (A list of 
the partial profiles from PowerPlex
®
 16HS can be found in Appendix 5.) 
 
4.3.2 Peak Height Assessment 
Peak height data could not be directly compared since the two kits were run on two 
different genetic analyser platforms.  The PowerPlex
®
 16HS data (for this study alone) 
were produced on an ABI 3130 Genetic Analyser while the PowerPlex
®
 18D data 
generated on an ABI 3500 Genetic Analyser.  According to documentation from 
Thermo Fisher Scientific, the “3500 series data has approximately 4x RFU dynamic 
range increase over the 31XX platforms”.  Figures 4.1 and 4.2 represent the average 
peak height data sets for all concordance samples processed using PowerPlex
®
 16HS 
and 18D, respectively.  D2S1338 and D19S433 are represented on the direct 
amplification figure only as they are only present in the PowerPlex
®
 18D kit. 
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Figure 4.1:  Bar graph representation of the average peak heights (in RFU) by 
locus for 150 profiles generated using the standard extraction method and profiled 
using PowerPlex
®
 16HS. Error bars represent the standard deviation. 
 
Figure 4.2:  Bar graph representation of the average peak heights (in RFU) by 
locus for 150 profiles generated using the standard extraction method and profiled 
using PowerPlex
®
 18D. Error bars represent the standard deviation. 
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Figure 4.3:  Bar graph representation of the average heterozygous peak height 
balance ratio by locus for 50 profiles generated for the Mexican population using 
both PowerPlex
®
 16HS and PowerPlex
®
 18D.   The red line indicates the 0.70 Hb 
threshold for the heterozygous peak balances.  Error bars represent the standard 
deviation. 
Figure 4.4:  Bar graph representation of the average heterozygous peak height 
balance ratio by locus for 50 profiles generated for the Caucasian population using 
both PowerPlex
®
 16HS and PowerPlex
®
 18D.   The red line indicates the 0.70 Hb 
threshold for the heterozygous peak balances.  Error bars represent the standard 
deviation. 
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Figure 4.5:  Bar graph representation of the average heterozygous peak height 
balance ratio by locus for 50 profiles generated for the African American 
population using both PowerPlex
®
 16HS and PowerPlex
®
 18D.   The red line 
indicates the 0.70 Hb threshold for the heterozygous peak balances.  Error bars 
represent the standard deviation. 
 
The peak maximum and minimum for PowerPlex
®
 16HS were 1574 RFU and 50 RFU 
respectively.  The peak maximum and minimum for PowerPlex
®
 18D were 5974 RFU 
and 50 RFU respectively. 
Peak balance (Hb) was observed more in PowerPlex
®
 18D with more heterozygous loci 
appearing above the 0.70 threshold.  Figures 4.3-4.5 represent a comparison of each of 
the populations which had samples displaying heterozygous alleles within their profiles. 
4.3.3 Variant Alleles 
During the analysis of the samples several microvariants and/or off ladder alleles were 
observed.  All microvariants and/or off ladder alleles were correctly called in both kits.  
A list of these alleles, their structure and size are listed in Table 4.2. 
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 4.3.4 CSF1PO 
Previous publications indicate that allele 9 in CSF1PO may be observed to drop out.   
For the data collected, no samples were observed to have a homozygous allele 9.  Six 
samples out of the 150 produced were observed to have a heterozygous CSF1PO 
containing an allele 9.  All six samples were called correctly.  In 4 of the 6 samples, 
PowerPlex
®
 18D provided peak balances closer to 1.0 which is reflected in Table 4.3.  
All samples produced alleles above the ˃0.70 Hb threshold. 
 
Table 4.3:  CSF1PO peak balance ratios for profiles containing allele 9 for 
PowerPlex
®
 16HS and PowerPlex
® 
18D. 
Sample Allele Call 
PP16HS  
Peak Height Percentage 
PP18D  
Peak Height Percentage 
9M 9,10 0.94 0.92 
13B 9,12 0.85 0.92 
15M 9,10 0.70 0.84 
17B 9,11 0.96 0.95 
23B 9,12 0.98 0.95 
33B 9,12 0.73 0.92 
 
 
 
 
 
Table 4.2:  Microvariant (MV) and off ladder (OL) alleles produced in both PowerPlex
®
 
16HS and PowerPlex
®
 18D kits.  
Sample Locus Allele Repeat Structure Size Reference 
25M D7 10.3 (MV) Not Published 234bp (Allor et al., 2005) 
46W D16 7 (OL) [GATA]7 272bp STRBase (Butler, 2015) 
41B D18 15.2 (MV) [AGAA]15AG 320 bp (Barber and Parkins, 1996) 
11M D18 16.1 (MV) [AGAA]3A[AGAA]13 323 bp (Allor et al., 2005) 
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4.3.5 Allele Frequencies 
While the samples collected were not sufficient for a population study, the allele 
frequencies were calculated and compared to the published allele frequency tables 
provided by Promega Corporation.  Allele frequency data for 16 STRs included in 
PowerPlex 16HS System (CSF1PO, D3S1358, D5S818, D7S820, D8S1179, D13S317, 
D16S539, D18S51, D21S11, FGA, Penta D, Penta E, TH01, TPO and VWA) and 18 
STRs included in PowerPlex 18d which contains all the loci listed above in addition to 
D19S433 and D2S1338 in a sample of 150 unrelated individuals was reported. The 
allele frequency, observed heterozygosity (Hob), expected heterozygosity (Hex), power 
of discrimination (PD) and probability of exclusion (PE) were also calculated using 
Powerstats version 1.2 (Promega Corporation) for all 150 samples (Appendix 9).  Data 
tables were also created to compare the allele frequencies calculated and the standard 
deviations for each calculated (Appendix 9).  Details of each of the loci contained in the 
kits can be found in Appendix 8. 
4.4 Discussion 
PowerPlex
®
 18D produced well-balanced profiles across all loci tested.  More profiles 
with heterozygosity peak height balances at or over 0.70 were observed with 18D (91%) 
than when compared to 16HS (63%).  The ability to produce higher quality profiles 
when using the direct amplification kit has been attributed to an improved Master Mix 
which helps to overcome inhibition and allows for some level of tolerance in primer 
mismatching.  While the exact components of the new reagents are not published one 
could guess that higher salt concentrations and possibly different DNA polymerases aid 
in reducing inhibition and allow for the tolerance of primer binding site mismatches 
(Zhang et al., 2010; Bellstedt et al., 2010). PowerPlex
®
 16HS
 
failed to produce full 
profiles for 28 of the samples and 12 profiles were not observed at all. Of the full and 
partial profiles which were produced all alleles matched when comparing both kits.   
 
Microvariants are common variations encountered when reviewing DNA profiles 
generated with STR markers.  Alleles that contain an incomplete repeat unit compared 
to the more commonly observed alleles are referred to as microvariants.   When 
reviewing the data generated for this chapter, three microvariants alleles were noted as 
reflected in Table 4.2.    These alleles were seen in both profiles generated by both kits, 
PowerPlex
®
 16HS
 
and PowerPlex
®
 18D. 
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Off-ladder alleles may also be noted when reviewing data.  Off-ladder alleles manifest 
themselves in two ways; 1) peaks that appear smaller or larger than the allelic ladder 
and/or 2) peaks that lie between the designated allelic ladder peaks. One off-ladder 
allele, 7 in D16, was also seen and falls between designated alleles in the allelic ladder.  
As this allele was repeated with a different kit with the same result, it is accepted as a 
true microvariant allele which falls between alleles 5 and 8 in the allelic ladder.  When 
reviewing the National Institute for Standards and Technology STRBase, the allele has 
been documented 3 other times; two in casework scenarios and one in a paternity case 
involving a mother and child (Butler, 2015).  This was noted in both profiles generated 
by both, PowerPlex
®
 16HS
 
and PowerPlex
®
 18D and is reflected in Table 4.2. 
 
4.4.1 CSF1PO 
Publications produced by NIST (The U.S. National Institute for Standards and 
Technology) and subsequently presented at the ISFG Conference (International Society 
of Forensic Genetics) show that CSF1PO exhibits drop-out in regards to allele 9 when 
analysing with PowerPlex
®
 16 (Vallone et al., 2011).  This comes from the C→T single 
nucleotide polymorphism (SNP) at the end of the CSF1PO reverse primer. In some 
cases when using PowerPlex
®
 16HS
®
, the allele is exhibited with a low signal resulting 
in a peak height imbalance within a heterozygous profile. PowerPlex
®
 18D has not 
shown any drop-out of the allele supporting the notion that the Master Mix has been 
enhanced.  The allele 9 drop-out/low signal (signal below the 0.70 Hb threshold) was 
not observed in any of the samples analysed for this experiment as described in Section 
4.3.4.  In future chapters of this thesis, an evaluation of the data will include an 
assessment of allele 9 as the known profile for sample A in the chemical enhancement 
of blood chapter (Chapter 6) and sample B in the enhancement of epithelial cells 
chapter (Chapter 5) , have a heterozygous 9, 12 allele call for CSF1PO. 
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CHAPTER 5. 
EVALUATION OF EPITHELIAL CELL SAMPLES 
PROCESSED WITH FINGERPRINT POWDERS 
 
 
The following section describes the evaluation and comparison of Promega
®
 
PowerPlex
®
 16HS and Promega
®
 PowerPlex
®
 18D human identifications systems on 
the mock latent fingerprint samples which have been processed with standard black 
powder, magnetic flake, and standard white powder.   
5.1 Overview 
A common physical method for processing latent fingerprints is the application of a fine 
powder to enhance or visualize the latent print (Bridges, 1942).  This is generally 
accomplished by utilizing a fibre-glass or camel hair brush for powder application to the 
latent fingerprint.   While the powder binds to the ridges which are deposited onto the 
substrate, biological material is also transferred to the surface providing a second viable 
source of DNA evidence which can be individualizing.  However, limitations apply 
when a fingerprint is smudged or does not contain enough identifying characteristics 
and the print cannot be analyzed.  In such cases, DNA evidence becomes the primary 
focus in identification and individualization of the print. 
While the deposit of the print varies greatly from individual to individual as outlined in 
Chapter 1, it is relevant to review the effects of fingerprint enhancements on subsequent 
DNA profiling.  This is especially crucial when evaluating a direct amplification 
method which does not require standard DNA extraction in order to provide a high 
quality, pure DNA sample free from potential contaminants and PCR inhibitors such as 
proteins, other cellular debris and the powder residue deposited on the print.  Through 
careful experimental design, which eliminates the variability of deposit by touching, a 
comparison can be conducted between two DNA profiling methods, one which employs 
extracted DNA and the other lysed cells which are directly amplified on samples which 
have been processed with various fingerprint powders.   
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A B 
Three common powders were selected for this study: black powder, magnetic flake, and 
white powder.  Black powder is manufactured from a variety of carbon-based powders 
(such as lampblack, graphite, and charcoal) which readily adheres to the deposit (Bleay 
et.al, 2012; Miller, 2013).  Black powder is applied with a fibre-glass brush (Figure 
5.1A).  Magnetic flake is composed of a black or other pigmented powder (black was 
used for the samples in this study) and a magnetic component such as iron particles 
(Miller, 2013).  A magnetic brush (Figure 5.1B) consisting of a magnet inside plastic 
sheath or a non-ferrous metal wand attracts the magnetic flake creating a bulb of 
powder at the end of the sheath/wand.  This is utilized like a brush and gently moved 
across the deposit to develop the area.  White powder is composed of titanium dioxide 
or other white powder which adheres to the deposit left on a surface (Bleay et.al, 2012).   
White powder is also applied with a fibre-glass brush.  A review of the different 
compositions of fingerprint powders can be seen in Chapter 1, Table 1.3. 
  
 
 
 
 
Figure 5.1: (A) Example of a fibre-glass brush used for powder processing 
(Evident, 2015). (B) Example of a magnetic wand with a ‘bulb’ of powder at the 
end of the wand (Arrowhead Forensics, 2015).  This ‘bulb’ acts as the brush when 
processing a surface. 
 
The specific objectives of this chapter are to: 
1.  Amplify and analyse samples which have been processed with three commonly 
used fingerprinting powders- black powder, magnetic flake, and white powder 
and used to generate DNA profiles with PowerPlex
®
 16HS and PowerPlex
®
 18D 
and  
2.  Assess the ability to generate complete DNA profile with PowerPlex
®
 16HS and 
PowerPlex
®
 18D under various sample dilutions which have been exposed to the 
commonly used fingerprinting powders. This is done by evaluating the 
electropherograms in terms of number of loci amplified and peak height 
imbalances; 
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3.  Evaluate the profiles for artefacts such as dye blobs, stutters, pull-up, and split 
peaks which may be present in the generated profiles.  
5.2 Experimental Design 
Two buccal swabs were collected from two unrelated individuals (individuals A and B) 
using sterile OmniSwabs (Whatman
®
).  Epithelial cells were then isolated using the 
process described in Section 2.4.3.  The cells were then deposited onto the laminate 
substrates, allowed to dry and then developed using the three selected powders: black 
powder, magnetic flake, and white powder following the procedure outlined in Section 
2.4.3.2.  Black and white laminate were used in order to maximize visual contrast of the 
powders once the samples were processed.  Standard black powder and magnetic flake 
were processed using a fibre-glass brush (black powder) and a magnetic wand 
(magnetic flake) on white laminate while white powder was processed using a fibre-
glass brush on black laminate.  Once processed with the individual powders, 
photographs were taken to document the developed deposit.  Using cotton swabs, 
samples from each of the laminates were then taken and subsequently processed in 
accordance with section 2.5. 
In addition to the samples processed with powder, a series of samples which were not 
exposed to powder processing were analysed using the same methods described in 
section 2.5.  This data was used for comparison and is labelled as ‘no powder’ on 
subsequent data charts. 
5.3 Results 
Results were generated utilizing three separate dilutions; x1, x2, and x10 as was 
determined in the sensitivity study to give a full profile above the 50 RFU threshold 
(Section 3.3.2).  Each sample was photographed post processing to document sample 
size consistency across samples, dilutions and powder types (Figure 5.2). The samples 
were photographed post-processing only due to the epithelial cell solution being 
transparent once dry.  Each sample deposit was approximately 10-15mm.  It was 
important for the sample sizes to be consistent in order for the powder deposit to be 
roughly the same. 
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Figure 5.2:  Photographs of white and black laminate which exhibit developed 
epithelial deposits with standard black powder, magnetic flake and white powder 
(left to right, respectively) for samples A and B with a x2 dilution.  Row 1 depicts 
sample A which was analysed with PowerPlex
®
 16HS.  Row 2 depicts sample A 
which was analysed with PowerPlex
®
 18D.  Row 3 depicts sample B which was 
analysed with PowerPlex
®
 16HS.  Row 4 depicts sample B which was analysed with 
PowerPlex
®
 18D. 
1 
2 
3 
4 
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5.3.1 Assessment of Profile Quality 
The effect on amplification effectiveness and autosomal STR kit sensitivity was 
evaluated using peak heights and locus/allele drop-out. Each sample was evaluated and 
placed into a chart based on their exhibition of alleles above the threshold of 50 RFU.  
Figures 5.3-5.5 are organized by powder and subsequently by the autosomal STR kit 
used to generate the profiles.  PowerPlex
®
 18D was more successful at generating 
profiles above the analytical values for samples which were enhanced using powders, in 
the dilutions which were previously determined during the sensitivity study, than 
PowerPlex
®
 16HS.  The PowerPlex
®
 18D samples were explicitly better when 
processed with standard black powder or white powder than with magnetic flake(Figure 
5.8).  While the magnetic flake was the least successful when evaluating both STR kits, 
the PowerPlex
®
 18D kit did produce a full profile and/or partial profiles for all dilutions 
which exceeded 12 loci for 4 of the 6 samples.  An evaluation of the individual powders 
and their comparisons to the untreated samples follow in section 5.3.2, ‘Comparison of 
Individual Factors’. 
DNA profiles were also assessed based on profile properties such as minimum peak 
heights, maximum peak heights, average peak heights, total PCR product and the PCR 
product concentration.  Standard deviations were also calculated for the triplicates and 
included in the chart.  For Tables 5.1 and 5.2, three replicates of each sample, A and B, 
were assessed.  Sample A presents 12 heterozygous loci and 3 homozygous loci when 
analysed with PowerPlex
®
 16HS and 14 heterozygous loci and 3 homozygous loci when 
analysed with PowerPlex
®
 18D.  Sample B presents 8 heterozygous loci and 7 
homozygous loci when analysed with PowerPlex
®
 16HS and 9 heterozygous loci and 8 
homozygous loci when analysed with PowerPlex
®
 18D.     
Profiles were successfully generated in both PowerPlex
®
 16HS and 18D; however, the 
quality of the profile was much better when processed with PowerPlex
®
 18D.  When 
evaluating two of the same samples processed with the same powder at the same 
dilution with different kits, the visual variability in peak heights is noted. 
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 Figure 5.3:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
® 
16HS (left) and PowerPlex
® 
18D (right) kits.  Different 
dilutions (x1, x2, x10) of the two DNA samples (A and B) were processed in triplicate using standard black powder and amplified with PowerPlex
®
 16HS and 
PowerPlex
®
 18D.  Green squares indicate that the full correct alleles were observed for those loci.  Yellow squares represent one allele drop out.  Red squares 
represent loci where both expected alleles are missing. 
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 Figure 5.4:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
® 
16HS (left) and PowerPlex
® 
18D (right) kits.  Different 
dilutions (x1, x2, x10) of the two DNA samples (A and B) were processed in triplicate using magnetic flake powder and amplified with PowerPlex
®
 16HS and 
PowerPlex
®
 18D.  Green squares indicate that the full correct alleles were observed for those loci.  Yellow squares represent one allele drop out.  Red squares 
represent loci where both expected alleles are missing. 
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 Figure 5.5:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
® 
16HS (left) and PowerPlex
® 
18D (right) kits.  Different 
dilutions (x1, x2, x10) of the two DNA samples (A and B) were processed in triplicate using white powder and amplified with PowerPlex
®
 16HS and 
PowerPlex
®
 18D.  Green squares indicate that the full correct alleles were observed for those loci.  Yellow squares represent one allele drop out.  Red squares 
represent loci where both expected alleles are missing. 
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 Table 5.1:  Results for profiles generated with PowerPlex
®
 16HS showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed with the 3 powders (black, magnetic, and white). The values are averages of three replicates. 
Powder Type Sample Dilution 
Profile Properties 
Total PCR Product 
(in RFU) 
PCR product concentration 
(in RFU/μl) 
Max PH Min PH Average PH 
Profile 
Type 
Black 
A 
x1 94 (s.d. 17.35) 63 (s.d. 1) 74.89 PP2 611 (s.d. 176.69) 55.55 (s.d. 1.35) 
x2 116 (s.d. 15.72) 52 (s.d. 0.58) 77.13 PP2 1157 (s.d. 33.08) 105.18 (s.d. 3.00) 
x10 -- -- -- NP -- -- 
B 
x1 736 (s.d. 194.10) 50 (s.d. 1.16) 144.07 PP9 2017 (s.d. 804.62) 267.45 (s.d. 73.15) 
x2 2157 (s.d. 463.77) 56 (s.d. 2.65) 471.75 PP15 32079 (s.d. 1188.26) 2916.17 (s.d. 107.97) 
x10 -- -- -- NP -- -- 
Magnetic 
A 
x1 -- -- -- NP -- -- 
x2 104 (s.d. 15.53) 56 (s.d. 8.33) 75.88 PP2 607 (s.d. 43.02) 55.18 (s.d. 3.90) 
x10 -- -- -- NP -- -- 
B 
x1 198 (s.d. 27.54) 52 (s.d. 23.09) 109.92 PP3 1492 (s.d. 117.00) 129.91 (s.d. 10.64) 
x2 1121 (s.d. 451.45) 53 (s.d. 34.64) 208.83 PP9 8562 (s.d. 2605.27) 778.36 (s.d. 236.84) 
x10 -- -- -- NP -- -- 
White 
A 
x1 405 (s.d. 133.10) 53 (s.d. 0.58) 118.32 PP7 5206 (s.d. 753.27) 473.27 (s.d. 68.48) 
x2 2157 (s.d. 463.77) 56 (s.d. 2.66) 471.75 PP14 32079 (s.d. 1188.26) 2916.27 (s.d. 108.02) 
x10 -- -- -- NP -- -- 
B 
x1 1320 (s.d. 280.10) 53 (s.d. 8.15) 314.75 PP14 19200 (s.d. 2222.15) 1745.46 (s.d. 202.02) 
x2 705 (s.d. 243.52) 53 (s.d. 2.52) 175.19 PP9 6482 (s.d. 1843.16) 589.27 (s.d. 167.56) 
x10 -- -- -- NP -- -- 
 
Note:    PH = Peak height; FP=Full Profile; PP# = Partial Profile and the number of loci genotyped; NP = No profile; s.d = standard deviation of the replicates.  
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Table 5.2: Results for profiles generated with PowerPlex
®
 18D  showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed with the 3 powders (black, magnetic, and white). The values are averages of three replicates. 
Powder Type Sample Dilution 
Profile Properties 
Total PCR Product 
(in RFU) 
PCR product concentration 
(in RFU/μl) 
Max PH Min PH Average PH 
Profile 
Type 
Black 
A 
x1 1540 (s.d.682.63) 50 (s.d. 20.60) 354.49 FP 29423 (s.d. 7258.21) 2674.82 (s.d. 659.8381) 
x2 6952 (s.d. 727.5) 51 (s.d. 15.37) 195.9 FP 18611 (s.d. 727.5) 1692 (s.d. 66.13) 
x10 188 (s.d. 45.54) 51 (s.d. 2) 85.14 PP6 2469 (s.d. 449.22) 224.45 (40.84) 
B 
x1 3261 (s.d. 475.98) 264 (s.d. 119.78) 1029.80 FP 83414 (s.d. 270.49) 7582.91 (s.d. 24.69) 
x2 946 (s.d. 112.71) 92 (s.d. 45.94) 325.06 FP 26330 (s.d. 856.66) 2393.64 (s.d. 77.88) 
x10 711 (s.d. 166.01) 54 (s.d. 11.24) 215.70 FP 16609 (s.d. 1242.39) 1509.91 (s.d. 112.94) 
Magnetic 
A 
x1 739 (s.d. 226.60) 50 (s.d. 7.23) 175.13 PP17 13310 (s.d. 3323.02) 1210 (s.d. 302.09) 
x2 568 (s.d. 142.85) 50 (s.d. 8.39) 142.36 FP 12670 (s.d. 1652.25) 1151.82 (s.d. 150.20) 
x10 -- -- -- NP -- -- 
B 
x1 3427 (s.d. 508.64) 323 (s.d. 44.55) 1135.99 FP 92015 (s.d. 3636.28) 8365 (s.d. 330.57) 
x2 704 (s.d. 220.95) 52 (s.d. 11.36) 182.27 PP17 14217 (s.d. 2753.87) 1292.45 (s.d. 250.35) 
x10 254 (s.d. 42.78) 50 (s.d. 2.89) 108.16 PP12 481.82 (s.d. 371. 67) 481.82 (s.d. 33.78) 
White 
A 
x1 370 (s.d. 22.12) 50 (s.d. 1.52) 123.90 PP16 10655 (s.d. 556.45) 322.87 (s.d. 50.58) 
x2 6369 (s.d. 3247.44) 56 (s.d. 286.35) 1381.80 FP 129889 (s.d. 34636.57) 11808.09 (s.d. 3148.78) 
x10 173 (s.d. 25.54) 51 (s.d. 4.93) 88.30 PP3 2384 (s.d. 204.16) 216.72 (s.d. 18.56) 
B 
x1 3400 (s.d. 622.87) 218 (s.d. 240.83) 1026.43 FP 83141 (s.d. 7324.73) 7558.27 (s.d. 665.89) 
x2 1592 (s.d. 99.16) 170 (s.d. 38.37) 580.67 FP 47034 (s.d. 1677.18) 7180.63 (s.d. 1636.54) 
x10 687 (s.d. 193.99) 52 (s.d. 13.58) 164.94 FP 12865 (s.d. 1522.71) 1169.55 (s.d. 138.43) 
Note:    PH = Peak height; FP=Full Profile; PP# = Partial Profile and the number of loci genotyped; NP = No profile; s.d = standard deviation of the replicates.  
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Figure 5.6: (1) Electropherogram of sample B processed with black powder, x1 
dilution and analysed with PowerPlex
®
 16HS on a scale of 560 RFU. (2)  
Electropherogram of sample B processed with black powder, x1 dilution and 
analysed with PowerPlex
®
 18D on a scale of 1050 RFU.  The x-axis represents 
relative fluorescent units (RFU) and the y-axis fragment size in base pairs. 
 
Magnetic flake powder was the least successful of the powders tested.  Most samples 
processed with PowerPlex
®
 16HS were unsuccessful in producing a profile; however, 
samples processed with PowerPlex
®
 18D were successful in completing either a full or 
partial profile at least three times across all three dilutions.  Figure 5.6 displays profiles 
2 
1 
          D3S1358          TH01                    D21S11                      D18S539                        Penta E 
         D5S818              D13S317           D7S820  D16S539                CSF1PO                                   Penta D 
 Amel              vWA                       D8S1179                     TPOX                          FGA 
             D3S1358                TH01     D21S11                                 D18S51                                         Penta E 
            D5S818                    D13S317                 D7S820                      D16S539               CSF1PO                 Penta D 
   Amel                      vWA                            D8S1179                          TPOX                                   FGA 
      D19S433                           D2S1338 
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 generated using PowerPlex
®
 16HS and PowerPlex
®
 18D (sample B, x2 dilution).  
PowerPlex
®
 18D was successful in producing a full profile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7:  (1) Electropherogram of sample B processed with magnetic flake 
powder, x2 dilutions and analysed with PowerPlex
®
 16HS on a scale of 100 RFU. (2) 
Electropherogram of sample B processed with magnetic flake powder, x2 dilution 
and analysed with PowerPlex
®
 18D on a scale of 900 RFU. The x-axis represents 
relative fluorescent units (RFU) and the y-axis fragment size in base pairs. 
 
 
 
 
1 
2       D3S1358                TH01                      D21S11                             D18S51                                         Penta E 
D5S818                    D13S317                  D7S820                    D16S539                     CSF1PO                            Penta D 
    Amel                      vWA                             D8S1179                           TPOX                                 FGA 
                  D19S433                 D2S1338 
          D3S1358              TH01                    D21S11                      D18S539                        Penta E 
         D5S818              D13S317           D7S820  D16S539                CSF1PO                                   Penta D 
vWA               D8S1179                     TPOX                          FGA  Amel 
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 5.3.2 Comparison of Individual Factors 
All profiles were evaluated to determine the overall completeness of the profile as well 
as to access the quality of the peaks within each profile.  The average RFU value of the 
total PCR product of all samples generated with each of the human identification kits 
above the 50 RFU thresholds was plotted using each of the powders against the dilutions 
present in the experiment.  For all samples analysed with PowerPlex
® 
18D, the data for 
the loci D2S1338 and D19S433 was removed from the totals in order to normalize the 
data when comparing it to PowerPlex
® 
16HS, which does not contain these loci.  
Samples which were not exposed to any powder enhancement and included only the 
epithelial cell deposit were labelled as ‘no powder’. The results are displayed in Figures 
5.8 and 5.9. 
When reviewing dilutions versus powders, PowerPlex
® 
16HS has the largest RFU values 
exhibited in the x2 dilutions across all powders with the x1 dilution and x10 dilutions 
following respectively. The mean in this case is not significantly different between the 
dilutions in regards to powder used to process the samples [F(2,12)= 1.22, p= 0.330].  
This was not seen when looking at the ‘no powder’ samples with the x2 dilution samples 
falling between the x1 and x10 dilutions.    The ‘no powder’ samples followed an 
expected trend given that the amount of DNA was being reduced as the dilutions 
increased. 
PowerPlex
®
 18D does show larger values than PowerPlex
® 
16HS in regards to average 
total PCR product (Figure 5.9). PowerPlex
®
 18D ‘no powder’ samples produced average 
PCR products which were much lower than any of the other dilution samples processed 
with powder.  When analysing the white powder, the x2 dilution exceeds the x1 and x10 
when compared to the two other powders. The white powder also shows the strongest 
overall RFU values for the x2 and x10 dilutions when processed with PowerPlex
®
 18D. 
However, the difference between the dilutions in regard to powder does not appear to be 
significantly different [F(2,12)= 1.54, p=0.231). 
When disregarding powder type (Figure 5.10) and focusing on the kit versus the dilutions 
only, the trend of the samples is as expected.  PowerPlex
®
 18D does show stronger RFU 
values than PowerPlex
®
 16HS and are statistically significant [F(1, 30)= 10.65, p=0.003). 
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 Figure 5.8:  Variation in the average total PCR product (RFU) between the powders 
and dilutions processed with PowerPlex
®
 16HS.  Error bars represent the standard 
deviation.  No samples with a x10 dilution produced a profile for any of the 
powders. 
 
Figure 5.9:  Variation in the average total PCR product (RFU) between the powders 
and dilutions processed with PowerPlex
®
 18D. Error bars represent the standard 
deviation. 
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 Figure 5.10:  Variation in the average total PCR product (RFU) between the 
dilutions and kits utilized to process the powder samples. Error bars represent the 
standard deviation. 
 
 
Figure 5.11:  Variation of the average total PCR product (RFU) between the 
powders and kits utilized to process the powder samples. Error bar represent the 
standard deviation. 
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 Another consideration when assessing the quality of the profiles generated is the 
evaluation of heterozygous peak balance (Hb) which is the ratio of the two peaks present 
at a heterozygous locus.  This is determined mathematically by dividing the allele with 
the lower peak height value by the allele with the greater peak height value.  Results 
range from 0 to 1 with 1 representing alleles of equal height.  An Hb value which is 
below 0.70 indicates peak imbalance.  Figures 5.12 through 5.17 exhibit heterozygous 
loci which are present in both sample A and B and are colour coded based on the 
different dilutions.  A red dotted line indicates the 0.70 Hb threshold for the results. 
For PowerPlex
®
 18D samples for all powder types and all dilutions, 237 of 432 of the 
samples appear over the Hb 0.70 threshold (Figure 5.13, 5.15, and 5.17).  PowerPlex
®
 
16HS was not as successful and only produced 46 of 432 samples above the Hb 0.70 
threshold (Figure 5.12, 5.14, and 5.16). 
Peak height ratios for samples at the x1 dilution revealed that only 19 of the 144 samples 
when analysed with PowerPlex
®
 16HS were above the 0.7 Hb threshold while x1 
dilution samples analysed with PowerPlex
®
 18D produced 98 of 144 samples above the 
threshold.  The majority (84 of the 144) of the samples processed with PowerPlex
®
 18D 
at the x2 dilution were above the 0.7 Hb limit.  PowerPlex
®
 16HS only produced samples 
above the threshold for 26 of the 144 samples at a x2 dilution.  PowerPlex
®
 16HS 
samples processed with x10 dilutions failed to produce any data for the samples in 
regards to heterozygous peak balance.  PowerPlex
®
 18D, however, was able to 
successfully amplify and produce samples which were above the 0.70 (Hb) threshold for 
34 of the 144 samples across all powder types.  While this is only 24% of the samples, it 
was still deemed a success in comparison to the PowerPlex
®
 16HS samples. 
Standard black powder and white powder produced 83 of 144 samples and 96 of 144, 
respectively when processed with PowerPlex
®
 18D (Figure 5.13 and 5.17).  Peak height 
ratios for samples exposed to black powder using PowerPlex
®
 16HS were less successful 
displaying 14 out of 144 samples (Figure 5.12).  The white powder deposits were slightly 
more successful 25 of 144 samples (figure 5.16). 
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 PowerPlex
®
 16HS was deemed unsuccessful when samples were processed with 
magnetic flake; few heterozygous loci (6 of the 144 samples) were above threshold when 
looking at all dilutions (Figure 5.14).  Of the heterozygous loci which exhibited both 
alleles when samples were processed with magnetic flake and analysed with PowerPlex
®
 
18D, 40 % (59 of 144) of the samples were above the 0.70 (Hb) leading to the conclusion 
that while the overall profile RFU totals were lower than the other two powders and did 
not include as many full profiles, the heterozygous peak balance for samples processed 
with magnetic flake did met analysis standards for acceptance. Of the samples analysed 
with PowerPlex
®
 18D and exposed to magnetic flake, all x1 and x2 dilution samples 
produced full or partial profiles which only lacked, D3 in sample A for x1 and Penta E in 
samples B for x2 dilution. 
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 Figure 5.12: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with black powder and analysed with PowerPlex
®
 16HS. 
The red line indicates the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond symbols represent x1 dilutions, green diamonds represent x2 
dilutions, and orange diamonds represent x10 dilution samples. 
Figure 5.13: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with black powder and analysed with PowerPlex
®
 18D. 
The red line indicates the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds represent x2 dilutions and the 
orange diamonds x10 dilution samples. 
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                         D3               D21             D18           Penta E          D13                D7             CSF              FGA 
                          D3               D21             D18           Penta E         D13             D7               CSF            FGA 
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 Figure 5.14: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with magnetic flake and analysed with PowerPlex
®
 
16HS. The red line indicates the 0.70 Hb threshold for the heterozygous peak 
balances. Blue diamond symbols represent x1 dilutions, green diamonds represent 
x2 dilutions, and orange diamonds represent x10 dilution samples. 
Figure 5.15: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with magnetic flake and analysed with PowerPlex
®
 18D. 
The red line indicates the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds represent x2 dilutions and the 
orange diamonds x10 dilution samples. 
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 Figure 5.16: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with white powder and analysed with PowerPlex
®
 16HS. 
The red line indicates the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond symbols represent x1 dilution, green diamonds represent x2 
dilutions, and orange diamonds represent x10 dilution samples. 
Figure 5.17: Peak height ratios of the various heterozygous loci present in both 
samples A and B processed with white powder and analysed with PowerPlex
®
 18D. 
The red line indicates the 0.70 Hb threshold for the heterozygous peak balances. 
Blue diamond represent x1 dilutions, green diamonds represent x2 dilutions and the 
orange diamonds x10 dilution samples. 
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 5.3.2.1 Evaluation of CSF1PO 
A heterozygous allele call of CSF1PO was present in sample B samples for the powder 
samples.  CSF1PO was more successful in displaying both alleles when processed with 
PowerPlex
®
 18D.  Both alleles were displayed in 2 of 27 samples analysed with 
PowerPlex
®
 16HS when compared to PowerPlex
®
 18D where both alleles were present 
in 26 of the 27 samples processed (Figures 5.2-5.4).  The two samples which displayed 
the heterozygous allele call for PowerPlex
®
 16HS both showed peak height balance ratio 
above the 0.70 Hb threshold (Figure 5.12, 5.16).  14 of 27 analysed with PowerPlex
®
 
18D were over 0.70 Hb threshold (Figure 5.13, 5.15, and 5.17). 
5.4 Discussion 
Powder dusting techniques are the simplest, most effective and most commonly used 
procedures when developing latent prints on nonporous surfaces (Sodhi and Kaur, 2001). 
While this process has been around for decades, the research to determine if it is possible 
to obtain a viable full or partial DNA profile from substrates that have been processed 
with these powders is limited (VanOorschot and Jones, 1997; VanHoofstat et al., 1999; 
Norlin et al., 2013).  Different studies have shown that skin contact to a surface does 
transfer enough biological material to obtain a full or partial profile and that the amount 
of DNA transferred is dependent on the individual who is touching the surface 
(VanOorschot and Jones, 1997; Alessandrini et al., 2003; Lowe et al., 2002).   
Results in a recent study by Tozzo (2014) indicate that it is possible to obtain a profile 
from samples which have been processed with various powders under laboratory 
conditions including magnetic powder.  In the study, magnetic powder did yield the 
lowest number of successfully typed samples.  The kit used in the study was not direct 
PCR.  The results of this project agreed with this study in regards to results reflected in 
the extraction based kit (PowerPlex
® 
16HS), however, found using a direct amplification 
kit (PowerPlex
® 
18D) was more successful when attempting to produce profiles from 
samples exposed to magnetic flake.  The extraction based samples (PowerPlex
® 
16HS) 
did not produce a full or partial profile for any of the samples except for sample B, x2 
dilution.  The direct amplification kit (PowerPlex
®
 18D) produced full or partial profiles 
at all dilutions.   
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 To date, the few publications that discuss direct amplification generally use samples 
which have been transferred to blood or buccal FTA
®
 cards (Park et al., 2008; Patel et 
al.; 2014).  This is the recommended method for samples that have not been extracted 
and it should be noted that the samples processed in this work were not placed on FTA
®
 
paper prior to processing.  In order for direct amplification to possibly be used in a field 
setting it was important for the samples in this work to be processed as if they were 
enhanced at a crime scene, collected and brought back to a laboratory for analysis.   
Sensitivity is a key factor in the acceptance of direct amplification.  When using direct 
amplification it is not necessary to undertake the extraction process.  Using an extraction 
method can reduce the amount of raw sample which was actually recovered from the 
substrate at the scene.  In this study, a range of dilutions (x1, x2, and x10) were 
evaluated.  The samples which were extracted and prepared at a x10 dilution failed to 
produce a profile whereas samples processed with PowerPlex
®
 18D gave partial profiles 
when exposed to the powders.   Since the deposit was of known quantity, the ability of an 
individual person to deposit cells on the surface was not a factor and the results appear to 
show that the low starting template could be a factor in the results (Raymond et al., 2004; 
Hanson and Ballantyne, 2005).  Future work could be conducted by altering the 
amplification parameters and retesting the samples with a higher number of amplification 
cycles.    
The white powder samples were the most successful for both kits when evaluating total 
PCR product concentration.  In regards to heterozygous peak balance (Hb) however, 
white powder samples analysed with PowerPlex
®
 16HS were less successful when 
reviewing all dilutions.  The samples processed with PowerPlex
®
 18D were better and 
the majority of all dilutions appear above the 0.70 Hb limit.  Black powder samples 
displayed similar results when evaluating the total PCR product concentration for both 
kits and were only slightly less successful when evaluating the heterozygous peak 
balance.  Previous publications have indicated that both white powder and black powder 
do not inhibit the STR profiling process ((Raymond et al., 2004; Roux et al., 1999; Stein 
et al., 1996; vanOorschot et al., 2003; vanOorschot et al., 2005).  The data generated for 
this study agrees with the earlier findings. 
This study has shown that it is possible to obtain a DNA profile using direct 
amplification from a surface which has been treated with various latent print 
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 enhancement powders and that the results of the direct amplification samples, when 
compared to the extracted samples, have a significantly stronger profile [F(1, 30)= 10.65, 
p=0.003]. 
Overall, PowerPlex
®
 16HS appears to be the less productive of the two kits when 
reviewing the data for samples which have been enhanced with powder.  One possible 
explanation for the lower total PCR product is the loss of biological sample during the 
extraction process which is eliminated when using a direct amplification system (Kemp 
et al., 2014; Qiagen, 2011).  Another possible explanation for the lack of profiles in 
PowerPlex
®
 16HS samples or low yields when processing with PowerPlex
®
 18D, could 
have been the starting amount of template DNA which ranged from 0.009 ng/µl (x10 
dilution) to 0.041 ng/µl (x1 dilution) (Chapter 3, Table 3.1).   
Despite, the positive results which were obtained in regards to the direct amplification 
system, PowerPlex
®
 18D, it should be noted these were obtained under laboratory 
conditions.  Casework materials are often exposed to foreign contaminants and personnel 
working the case.  Shedder status is also a factor which must be carefully considered 
when employing these techniques (Zoppis et al., 2004; Alessandrini et al., 2003; Lowe et 
al., 2002).  The samples in the experiment were also not exposed to cyanoacrylate ester 
fuming, also referred to as superglue fuming.  Applying this technique to the fingerprints 
prior to powder processing may help in stabilize the print and minimizing the loss of 
additional epithelial cells which can come with direct powder processing (Bhoelai et al., 
2011; Bille et al., 2009). In addition, PowerPlex
®
 16HS has also been marketed as a kit 
which could be used in a ‘direct’ amplification capacity.  A further study on the 
difference between extracted and direct samples utilizing the same kit may prove 
beneficial in determining the loss of biological sample during the extraction process. 
Future work must be undertaken to explore these areas and evaluate their individual 
effects on the samples.  While more work needs to be conducted, the PowerPlex
®
 18D, 
direct amplification kit does appear to be a possible alternative to traditional typing 
methods. 
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Chapter 6.                                                                      
EVALUATION OF BLOOD SAMPLES ENHANCED 
WITH CHEMICAL PROCESSES 
 
The following section describes the evaluation and comparison of Promega
®
 PowerPlex
®
 
16HS and Promega
®
 PowerPlex
®
 18D human identifications systems on the mock blood 
marks which have been processed with leucocrystal violet (LCV), amido black and 
ninhydrin on a variety of substrates. 
 
6.1 Overview 
Improvements in DNA analysis by increasing speed and accuracy for the development of 
profiles has become an invaluable tool for the forensic community over the past several 
years.  Many techniques and advancements strive to increase the rate at which a DNA 
profile can be produced while also being cost effective.  As many agencies battle budget 
constraints the ability to increase efficiency and productivity are on the rise.  There is 
also increased emphasis in producing mobile or portable devices capable of producing 
rapid real-time results (Gray et al., 2014) which would eliminate time consuming 
practices and limit consumables and equipment in the laboratories.  These advancements 
have the potential to revolutionize the field; however, much research needs to be 
conducted on the effects of enhancement chemicals which are used to better visualize 
and document evidence in the field.  Direct amplification has been successful in 
generating profiles from a variety of different types of crime scene samples such as a 
single hair follicle, tape lifts, swabs and FTA based samples, however, not much research 
has been conducted on the chemical enhancement techniques in relation to blood (Gray 
et al., 2014).  Latent blood transfers can occur under a variety of scenarios during the 
commission of a crime and may not always contain ridge detail for fingerprint analysis; 
however, they could yield clues as to the identity of the perpetrator via DNA profile.  In 
order for direct amplification to be a viable option for crime laboratories these samples 
need to be rigorously tested. 
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Glass, gypsum, raw wood, lead, plastic, glass, laminate, and tile were used as substrates 
for the work.  The substrates were selected based on published works which contained 
samples processed on these substrates and/or were noted limitation in other works as 
substrates which should be considered in future research (Gino and Omedei, 2011; 
Praska and Langenberg, 2013; Swaran and Welch, 2012; Bhoelai et al., 2011; Frégeau et 
al., 2000; Alessandri et al., 2003; Daly et al., 2012; Zoppis et al., 2014). 
Leucocrystal violet (LCV) is a haem reactive chemical responding to the haemoglobin 
found within red blood cells (Praska and Langenburg, 2013).  The components of the 
chemical contain hydrogen peroxide which aids in binding to the haemoglobin and the 
crystal violet stain colours the stain a bright purple (Bodziak et al., 1996).  LCV can be 
used on porous and nonporous surfaces which may be encountered at scenes of crime.  
LCV has been shown to not inhibit profiles generated with extraction based PCR 
products (Spear et al., 2002; Bleay et al., 2012).  Amido black is a protein reactive 
chemical.  Amido black binds to the cationic groups of proteins found in blood and is the 
most specific of the dye stain proteins (Bosser, 2011).  Amido black stain is dark blue to 
black in colour and can be used on nonporous surfaces.  It has also been shown not to 
inhibit profiles generated with extraction-based PCR products (Spear et al., 2002; Bleay 
et al., 2012).  Ninhydrin is a chemical which reacts to amino acids within the stain.  It 
stains a dark purple colour.  Ninhydrin is used on porous surfaces and has shown no 
inhibition when generating DNA profiles (Bleay et al., 2012; Bever et al.; Stein et al., 
1996). 
Leucocrystal violet, amido black and ninhydrin were used for this study. Chemicals 
chosen were selected based on accessibility, usage in laboratories and ultimately with 
which molecules they react.  It was the goal of the work to target chemicals which 
responded to each component found within the blood, i.e. haem-reactive, protein-reactive 
and amino acid-reactive.  Substrates identified as those commonly encountered at crime 
scenes were processed.  The substrates include glass, gypsum, raw wood, lead, plastic, 
glass, laminate, and tile. Specific objectives for this chapter are to: 
1. Amplify and analyse samples which have been processed with the three chemicals 
selected for analysis- leucocrystal violet, amido black, and ninhydrin, and used to 
generate DNA profiles with PowerPlex
®
 16HS and PowerPlex
®
 18D;  
2.  Consider any visual abnormalities which may have occurred while processing the 
substrates with their respective chemicals; 
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3. Assess the ability to generate complete and good quality profiles for each dilution 
across multiple substrates for each chemical and kit, PowerPlex
®
 16HS and PowerPlex
®
 
18D under various sample dilutions; 
4. Evaluate the profiles for artefacts such as dye blobs, stutters, pull-up, and split 
peaks which may be present in the generated profiles. 
6.2 Experimental Design 
All substrates were prepared using 20μl bloody marks which were applied to white 
laminate (12in x 12in carrara marble), tile (Value White Wall Tile 150mm x 150mm), 
glass (Microscope slide), metal (lead), plastic (acetate sheets), gypsum board and raw 
wood (Section 2.3).   These substrates were selected based on their usage as substrates in 
other publications regarding DNA analysis.  Metal (lead), gypsum board and raw wood 
have also been noted as samples which have produced little to no profile when using 
standard DNA analysis techniques (Spear et al., 2002).  Each substrate was then labelled 
and photographed.  After photographing the substrates were then processed using 
leucocrystal violet, amido black, and ninhydrin as depicted in Table 2.3.  Each of the 
substrates was again photographed post chemical exposure to note the colour change 
which indicates that a biological substance is present.  A Swabstick (Dynarex
®
) was used 
to swab the area which produced a colour change on the substrate using the dual swab 
technique (Sweet et al., 1997).  The colour change indicates the chemical reacted with 
the biological material.  The samples were then processed in accordance to the whole 
blood procedure outlined in section 2.5.  All samples were conducted in triplicate. 
An additional set of samples were run with the three dilutions on the substrates listed 
above with no chemical processing.  These samples were analysed to see if the substrate 
played a possible role in profile inhibition and were also used to compare the overall 
peak heights and PCR product concentrations between the ‘no chemical’ samples in 
comparison to those processed with the chemicals. These samples were also processed in 
accordance to the whole blood procedure outlined in section 2.5.  All samples were 
conducted in triplicate. 
All PowerPlex
®
 18D data used in comparative figures with PowerPlex
®
 16HS have been 
normalized by removing the data for D2S1338 and D19S433.  D2S1338 and D19S433 
are not present in PowerPlex
®
 16HS. 
 
112
6.3 Results and Discussion 
6.3.1 Leucocrystal Violet (LCV) 
Overall results for samples processed with LCV indicated that the extracted samples 
produced with PowerPlex
®
 16HS gave lower peak heights and PCR product 
concentrations compared to samples which were subjected to direct amplification with 
PowerPlex
®
 18D.    
The kits were also compared to samples on substrates which were not exposed to LCV 
(no chemical processing).  In this case, the samples which were not exposed to LCV 
showed much higher peak heights and PCR product concentrations when evaluating both 
kits.  The difference was statistically significant yielding a p-value<0.05 [F(1, 82)= 4.48, 
p-value= 0.038].  Figure 6.1 displays the average PCR product concentration for all 
samples and dilutions processed with both PowerPlex
®
 16HS and 18D compared to all 
samples and dilutions analysed with PowerPlex
®
 16HS and 18D which contained no 
LCV on the substrates. 
 
 
Figure 6.1:  Graph displaying the average PCR product concentration (RFU/µl) for 
each kit, PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples processed using 
LCV (purple bars) and for all samples processed with no chemical enhancement 
(grey bars).  The error bars represent the standard deviations for each of the kits. 
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The successfulness of direct PCR amplification and autosomal STR kit sensitivity were 
evaluated using peak heights and locus/allele drop-out. Each sample was evaluated and 
placed into a chart based on their exhibition of alleles above the predetermined threshold 
of 50 RFU.    Sample A presents 12 heterozygous loci and 3 homozygous loci when 
analysed with PowerPlex
®
 16HS and 14 heterozygous loci and 3 homozygous loci when 
analysed with PowerPlex
®
 18D.  Sample B presents 8 heterozygous loci and 7 
homozygous loci when analysed with PowerPlex
®
 16HS and 9 heterozygous loci and 8 
homozygous loci when analysed with PowerPlex
®
 18D. 
Figures 6.2 -6.8 are organized by substrate processed with LCV and subsequently by the 
autosomal STR kit used to generate the profiles.    These figures were used to examine 
the variation in the amplification between the different dilution volumes, chemicals, 
substrates and autosomal STR kits.  They were also used to assess each locus to 
determine if all alleles were present.  If all alleles were present the locus was determined 
to be complete.  Profiles were noted as either full profiles (FP) where all alleles at all 
locations were observed, partial profiles (PP) where the number after indicates the 
number of loci which presented the alleles and no profile (NP) where the chromosomal 
location did not display the proper allele call at any location in the whole profile.  This 
information is reflected under ‘Profile Type’ in Tables 6.1-6.2. 
Direct PCR gave full profiles in almost all (31 of 39) the substrates which were 
processed with LCV across all three dilutions (Table 6.2).  Direct amplification exhibited 
a gradual decrease as the amount of starting biological material decreased. Plastic was 
the only substrate which yielded a higher RFU value for all dilutions when analysed with 
PowerPlex
®
 16HS.  While the RFU values were higher with PowerPlex
®
 16HS, a full 
profile was obtained with PowerPlex
®
 18D in all dilutions where PowerPlex
®
 16HS only 
produced partial profiles at the x10 dilution.  These results are consistent with results 
obtained from Swaran and Welch (2012); however, it should be noted that in Swaran and 
Welch (2012) the substrates were only placed on a variety of substrates with no chemical 
exposure.  Lead also failed to give full profiles for most of the dilutions processed and 
was even less successful when using the extracted method, PowerPlex
®
 16HS.  Tile 
yielded the highest RFU values and produced full profiles in both kits when reviewing 
samples created with the x1 and x2 dilutions. 
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 Figure 6.2:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Plastic and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles 
were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing.  
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Figure 6.3:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Tile and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles were 
observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.4:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Raw Wood and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.5:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Lead and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles 
were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.6:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Laminate and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles 
were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.7:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Gypsum and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles 
were observed for that locus.  Yellow squares represent one allele drop out.  Red squares specify loci where both expected alleles are missing. 
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Figure 6.8:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using LCV on Glass and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct alleles 
were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Table 6.1: Results for LCV profiles using PowerPlex
®
 16HS showing the minimum, maximum and average peak heights, the profile 
type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) reactions, 
and processed on various substrates. The values are averages of three replicates. 
Su
b
st
ra
te
 
Sa
m
p
le
 
 
D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Glass 
A 
x1 694 (s.d. 152) 54 (s.d. 1.15) 220.05 PP13 12983 (s.d. 1622.87) 1038.6 (s.d. 129.8) 
x2 -- -- -- -- -- -- 
x10 1262 (s.d. 290.24) 50 (s.d. 10.81) 223.08 PP13 14500 (s.d. 1834.49) 1160 (s.d. 146.7) 
B 
x1 9208 (s.d. 1085.15) 56 (s.d. 38.02) 2207.27 FP 150094 (s.d. 10374.02) 12007.5 (s.d.829.9) 
x2 -- -- -- -- -- -- 
x10 6195 (s.d. 512.11) 293 (s.d. 29.14) 1561.64 FP 112438 (s.d. 2356.71) 8995.0 (s.d. 188.5) 
Gypsum 
A 
x1 666 (s.d. 198.68) 51 (s.d. 5.29) 178.65 PP10 9647 (s.d. 3215.67) 771.8 (s.d. 93.4) 
x2 149 (s.d. 53.43) 50 (s.d. 11.68) 69.85 PP1 489 (s.d. 91.16) 39.1 (s.d.7.3) 
x10 826 (s.d. 221.50) 50 (s.d. 3.79) 169.07 PP7 7101 (s.d. 539.26) 568.1 (s.d.43.1) 
B 
x1 4666 (s.d. 1441.76) 106 (s.d. 44.43) 760.79 PP13 42604 (s.d. 5840.47) 3408.3 (s.d. 467.2) 
x2 -- -- -- -- -- -- 
x10 1076 (s.d. 68.43) 55 (s.d. 5.50) 309.55 PP14 18573 (s.d. 1734.60) 1485.8 (s.d. 138.8) 
Laminate 
A 
x1 4817 (s.d. 1187.35) 51 (s.d. 46.87) 1005.97 PP14 75448 (s.d. 8745.46) 6035.8 (s.d. 699.6) 
x2 68 (s.d. 35.91) 68 (s.d. 35.91) 61 NP 122 (s.d. 35.91) 9.8 (s.d. 2.9) 
x10 3977 (s.d. 1054.33) 50 (s.d. 24.66) 551.20 FP 45750 (s.d. 2815.17) 3660 (s.d. 225.2) 
B 
x1 1440 (s.d. 477.19) 50 (s.d. 4.58) 369.04 PP13 20297 (s.d. 2921.17) 1623.08 (s.d.233.7) 
x2 -- -- -- -- -- -- 
x10 1095 (s.d. 229.65) 51 (s.d. 34.70) 301.39 PP14 19289 (s.d. 2506.31) 1543.12 (s.d. 200.5) 
Lead 
A 
x1 1192 (s.d. 223.50) 53 (s.d. 11.72) 297.03 PP13 19604 (s.d. 1654.93) 1568.3 (s.d. 132.4) 
x2 2499 (s.d. 822.05) 54 (s.d. 12.74) 448.65 PP1 32303 (s.d. 3914.68) 2584.2 (s.d. 313.2) 
x10 1221 (s.d.  380.40) 52 (s.d. 1.53) 244.16 PP11 17091 (s.d. 2299.44) 1367.3 (s.d. 183.9) 
B 
x1 1341 (s.d. 185.63) 56 (s.d. 31.56) 373.53 PP13 20544 (s.d. 1512.09) 1643.5 (s.d. 120.9) 
x2 -- -- -- NP -- -- 
x10 1370 (s.d. 481.88) 52 (s.d. 6.03) 252.57 PP14 15154 (s.d. 1276.31) 1212.32 (s.d. 102.1) 
Plastic 
A 
x1 16166 (s.d. 4422.25) 591 (s.d. 269.69) 4267.52 FP 358472 (s.d. 50015.92) 28677.8 (s.d. 4001.2) 
x2 1414 (s.d. 87.61) 83 (s.d. 27.14) 451.51 FP 37927 (s.d. 834.52) 3034.2 (s.d. 66.8) 
x10 1749 (s.d. 489.25) 60 (s.d. 24.85) 338.75 PP14 26761 (s.d. 1826.98) 2140.9 (s.d. 146.2) 
B 
x1 8374 (s.d. 1209.49) 97 (s.d. 239.45) 3203.60 FP 230659 (s.d. 12675.04) 18452.7 (s.d. 1014) 
x2 13975 (s.d. 2595.32) 553 (s.d. 121.70) 3684.93 FP 265315 (s.d. 11204.71) 21225.2 (s.d. 896.4) 
x10 520 (s.d. 113.90) 50 (s.d. 4.16) 187.49 PP13 9937 (s.d. 1260.82) 794.9 (s.d. 100.9) 
Raw 
Wood 
A 
x1 21696 (s.d. 1374.60) 1319 (s.d. 234.51) 6703.66 FP 563107 (s.d. 18312.81) 45048.6 (s.d. 1465) 
x2 3114 (s.d. 949.90) 77 (s.d. 3.61) 625.95 FP 51328 (s.d. 8044.37) 4106.2 (s.d. 643.5) 
x10 1452 (s.d.78.01 ) 52 (s.d. 8.08) 342.29 PP15 27041 (s.d. 1502.75) 2163.3 (s.d. 120.2) 
B 
x1 19871 (s.d. 4541.80) 863 (s.d. 100.18) 5362.72 FP 386116 (s.d. 31887.91) 30889.13 (s.d. 2551.0) 
x2 1472 (s.d. 481.57) 52 (s.d. 29.57) 295.30 PP13 16832 (s.d. 2838.23) 1346.6 (s.d. 227.1) 
x10 1795 (s.d. 377.59) 71 (s.d. 7) 401.72 PP14 26915 (s.d. 1823.00) 2153.2 (s.d. 145.8) 
Tile 
A 
x1 24963 (s.d. 2918.66) 1701 (s.d. 305.93) 8119.94 FP 682075 (s.d. 8976.29) 54566 (s.d. 718.1) 
x2 667 (s.d. 81.57) 51 (s.d. 10.69) 181.76 FP 13632 (s.d. 468.12) 1090.6 (s.d. 37.4) 
x10 1700 (s.d. 200.85) 62 (s.d. 8.89) 466.96 PP15 38291 (s.d. 3468.11) 3063.3 (s.d. 277.4) 
B 
x1 20189 (s.d. 2262.67) 1812 (s.d. 115.70) 7870.76 FP 566695 (s.d. 15063.92) 45335.6 (s.d. 1205.1) 
x2 8309 (s.d. 1235.50) 484 (s.d. 114.96) 2904.36 FP 209114 (s.d. 9084.61) 167929.1 (s.d. 726.8) 
x10 2203 (s.d. 781.86) 50 (s.d. 19.08) 471.28 PP15 32518 (s.d. 3699.13) 2601.4 (s.d. 295.9) 
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1
 The alleles obtained in this profile were one of two in a heterozygous locus (yellow box) or a homozygous peak in a locus (green 
box); however, in both cases, were not reproducible thus not added to the ‘profile type’ determination.     
 
 
 
Table 6.2:  Results for LCV profiles using PowerPlex
®
 18D showing the minimum, maximum and average peak heights, the profile 
type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) reactions, 
and processed on various substrates. The values are averages of three replicates.   
Su
b
st
ra
te
 
Sa
m
p
le
 
 
D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Glass 
A 
x1 19558 (s.d. 3704.26) 334 (s.d. 2368.95) 7657.30 FP 735101 (s.d. 36771.26) 58808.1 (s.d.2941.7) 
x2 3718 (s.d. 471.05) 438 (s.d. 163.79) 1205.60 NP 115738 (s.d. 9183.91) 9259.0 (s.d.734.7) 
x10 218 (s.d. 14.93) 51 (s.d. 2.08) 96.19 PP14 7503 (s.d. 367.04) 600.2 (s.d. 29.4) 
B 
x1 3310 (s.d. 502.43) 108 (s.d. 83.69) 784.36 FP 68239 (s.d. 1451.52) 5459.1 (s.d. 116.1) 
x2 156 (s.d. 24.68) 50 (s.d. 4.04) 81.4 NP 3256 (s.d. 212.86) 260.5 (s.d. 17.0) 
x10 639 (s.d. 154.63) 64 (s.d. 2) 182.99 FP 14639 (s.d. 646.36) 1171.1 (s.d. 51.7) 
Gypsum 
A 
x1 14923 (s.d. 2787.38) 239 (s.d. 694.87) 4861.54 FP 466708 (s.d. 32773.74) 37336.6 (s.d. 2621.9) 
x2 4343 (s.d. 23.46) 51 (s.d. 385.52) 1857.12 FP 180141 (s.d. 6943.96) 14411.3 (s.d. 555.5) 
x10 919 (s.d. 118.59) 124 (s.d. 11.02) 349.48 FP 33550 (s.d. 2028.29) 2684 (s.d. 162.3) 
B 
x1 14967 (s.d. 805.98) 193 (s.d. 707.67) 5845.51 FP 473486 (s.d. 16101.98) 37878.9 (s.d. 1288.2) 
x2 5846 (s.d. 483.17) 966 (s.d. 45.76) 2516.99 FP 203876 (s.d. 5877.48) 16310.1 (s.d. 470.2) 
x10 971 (s.d. 87.69) 121 (s.d. 6.24) 374.10 FP 30302 (s.d. 520.76) 2424.2 (s.d. 41.7) 
Laminate 
A 
x1 22050 (s.d. 1743.80) 535 (s.d. 2425.11) 8673.31 FP 832638 (s.d. 18691.51) 66611.0 (s.d. 1495.3) 
x2 1609 (s.d. 328.07) 238 (s.d. 60.26) 451.92 FP 43384 (s.d. 4118.29) 3470.7 (s.d. 329.5) 
x10 665 (s.d. 71.60) 67 (s.d. 35.02) 211.39 FP 20293 (s.d. 1176.53) 1623.4 (s.d. 94.1) 
B 
x1 6164 (s.d. 1368.25) 340 (s.d. 164.43) 1824.60 FP 147793 (s.d. 8750.86) 11823.4 (s.d. 700.1) 
x2 112 (s.d. 64.66)1 52 (s.d. 30.02) 70.14 NP 491 (s.d. 283.48) 39.3 (s.d. 22.7) 
x10 193 (s.d. 20.66) 51 (s.d. 8.89) 95.87 PP11 3643 (s.d. 194.64) 291.4 (s.d. 15.6) 
Lead 
A 
x1 2533 (s.d. 127.69) 108 (s.d. 74.54) 757.48 FP 71961 (s.d. 7083.82) 5758.9 (s.d. 566.7) 
x2 242 (s.d. 95.13) 50 (s.d. 0.58) 74.31 PP1 966 (s.d. 149.36) 77.3 (s.d. 11.9) 
x10 323 (s.d. 38.44) 50 (s.d. 0.58 119.54 FP 10998 (s.d. 387.79) 879.8 (s.d. 31.0) 
B 
x1 2471 (s.d. 406.25) 101 (s.d. 15.87) 544.51 PP4 40294 (s.d. 699.85) 3223.5 (s.d. 55.9) 
x2 183 (s.d. 96.39) 50 (s.d. 96.39) 163.5 PP1 327 (s.d. 96.39) 26.2 (s.d. 7.7) 
x10 107 (s.d. 10.97) 51 (s.d. 3.79) 74.73 PP6 1644 (s.d. 231.92) 131.5 (s.d. 18.6) 
Plastic 
A 
x1 5299 (s.d. 1614.24) 316 (s.d. 368.57) 1480.22 FP 142101 (s.d. 21347.76 11368.0 (s.d. 1707.8) 
x2 6288 (s.d. 886.31) 834 (s.d. 203.44) 2245.49 FP 215567 (s.d. 2881.03) 17245.4 (s.d. 230.5) 
x10 312 (s.d. 46.82) 50 (s.d. 1.15) 120.65 PP16 10979 (s.d. 310.70) 878.3 (s.d. 24.8) 
B 
x1 7505 (s.d. 1457.58) 762 (s.d. 314) 2555.95 FP 207032 (s.d. 12223.42) 16562.6 (s.d. 977.9) 
x2 6812 (s.d. 900.60) 800 (s.d. 264.83) 2663.26 FP 215724 (s.d. 3834.25) 17257.9 (s.d. 306.7) 
x10 590 (s.d. 170.16) 58 (s.d. 6.35) 184.80 PP17 13675 (s.d. 1399.30) 1094 (s.d. 111.9) 
Raw 
Wood 
A 
x1 16848 (s.d. 4654.91) 2145 (s.d. 766.87) 5652.81 FP 542670 (s.d 55405.93) 43413.6 (s.d. 4432.5) 
x2 4616 (s.d. 165.06) 557 (s.d. 116.65) 1953.74 FP 187559 (s.d. 6297.10) 15004.7 (s.d. 503.8) 
x10 1024 (s.d. 86.60) 111 (s.d. 44.23) 390.16 FP 37455 (s.d. 1569.59) 2996.4 (s.d. 125.6) 
B 
x1 10648 (s.d. 2677.06) 1003 (s.d. 520.17) 3576.59 FP 289704 (s.d. 36083) 23176.3 (s.d. 2886.6) 
x2 7401 (s.d. 1560.54) 544 (s.d. 228.58) 2555.67 FP 207009 (s.d. 15777.90) 16560.7 (s.d. 1262.2) 
x10 592 (s.d. 119.65) 71 (s.d. 6.51) 215.13 FP 16995 (s.d. 2122.40) 1359.6 (s.d. 169.8) 
Tile 
A 
x1 9190 (s.d. 1797.22) 1313 (s.d 491.99) 3526.33 FP 338528 (s.d. 33517.45) 27082.2 (s.d. 2681.4) 
x2 22680 (s.d. 6013.82) 51 (s.d. 2141.12) 6074.65 FP 589241 (s.d. 63291.16) 47139.3 (s.d. 5063.3) 
x10 886 (s.d. 144.44) 119 (s.d. 11.02) 308.06 FP 29574 (s.d. 1386.85) 2365.9 (s.d. 110.9) 
B 
x1 1841 (s.d. 389.23) 117 (s.d. 64.30) 688.46 FP 55765 (s.d. 2643.46) 4461.2 (s.d. 211.5) 
x2 29197 (s.d. 2843.63) 4895 (s.d. 103.23) 13136.31 FP 1064041 (s.d. 32860.98) 85123.3 (s.d. 2628.9) 
x10 660 (s.d. 28.36) 67 (s.d. 26.46) 271.42 FP 21985 (s.d. 444.71) 1758.8 (s.d. 35.6) 
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 Dilutions were a significance factor when evaluating the samples [F(2,74)= 13.11, p= 
0.001) without regard to the kit used.  This was to be expected since decreasing dilutions 
of DNA were used in the study. Figure 6.9 displays each dilution in regard to average 
PCR product concentration and compares ‘no chemical’ samples to samples processed 
with LCV.   
 
Figure 6.9:  Average PCR product concentration (RFU/µl) for each kit, PowerPlex
®
 
16HS and PowerPlex
®
 18D, for all samples processed using LCV (purple bars) and 
for all samples processed with no chemical enhancement (grey bars).  The error 
bars represent the standard deviations for each of the dilutions. 
The substrates proved to play a noteworthy role in the average PCR product 
concentration values with a significant variance noted [F(6, 32)= 2.96, p-value 0.012]. 
Tile yielded the strongest profiles and lead the weakest across all dilutions. Gypsum also 
provided full profiles with high peak height values across all dilutions but the total PCR 
product concentrations were lower than those of tile. This is also consistent with results 
obtained from Swaran and Welch (2012).  Figures 6.10 (A-G) show a comparison of 
both kits for each substrate by average PCR product concentration.  Both the ‘no 
chemical’ samples and LCV processed samples can be seen broken down by dilution. 
An evaluation of the samples used in the study, A and B, showed no significant 
difference [F(1, 82)= 0.48, p-value= 0.491).   
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Figure 6.10 (A-G): The average PCR product concentration in (RFU/µl) by dilution 
for samples processed with no chemicals and samples processed with LCV on A) 
glass, B) gypsum, C) laminate, D) lead, E) plastic, F) raw wood, and G) tile.  The 
error bars represent the standard deviations for each of the dilutions and 
processed/unprocessed sample averages. 
6.3.1.1 Heterozygous Peak Height Balance 
Heterozygous peak balance was also assessed for each heterozygous locus present in 
both sample A and B.  Heterozygous peak balance (Hb) is the ratio of the two peaks 
present at a heterozygous locus.  This is determined mathematically by dividing the allele 
with the lower peak height value by the allele with the greater peak height value (Frégeau 
et al. 2004).  Results range from 0 to 1 with 1 representing alleles of equal height.  An 
Hb value which is below 0.70 indicates peak height imbalance.  Symbols which are 
present at the baseline (0) indicate that only 1 of the 2 alleles present in the heterozygous 
locus was above threshold.  Figures 6.11 through 6.18 exhibit heterozygous loci which 
are present in both sample A and B and their dilutions by substrate processed.  A red 
dotted line indicates the 0.7 Hb threshold for the results. 
Profiles which displayed peak imbalance (Hb <0.70) were observed in both extracted and 
direct PCR samples. Overall peak imbalance within the PowerPlex
®
 18D processed 
samples was lower than those processed with PowerPlex
®
 16HS for all observed loci.  
Samples which were exposed to the x10 dilution fell below the 0.7 limit more often; this 
was to be expected given the decreased amount of DNA template available.  The 
majority appear to be from sample B which quantitatively was weaker than sample A 
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(Data Quantitation) and samples which were prepared with the x10 dilution.  Tile 
contained the fewest loci with peak imbalances for all samples, dilutions and loci 
evaluated.  Loci Penta E, D18, CSF, and FGA displayed the most peak imbalances for 
both kits. 
6.3.1.1.1 Evaluation of CSF1PO  
The heterozygous allele of CSF1PO was present in sample A.  CSF1PO was more 
successful in displaying both alleles when processed with PowerPlex
®
 18D.  Both alleles 
were displayed in 25 of 63 samples analysed with PowerPlex
®
 16HS as compared to 
PowerPlex
®
 18D where both alleles were present in 50 of the 63 samples processed 
(Figures 6.2-6.8).  Of the samples producing both alleles, 15 of the 25 samples processed 
with PowerPlex
®
 16HS displayed peak height balance ratios of 0.70 Hb or higher.  This 
is a lower percentage than the 42 of 50 which were over 0.70 when analysed with 
PowerPlex
®
 18D.  
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Figure 6.11:  (Top) Peak height ratios for CSF1PO produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for CSF1PO 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.12:  (Top) Peak height ratios for D13S317 produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for D13S317 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.13:  (Top) Peak height ratios for D18S51 produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for D18S51 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.14:  (Top) Peak height ratios for D21S11 produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for D21S11 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
 
 
                Glass                Gypsum         Laminate            Lead               Plastic            Raw Wood            Tile 
                   Glass                Gypsum         Laminate            Lead            Plastic            Raw Wood         Tile 
132
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8
H
e
te
ro
zy
go
u
s 
P
e
ak
 H
e
ig
h
t 
B
al
an
ce
 R
at
io
 
Substrate 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8
H
e
te
ro
zy
go
u
s 
P
e
ak
 H
ei
gh
t 
B
al
an
ce
 R
at
io
 
Substrate  
 
 
Figure 6.15:  (Top) Peak height ratios for D3S1358 produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for D3S1358 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.16:  (Top) Peak height ratios for D7S820 produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for D7S820 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.17:  (Top) Peak height ratios for FGA produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for FGA 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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Figure 6.18:  (Top) Peak height ratios for Penta E produced for various substrates 
when analysed with PowerPlex
®
 16HS.  (Bottom)  Peak height ratios for Penta E 
produced for various substrates when analysed with PowerPlex
®
 18D.  All three 
replicates of each sample (A and B) for each dilution are represented. 
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In general, the profiles generated from direct amplification gave higher peak height 
values and were less prone to peak imbalances than those processed after DNA 
extraction.  An example of this is Glass, x1 dilution.  Figure 6.19, shows sample A which 
was processed with LCV on glass at the x1 dilution.  Powerplex
®
 18D exhibits stronger 
overall peak heights (over 2,000RFU for all loci) and less peak imbalance than 
PowerPlex
®
 16HS. 
 
 
 
 
 
 
 
 
 
Figure 6.19: Combined dye electropherogram displaying (1) sample A (Glass, x1) 
processed with PowerPlex
®
 16HS displayed at 500 RFU. Combined dye 
electropherogram displaying (2) sample A (Glass, x1) processed with PowerPlex
®
 
18D displayed at 15000 RFU. 
 
Lead was the weakest substrate, yielding the lowest total PCR product and peak heights.  
While processing the surface prior to swabbing a noticeable reaction occurred after 
exposing the lead to the LCV solution.  It is hypothesized that the LCV caused an 
oxidation effect possibly affecting the blood on the surface and negatively impacting the 
profile.  Figure 6.20 shows sample A, x1 dilution substrate after processing with the LCV 
solution.  The photograph on the right was the sample swabbed and analysed with 
PowerPlex
®
 18D and the left with PowerPlex
®
 16HS.  Electropherograms displaying the 
profiles generated from the samples in Figure 6.20 can be seen in Figure 6.21. 
 
 
 
 
 
Figure 6.20:  Sample A, x1 dilution (left) and processed with PowerPlex
®
 16HS. 
Sample A, x1 dilution (right) processed with PowerPlex
®
 18D. 
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Figure 6.21:  Electropherograms demonstrating profiles produced with PowerPlex
®
 
16HS and 18D.  (1) Sample A, x1 dilution and processed with PowerPlex
®
 16HS on 
lead. (2) Sample A, x1 dilution and processed with PowerPlex
®
 18D on lead.  The x-
axis represents relative fluorescent units (RFU) and the y-axis fragment size in base 
pairs. 
D3S1358               TH01                  D21S11                   D18S51  Penta E 
D5S818               D13S317         D7S820                  D16S539 CSF1PO                 Penta D 
                    Amel                    vWA           D8S1179                      TPOX           FGA 
D3S1358          TH01             D21S11                                        D18S51               Penta E 
          D5S818               D13S317         D7S820                  D16S539 CSF1PO                 Penta D 
                        Amel                    vWA           D8S1179                         TPOX            FGA 
                   D19S433       D2S1338 
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6.3.1.2 Stutter and other Artefacts 
Stutter peaks are commonly seen in electropherograms when analysing data.  Stutter is 
identified as a small peak which is generally one repeat unit less/more than the true 
allele.  The levels of stutters were all lower (10.1% for a combined average of both kits) 
than the limit recommended by the manufacturer, which is usually 15%.  
The profiles generated from the amplification of x2 and x10 dilutions, in general, were of 
good quality, with no drop-ins or split peaks. The only exception was the profiles 
generated from x1 solution of DNA. An abundance of biological material within the 
smaller loci gave peaks which were split.  Split peaks, also referred to as +A/-A peaks, 
are due to non-template addition generally of adenosine which occurs at the 3'-end of the 
PCR product.   Amplifying higher quantities of DNA than the recommended amount can 
result in the incomplete 3' A nucleotide addition. 
6.3.2 Amido Black 
Overall results for amido black samples indicated that the extracted samples produced 
with PowerPlex® 16HS gave lower peak heights (RFU) compared to samples which 
were subjected to direct amplification with PowerPlex
®
 18D.   
The kits were also compared to samples on substrates which were not exposed to amido 
black (no chemical processing).  In this case, the samples which were not exposed to 
amido black showed higher peak heights and PCR product concentrations when 
evaluating both kits.  The difference was statistically significant yielding a p-value<0.05 
[F(1, 58)= 4.75, p-value= 0.014].  Figure 6.22 displays the average PCR product 
concentration for all samples and dilutions processed with both PowerPlex
®
 16HS and 
18D compared to all samples and dilutions analysed with PowerPlex
®
 16HS and 18D 
which contained no chemicals on the substrates.  
The successfulness of direct PCR amplification and autosomal STR kit sensitivity were 
evaluated for amido black in the same manner as described in Section 6.3.1.  Figures 
6.23-6.27 are organized by substrate processed with amido black and subsequently by the 
autosomal STR kit used to generate the profiles.  These figures were used to examine the 
variation in the amplification between the different dilution volumes, chemicals, 
substrates and autosomal STR kits. 
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Figure 6.22:  The average PCR product concentration (RFU/µl) for each kit, 
PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples processed using amido 
black and for all samples processed with no chemical enhancement.  The error bars 
represent the standard deviations for each of the kits. 
 
Profiles generated using amido black were also used to assess how complete a profile 
was and to determine the maximum and minimum peak heights for each allele present.  
The PCR product concentrations and total RFUs were used for this assessment.  Profiles 
were also noted as either full profiles (FP) where all alleles at all locations were 
observed, partial profiles (PP) where the number after indicates the number of loci which 
presented the alleles for that specific location and no profile (NP) where the 
chromosomal location did not display the proper allele call at any location in the whole 
profile.  This information is reflected under ‘Profile Type’ in Tables 6.2-6.3. 
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Figure 6.23:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Amido Black on Plastic and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.24:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Amido Black on Tile and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.25:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Amido Black on Lead and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.26:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Amido Black on Laminate and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full 
correct alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.27:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Amido Black on Glass and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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 The alleles obtained in this profile were one of two in a heterozygous locus (yellow box) or a homozygous peak in a locus (green 
box); however, in both cases, were not reproducible thus not added to the ‘profile type’ determination.  
Table 6.3: Results for Amido Black profiles using PowerPlex
®
 16HS showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed on various substrates. The values are averages of three replicates. 
Su
b
st
ra
te
 
Sa
m
p
le
 
 
D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Glass 
A 
x1 1661 (s.d. 104.52) 64 (s.d. 17.16) 534.88 PP14 38511 (s.d. 851.72) 3080.9 (s.d. 68.1) 
x2 1324 (s.d. 613.05) 53 (s.d. 8.39) 288.92 PP7 13868 (s.d. 5481.04) 1109.4 (s.d. 438.5) 
x10 1868 (s.d. 471.71) 64 (s.d. 9.54) 360.63 PP15 28490 (s.d. 711.33) 2279.2 (s.d. 56.9) 
B 
x1 2664 (s.d. 282.00) 50 (s.d. 18.72) 659.933 PP14 39596 (s.d. 1258.04) 3167.7 (s.d. 100.6) 
x2 2497 (s.d. 516.66) 50 (s.d. 3.46) 502.93 NP2 29673 (s.d. 2020.39) 2373.8 (s.d. 161.6) 
x10 2150 (s.d. 614.70) 56 (s.d. 59.02) 531.99 FP 37771 (s.d. 4464.37) 3021.7 (s.d. 357.1) 
Laminate 
A 
x1 3679 (s.d. 511.85) 119 (s.d. 23.01) 1032.69 PP14 74354 (s.d. 4635.73) 5948.3 (s.d. 370.8) 
x2 5465 (s.d. 3099.28) 50 (s.d. 9.71) 1221.15 PP2 41519 (s.d. 23502.60) 3321.5 (s.d. 1880.2) 
x10 4352 (s.d. 820.98) 186 (s.d. 49.33) 928.25 FP 77973 (s.d. 2624.52) 6237.8 (s.d. 209.9) 
B 
x1 1611 (s.d. 143.12) 53 (s.d. 22.54) 464.89 PP13 26499 (s.d. 385.95) 2119.9 (s.d. 30.9) 
x2 605 (s.d. 145.11) 50 (s.d. 8.14) 152.33 PP9 6093 (s.d. 606.33) 487.4 (s.d. 48.5) 
x10 1656 (s.d. 410.97) 51 (s.d. 21.22) 316.84 FP 21862 (s.d. 1789.00) 1748.9 (s.d. 143.1) 
Lead 
A 
x1 423 (s.d. 31.76) 52 (s.d. 4.04) 150.32 PP10 7967 (s.d. 472.89) 637.3 (s.d. 37.8) 
x2 -- --  NP -- -- 
x10 331 (s.d. 9.24) 51 (s.d. 2) 123.15 PP9 6527 (s.d. 235.84) 522.1 (s.d. 18.8) 
B 
x1 1378 (s.d. 166.01) 55 (s.d. 12.29) 386.29 PP13 21632 (s.d. 610.76) 1730.5 (s.d. 48.8) 
x2 -- -- -- NP -- -- 
x10 1759 (s.d. 573.20) 51 (s.d. 5.51) 384.75 PP15 25778 (s.d. 4362.07) 2062.2 (s.d. 348.9) 
Plastic 
A 
x1 22975 (s.d. 2946.32) 1767 (s.d. 353.84) 7182.79 FP 603354 (s.d. 21139.86) 48268.3 (s.d. 1691.2) 
x2 1891 (s.d. 187.80) 63 (s.d. 27.07) 494.84 FP 41072 (s.d. 2757.07) 3285.7 (s.d. 220.6) 
x10 1275 (s.d. 274.38) 60 (s.d. 12.66) 294.68 FP 23869 (s.d. 2021.36) 1909.5 (s.d. 161.7) 
B 
x1 15946 (s.d. 2262.56) 1184 (s.d. 244.25) 6179.51 FP 444925 (s.d. 17965.93) 35594 (s.d. 1437.2) 
x2 3437 (s.d. 322.97) 167 (s.d. 118.03) 1191.36 PP12 85778 (s.d. 3206.34) 6862.2 (s.d. 256.5) 
x10 1747 (s.d. 351.42) 55 (s.d. 39.72) 465.88 PP15 31680 (s.d. 2138.60) 2534.4 (s.d. 171.1) 
Tile 
A 
x1 17262 (s.d. 1930.67) 1529 (s.d. 326.17) 5963.45 FP 500930 (s.d. 27876.16) 40074.4 (s.d. 2230.0) 
x2 1065 (s.d. 228.41) 64 (s.d. 6.81) 320.75 PP15 25660 (s.d. 1734.48) 2052.8 (s.d. 138.7) 
x10 1096 (s.d. 243.69) 53 (s.d. 9.29) 253.84 PP14 19292 (s.d. 683.18) 1543.3 (s.d. 54.6) 
B 
x1 23519 (s.d. 1553.36) 1599 (s.d. 84.04) 8005.08 FP 5763.66 (s.d. 9115.91) 46109.2 (s.d. 729.3) 
x2 680 (s.d. 29.96) 56 (s.d. 17.93) 251.02 FP 14559 (s.d. 1197.22) 1164.7 (s.d. 95.7) 
x10 2234 (s.d. 483.63) 53 (s.d. 14.19) 462.36 FP 33290 (s.d. 582.70) 2663.2 (s.d. 46.6) 
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Table 6.4: Results for Amido Black profiles using PowerPlex
®
 18D showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed on various substrates. The values are averages of three replicates. 
Su
b
st
ra
te
 
Sa
m
p
le
 
 
D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Glass 
A 
x1 20028 (s.d. 1267.01) 3727 (s.d. 442.85) 7544.29 FP 724252 (s.d. 27750) 57940.1 (s.d. 2220) 
x2 5703 (s.d. 541.00) 818 (s.d. 80.53) 1965.53 FP 188691 (s.d. 6738.15) 15095.2 (s.d. 539.0) 
x10 821 (s.d. 46.92) 86 (s.d. 15.01) 258.04 FP 24772 (s.d. 418.72) 1981.7 (s.d. 33.4) 
B 
x1 23301 (s.d. 1321.30) 104 (s.d. 2246.17) 9857.20 FP 798433 (s.d. 16326.32) 63874.6 (s.d. 1306.1) 
x2 573 (s.d. 117.41) 59 (s.d. 6.51) 194.23 NP 15733 (s.d. 1170.83) 1258.6 (s.d. 93.6) 
x10 1370 (s.d. 200.25) 229 (s.d. 34.30) 563.98 FP 45682 (s.d. 1829.21) 3654.5 (s.d. 146.3) 
Laminate 
A 
x1 23654 (s.d. 3908.26) 236 (s.d. 2365.27) 8226.35 FP 789730 (s.d. 33207.55) 63178.4 (s.d. 2656.6) 
x2 743 (s.d. 60.92) 67 (s.d. 10.69) 250.04 FP 24004 (s.d. 303.98) 1920.3 (s.d. 24.3) 
x10 899 (s.d. 257.93 ) 70 (s.d. 56.57) 248.78 FP 23883 (s.d. 2292.53) 1910.6 (s.d. 183.4) 
B 
x1 21667 (s.d. 2202.45) 2519 (s.d. 667.16) 8501.51 FP 688622 (s.d. 26281.34) 55089.7 (s.d. 2102.5) 
x2 320 (s.d. 55.37) 51 (s.d. 0) 108.31 PP12 6607 (s.d. 271.02) 528.5 (s.d. 21.6) 
x10 859 (s.d. 111.84) 126 (s.d. 5.51) 312.53 FP 25315 (s.d. 1063.65) 2025.2 (s.d. 85.0) 
Lead 
A 
x1 1411 (s.d. 585.84) 364 (s.d. 585.84) 735.67 PP1 2207 (s.d. 585.84) 176.5 (s.d. 46.8) 
x2 -- -- -- NP -- -- 
x10 -- -- -- NP -- -- 
B 
x1 1674 (s.d. 165.29) 102 (s.d. 38.63) 539.50 PP4 6474 (s.d. 347.64) 517.9 (s.d. 27.8) 
x2 -- -- -- -- -- -- 
x10 77 (s.d. 12.53) 52 (s.d. 8.08) 62.60 PP2 313 (s.d. 47.01) 25.0 (s.d. 3.7) 
Plastic 
A 
x1 17007 (s.d. 318.40) 3925 (s.d. 268.97) 6763.46 FP 649292 (s.d. 9118.68) 51943.3 (s.d. 729.4) 
x2 3566 (s.d. 1007.41) 280 (s.d. 253.99) 1132.20 FP 108691 (s.d. 13728.29) 8695.2 (s.d. 1098.2) 
x10 412 (s.d. 52.85) 50 (s.d. 4.58) 130.52 PP17 12138 (s.d. 344.91) 971.0 (s.d. 27.5) 
B 
x1 6750 (s.d. 1863.11) 424 (s.d. 673.19) 2044.53 FP 165607 (s.d. 32166.49) 13248.5 (s.d. 2573.3) 
x2 4549 (s.d. 398.95) 743 (s.d. 87.18) 2019.31 FP 163564 (s.d. 1497.65) 13085.12 (s.d. 119.8) 
x10 341 (s.d. 70.50) 51 (s.d. 0.58) 104.15 PP12 6457 (s.d. 396.40) 516.5 (s.d. 31.7) 
Tile 
A 
x1 11594 (s.d. 1982.86) 61 (s.d. 1280.21) 3701.92 FP 355384 (s.d. 31587.03) 28430.7 (s.d. 2526.9) 
x2 4204 (s.d. 479.28) 542 (s.d. 47.63) 1487.53 FP 142803 (s.d. 2911.79) 11424.2 (s.d. 232.9) 
x10 510 (s.d. 81.59) 56 (s.d. 1716) 173.01 FP 16609 (s.d. 641.36) 1328.7 (s.d. 51.3) 
B 
x1 380 (s.d. 77.03) 50 (s.d. 3.06) 117.78 FP 8127 (s.d. 676.35) 650.1 (s.d. 54.1) 
x2 397 (s.d. 122.40) 50 (s.d. 0.58) 125.61 PP12 7411 (s.d. 763.20) 592.8 (s.d. 61.0) 
x10 135 (s.d. 20.11) 51 (s.d. 0.58) 75.56 PP15 1889 (s.d. 68.99) 151.1 (s.d. 5.5) 
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 Dilutions were a significant factor when evaluating the samples, p<0.05 [F(2,23)= 8.03, 
p-value= 0.002].  Again, this was again to be expected as decreasing dilution samples 
were used for amido black as well.  Figure 6.28 displays each dilution in regard to 
average PCR product concentration and compares ‘no chemical’ samples to samples 
processed with amido black. 
 
 
 
Figure 6.28:  The average PCR product concentration (RFU/µl) for each kit, 
PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples processed using amido 
black (green bars) and for all samples processed with no chemical enhancement 
(grey bars).  The error bars represent the standard deviations for each of the 
dilutions.   
 
The substrates had a significant effect on the average PCR product concentration with a 
significant variance noted [F(4, 23)= 3.11, p-value 0.035]. Overall, plastic was observed 
yielded the strongest PCR product concentration when observing the PowerPlex
®
 16HS 
was used and glass the strongest PowerPlex
®
 18D data was used.  Lead was the weakest 
across all dilutions and both kits.  Figure 6.29 (A-E) reflects a comparison of both kits 
for each substrate by average PCR product concentration.  Both the ‘no chemical’ 
samples and amido black processed samples can be seen broken down by dilution. 
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Figure 6.29 (A-E): The average PCR product concentration in (RFU/µl) by dilution 
for samples processed with no chemicals and samples processed with amido black 
on A) Glass, B) Laminate, C) Lead, D) Plastic, and E) Tile.  The error bars 
represent the standard deviations for each of the dilutions and 
processed/unprocessed sample averages. 
6.3.2.1 Heterozygous Peak Height Balance 
Heterozygous peak balance was also assessed for each heterozygous locus present in 
both sample A and B.  Heterozygous peak balance (Hb) exhibits the ratio of the two 
peaks present at a heterozygous locus.  Again, this was determined mathematically by 
utilizing methods described by Leclair, et al. (2004).  Results range from 0 to 1 with 1 
representing alleles of equal height.  An Hb value which is below 0.70 indicates peak 
height imbalance.  Symbols (sample representation) which are present at the baseline (0) 
D 
E 
150
indicate that allele drop-out was present in the heterozygous locus and only 1 allele was 
above threshold.  Figures 6.26 through 6.33 exhibit heterozygous loci which are present 
in both sample A and B and their dilutions by substrate processed.  A red dotted line 
indicates the 0.70 Hb threshold for the results. 
Profiles which displayed peak imbalance were observed in both extracted and direct PCR 
samples. Overall peak imbalance within the PowerPlex
®
 18D processed samples was 
lower than those processed with PowerPlex
®
 16HS for all observed loci.  x10 dilution 
samples fell below the 0.70 limit more often which was to be expected with the 
decreased amount of DNA template available.  All loci seen at ‘0’ (the baseline) indicate 
allele drop-out was present in the heterozygous locus present in the profile.  An example 
of this is seen in all the substrates in Figure 6.30 (Top).    The majority of the samples 
which appear at ‘0’ appear to be from sample B which quantitatively was weaker than 
sample A (Output Data) and samples which were prepared with the x10 dilution.  Glass 
contained the least amount of peak imbalances for all samples, dilutions and loci 
evaluated.  Loci Penta E, D21S11, D13S1358, and FGA displayed the most peak 
imbalances for both kits. 
 
6.3.2.1.1 Evaluation of CSF1PO 
A heterozygous allele call of CSF1PO was present in sample A during the course of this 
project.  Both CSF1PO alleles were observed more consistently when samples were 
processed with PowerPlex
®
 18D.  Both alleles were displayed in 21 of 45 samples 
analysed with PowerPlex
®
 16HS as compared to PowerPlex
®
 18D where both alleles 
were present in 29 of the 45 samples processed (Figures 6.23-6.27).  Of the samples 
producing both alleles, 8 of the 21 samples processed with PowerPlex
®
 16HS displayed 
peak height balance ratios of 0.70 Hb or higher (Figure 6.30).  This is a lower percentage 
than the 24 of 29 which were over 0.70 Hb when analysed with PowerPlex
®
 18D (Figure 
6.30). 
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Figure 6.30:  (Top) Peak height ratios for CSF1PO produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for CSF1PO produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
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Figure 6.31:  (Top) Peak height ratios for D13S317 produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D13S317 produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
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Figure 6.32:  (Top) Peak height ratios for D18S51 produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D18S51 produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D. All three replicates of each sample (A 
and B) for each dilution are represented. 
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Figure 6.33:  (Top) Peak height ratios for D21S11 produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D21S11 produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
 
                              Glass                     Laminate              Lead      Plastic                     Tile 
                               Glass                     Laminate                Lead        Plastic                     Tile 
155
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6
H
e
te
ro
zy
go
u
s 
P
e
ak
 H
e
ig
h
t 
B
al
an
ce
 R
at
io
  
Substrate 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6
H
et
er
o
zy
go
u
s 
P
ea
k 
H
ei
gh
t 
B
al
an
ce
  R
at
io
 
 
Substrate  
Figure 6.34:  (Top) Peak height ratios for D3S1358 produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D3S1358 produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
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Figure 6.35:  (Top) Peak height ratios for D7S820 produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D7S820 produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
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Figure 6.36:  (Top) Peak height ratios for FGA produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for FGA produced for various substrates processed with amido black 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.37:  (Top) Peak height ratios for Penta E produced for various substrates 
processed with amido black and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for Penta E produced for various substrates processed with amido 
black and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A 
and B) for each dilution are represented. 
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The overall profiles generated using substrates processed with amido black paralleled 
those used with LCV. The profiles generated from direct PCR gave higher peak heights 
and were less prone to peak imbalances than those processed with extracted samples.   
Figure 6.38 shows sample B which was processed with amido black on laminate at the 
x1 dilution.  Powerplex
®
 18D exhibits strong overall peak heights and less peak 
imbalance (2) than the sample processed with PowerPlex
®
 16HS (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.38: Electropherograms of (1) Sample B (x1, Laminate) processed with 
PowerPlex
®
 16HS and displayed at 2000RFU. (2) Sample B (x1, Laminate) 
processed with PowerPlex
®
 18D and displayed at 20000RFU. The y-axis shows the 
relative fluorescent units (RFU) and x-axis numbers indicate the fragment size in 
base pairs. 
  D3S1358        TH01                  D21S11                   D18S51  Penta E 
    D5S818               D13S317         D7S820                  D16S539 CSF1PO                 Penta D 
                   Amel                    vWA           D8S1179                      TPOX           FGA 
D5S818            D13S317         D7S820                   D16S539 CSF1PO                 Penta D 
  D3S1358        TH01                  D21S11                   D18S51  Penta E 
                    Amel                    vWA           D8S1179                      TPOX           FGA 
                D19S433         D2S1338 
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 Lead was the weakest substrate processed yielding the lowest peak heights and total PCR 
product.  While processing the surface a noticeable reaction occurred after exposing the 
lead to the amido black solution.  It is hypothesized that in the same manner as LCV, the 
acidic component of the solution caused an oxidation effect possibly affecting the blood 
on the surface and negatively impacting the profile.  Amido black does differ in its 
appearance of the reaction in that the lead almost appears to have a ‘marble’.  The best 
examples of this were captured via photograph on samples A, x1 dilution processed with 
PowerPlex
®
 16HS and A, x2 dilutions processed with PowerPlex
®
 18D (Figure 6.39). 
 
 
 
 
 
 
 
Figure 6.39:  (Left) Sample A prepared with x1 dilution on lead and processed with 
amido black. This sample was processed with PowerPlex
®
 16HS.  (Right) Sample A 
prepared with x2 dilution on lead and processed with amido black. This sample was 
processed with PowerPlex
®
 18D. 
 
6.3.2.2 Stutter and other Artefacts 
Stutter peaks are commonly seen in electropherograms when analysing data.  Stutter is 
identified as a small peak which is generally one repeat unit less/more than the true 
allele.  The levels of stutters were all lower (8.2% for a combined average of both kits) 
than the limit recommended by the manufacturer, which is usually 15%. 
 
The profiles generated from the amplification of x2 and x10 dilutions, in general, were of 
good quality, with no drop-ins or split peaks. The only exception was the profiles 
generated from x1 solution of DNA. An abundance of biological material within the 
smaller loci gave peaks which were split.  Split peaks, also referred to as +A/-A peaks, 
are due to non-template addition generally of adenosine which occurs at the 3'-end of the 
PCR product.   Amplifying higher quantities of DNA than the recommended amount can 
result in the incomplete 3' A nucleotide addition.   
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6.3.3 Ninhydrin 
In contrast to the previous two chemicals, ninhydrin samples showed that the extracted 
samples produced with PowerPlex
®
 16HS gave higher peak heights (RFU) and PCR 
product concentrations (RFU/µl) compared to samples which were subjected to direct 
amplification with PowerPlex
®
 18D.  However, more full profiles were developed and 
less peak height imbalances were exhibited with PowerPlex
®
 18D.  
 
The kits were also compared to samples on substrates which were not exposed to 
ninhydrin (no chemical processing).  In this case, the samples which were not exposed to 
ninhydrin showed higher peak heights and PCR product concentrations when evaluating 
PowerPlex
®
 18D but this was not the case with samples processed with ninhydrin and 
analysed with PowerPlex
®
 16HS.  In this instance, the extracted samples obtained a 
higher average PCR product concentration after exposure to the chemical.  While the 
numerical values are visibly noticeable the difference was not statistically significant 
yielding a p-value>0.05 [F(1, 18)= 2.28, p-value= 0.149].  Figure 6.40 shows the average 
PCR product concentration for all samples and dilutions processed with both PowerPlex
®
 
16HS and 18D compared to all samples and dilutions analysed with PowerPlex
®
 16HS 
and 18D which contained no ninhydrin on the substrates. 
Figure 6.40:  Graph displaying the average PCR product concentration (RFU/µl) 
for each kit, PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples processed using 
ninhydrin and for all samples processed with no chemical enhancement.  The error 
bars represent the standard deviations for each of the kits. 
162
Figures 6.41 and 6.42 are organized by substrate processed with Ninhydrin and 
subsequently by the autosomal STR kit used to generate the profiles.  The boxes are 
reflective of information as previously described in Section 6.3.1.  These figures were 
used to examine the variation in the amplification between the different dilution volumes, 
chemicals, substrates and autosomal STR kits. 
Profiles generated using ninhydrin were also used to assess how complete a profile was 
and to determine the maximum and minimum peak heights for each allele present.  The 
PCR product concentrations and total RFUs were also calculated.  Profiles were noted as 
either full profiles (FP) where all alleles at all locations were observed, partial profiles 
(PP) where the number after indicates the number of loci which presented the alleles for 
that specific location and no profile (NP) where the chromosomal location did not 
display the proper allele call at any location in the whole profile.  This information is 
reflected under ‘Profile Type’ in Tables 6.5 and 6.6. 
Dilutions were a factor of significance when evaluating the samples, p-value<0.05 [F(2, 
18)= 11.22, p-value=0.001).  This was again to be expected since, just with the other two 
chemicals, a decreasing dilution was used. 
Samples processed with ninhydrin using direct PCR (PowerPlex
®
 18D) gave full profiles 
in all x1 and x2 dilutions for both substrates.        
The substrates [F(1, 18)= 0.14, p-value=0.708] and samples [F(1, 18)= 1.06, p-value= 
0.318] when processed with ninhydrin did not yield a significant difference as their 
values were both well above 0.05 (p-value>0.05). 
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Figure 6.41:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Ninhydrin on Raw Wood and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Figure 6.42:  A diagrammatic representation of the quality of the profiles obtained from the PowerPlex
®
 16HS (left) and PowerPlex
®
 18D (right) kits.  Different dilutions (x1, x2, and x10) of 
the two samples (A and B) were processed in triplicate using Ninhydrin on Gypsum and amplified with PowerPlex
®
 16HS and PowerPlex
®
 18D.  Green squares indicate that the full correct 
alleles were observed for that locus.  Yellow squares represent one allele drop out.  Red squares represent loci where both expected alleles are missing. 
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Table 6.5: Results for Ninhydrin profiles using PowerPlex
®
 16HS showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed on various substrates. The values are averages of three replicates. 
Su
b
st
ra
te
 
Sa
m
p
le
 
 
D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Gypsum 
A 
x1 27105 (s.d. 5156.78) 1403 (s.d. 239.50) 5954.86 FP 500208 (s.d. 28149.02) 40016.6 (s.d. 2251.9) 
x2 679 (s.d. 115.76) 53 (s.d. 7.23) 200.84 PP9 11247 (s.d. 705.92) 899.7 (s.d. 56.4) 
x10 2305 (s.d. 779.98) 55 (s.d. 7.81) 298.41 PP15 23873 (s.d. 1556.10) 1909.8 (s.d. 124.4) 
B 
x1 18773 (s.d. 1551.65) 1056 (s.d. 525.83) 5709.28 FP 411068 (s.d. 29556.51) 32885.4 (s.d. 2364.5) 
x2 393 (s.d. 77.11) 52 (s.d. 18.48) 150.33 PP7 4961 (s.d. 436.56) 396.8 (s.d. 34.9) 
x10 1607 (s.d. 312.63) 51 (s.d. 8.96) 358.42 PP14 24014 (s.d. 1040.37) 1921.1 (s.d. 83.2) 
Raw 
Wood 
A 
x1 12604 (s.d. 1918.51) 82 (s.d. 473.22) 3650.91 FP 306676 (s.d. 14012.81) 24534.0 (s.d. 1121.0) 
x2 2481 (s.d. 223.60) 106 (s.d. 36.91) 668.61 FP 56163 (s.d. 2444.56) 4493.0 (s.d. 195.5) 
x10 1069 (s.d. 202.15) 53 (s.d. 5.77) 218.64 PP14 16398 (s.d. 1198.67) 1311.8 (s.d. 95.8) 
B 
x1 21860 (s.d. 1207.16) 1254 (s.d. 174.02) 6884.57 FP 495689 (s.d. 13298.51) 39655.1 (s.d. 1063.8) 
x2 9745 (s.d. 1504.36) 792 (s.d. 96.74) 3229.83 FP 232548 (s.d. 14289.08) 18603.8 (s.d. 1143.1) 
x10 2035 (s.d. 155.09) 54 (s.d. 24.97) 512.79 PP15 34870 (s.d. 2521.26) 278.9 (s.d. 201.7) 
Table 6.6: Results for Ninhydrin profiles using PowerPlex
®
 18D showing the minimum, maximum and average peak heights, the 
profile type, total PCR product and PCR concentration for the various dilutions of samples A and B, amplified using half (12.5μl) 
reactions, and processed on various substrates. The values are averages of three replicates. 
Su
b
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ra
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Sa
m
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D
ilu
ti
o
n
 Profile Properties 
Total PCR Product 
(in RFU) 
PCR product 
concentration 
(in RFU/μl) Max PH Min PH 
Average 
PH 
Profile 
Type 
Gypsum 
A 
x1 14192 (s.d. 989.85) 2489 (s.d. 273.23) 5186.57 FP 497911 (s.d. 14269.19) 39832.8 (s.d. 1141.5) 
x2 1982 (s.d. 158.00) 50 (s.d. 126.06) 735.23 FP 71317 (s.d. 2117.90) 5705.3 (s.d. 169.4) 
x10 370 (s.d. 69.95) 66 (s.d. 3.51) 136.27 PP17 12673 (s.d. 459.41) 1013.8 (s.d. 36.7) 
B 
x1 6951 (s.d. 434.84) 586 (s.d. 133.99) 2574.69 FP 208550 (s.d. 2855.03) 16684 (s.d. 228.4) 
x2 18277 (s.d. 5011.88) 240 (s.d. 1056.96) 4945.63 FP 395650 (s.d. 57820.21) 31652 (s.d. 4625.6) 
x10 410 (s.d. 96.03) 51 (s.d. 6.50) 135.19 PP17 10680 (s.d. 334.34) 854.4 (s.d. 26.7) 
Raw 
Wood 
A 
x1 6809 (s.d. 382.57) 1119 (s.d. 208.16) 2659.32 FP 255295 (s.d. 1485.66) 20423.6 (s.d. 118.8) 
x2 1654 (s.d. 244.08) 81 (s.d. 104.07) 634.60 FP 60922 (s.d. 2166.67) 4873.7 (s.d. 173.3) 
x10 166 (s.d. 24.01) 50 (s.d. 2.65) 83.09 PP7 4819 (s.d. 305.91) 385.5 (s.d. 24.4) 
B 
x1 14108 (s.d. 2652.13) 67 (s.d. 1412.12) 5257.47 FP 425855 (s.d. 18240.38) 34068.4 (s.d. 1459.2) 
x2 1762 (s.d. 145.75) 195 (s.d. 62.51) 737.78 FP 59760 (s.d. 387.28) 4780.8 (s.d. 30.9) 
x10 367 (s.d. 41.86) 55 (s.d. 5.57) 157.85 FP 12628 (s.d. 291.25) 1010.2 (s.d. 23.2) 
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Figure 6.43:  The average PCR product concentration (RFU/µl) for each kit, 
PowerPlex
®
 16HS and PowerPlex
®
 18D, for all samples processed using ninhydrin 
and for all samples processed with no chemical enhancement.  The error bars 
represent the standard deviation for each dilution. 
6.3.3.1 Heterozygous Peak Height Balance 
Heterozygous peak balance was also assessed for each heterozygous locus present in 
both sample A and B.  Heterozygous peak balance (Hb) was generated the same as in the 
previous two sections.  Figures 6.44 through 6.51 exhibit heterozygous loci which are 
present in both sample A and B and their dilutions by substrate processed.  A red dotted 
line indicates the 0.70 Hb threshold for the results. 
 
Profiles which displayed peak imbalance were observed in both extracted and direct PCR 
samples. Overall peak imbalance within the PowerPlex
®
 18D processed samples was 
lower than those processed with PowerPlex
®
 16HS for all observed loci.  Samples which 
were exposed to the x10 dilution fell below the 0.7 limit more often which was to be 
expected with the decreased amount of DNA template available.  All loci exhibited on 
the baseline when evaluating laminate and gypsum indicate allele drop-out was present 
in the heterozygous locus.  Glass contained the least amount of peak imbalances for all 
samples, dilutions and loci evaluated.  Penta E has the most imbalanced heterozygous 
loci. 
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Figure 6.44:  (Top) Peak height ratios for CSF1PO produced for various substrates 
processed with ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for CSF1PO produced for various substrates processed with ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
 
                                                       Gypsum                                              Raw Wood 
                                                       Gypsum                                              Raw Wood 
168
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3
P
e
a
k
 H
e
ig
h
t 
B
a
la
n
c
e
 i
n
 P
e
r
c
e
n
ta
g
e
 
Substrates 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3
P
e
a
k
 H
e
ig
h
t 
B
a
la
n
c
e
 i
n
 P
e
r
c
e
n
ta
g
e
 
Substrates 
Figure 6.45:  (Top) Peak height ratios for D13S317 produced for various substrates 
processed with ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D13S317 produced for various substrates processed with ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.46:  (Top) Peak height ratios for D18S51 produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D18S51 produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.47:  (Top) Peak height ratios for D21S11 produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D21S11 produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.48:  (Top) Peak height ratios for D3S1358 produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D3S1358 produced for various substrates processed with 
Ninhydrin and analysed with PowerPlex
®
 18D.  All three replicates of each sample 
(A and B) for each dilution are represented. 
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Figure 6.49:  (Top) Peak height ratios for FGA produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for FGA produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.50:  (Top) Peak height ratios for D7S820 produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for D7S820 produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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Figure 6.51:  (Top) Peak height ratios for Penta E produced for various substrates 
processed with Ninhydrin and analysed with PowerPlex
®
 16HS.  (Bottom)  Peak 
height ratios for Penta E produced for various substrates processed with Ninhydrin 
and analysed with PowerPlex
®
 18D.  All three replicates of each sample (A and B) 
for each dilution are represented. 
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 PowerPlex
®
 16HS exhibited higher total PCR product values (500,208 RFU for x1 
Gypsum, sample A) with PowerPlex
®
 18D giving a slightly lesser number (497,911 
RFU) for the same sample; the overall peak quality of the in regards to peak balance (Hb 
>.70) was superior when analysed with PowerPlex
®
18D (Table 6.5 and 6.6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.52:  Electropherograms demonstrating the two profiles generated from 
sample A (x1, Gypsum).  (Top) The profile generated with PowerPlex
®
 16HS.  
(Bottom)  The profile generated with PowerPlex
®
 18D. 
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 6.3.3.1.1 Evaluation of CSF1PO 
A heterozygous allele call of CSF1PO was present in sample A.  CSF1PO was more 
successful in displaying both alleles when processed with PowerPlex
®
 18D.  Both alleles 
were displayed in 21 of 45 samples analysed with PowerPlex
®
 16HS when compared to 
PowerPlex
®
 18D where both alleles were present in 29 of the 45 samples processed 
(Figures 6.23-6.27).  Of the samples producing both alleles, 8 of the 21 samples 
processed with PowerPlex
®
 16HS displayed peak height balance ratios of 0.70 Hb or 
higher (Figure 6.30).  This is a lower percentage than the 24 of 29 which were over 0.70 
Hb when analysed with PowerPlex
®
 18D (Figure 6.30). 
6.3.3.2 Stutter and other Artefacts 
The profiles generated from the amplification of x1, x2 and x10 dilutions were of good 
quality, with no drop-ins or split peaks. The levels of stutters were all lower (11.1% for a 
combined average of both kits) than the limit recommended by the manufacturer, which 
are usually 15%. 
6.3.4 Collective Evaluation of All Chemicals 
Sections 6.3.1-6.3.3 has evaluated each chemical independently but it is also important to 
analyse both kits with all chemicals, dilutions, and substrates as factors. 
6.3.4.1 Chemicals 
Prior to the study, amido black was thought to give the lowest peak height values due to 
the methodology employed to use this stain.  Amido black is the only chemical in this 
experiment with a rinse step which was thought to possibly cause additional loss of the 
DNA sample.  Careful consideration was taken when gently rinsing the substrates, 
however, the data does indicate that the overall sample totals were lower than the other 
two chemicals. 
Ninhydrin was observed to give the highest total PCR product.  This was to be expected 
as the blood soaked into the substrate and when swabbing a lot of the blood would 
adhere to the swab.   Ninhydrin did not have a rinse step and appeared to retain the most 
in regards to blood on surface.  Numerical values only slightly differed and there was no 
statistical difference between any of the chemicals [F(2, 165)= 1.57, p-value= 0.210). 
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 Figure 6.53:  Average of the total PCR products for each of the chemicals used as 
enhancements for the substrates in this project. Error bars represent the standard 
deviations for each of the chemicals. 
 
6.3.4.2 Dilutions 
Across all chemicals, the dilution factor was in most cases statistically significant.  The 
same conclusion can be drawn for dilutions when compared across kits, all chemicals 
and all substrates where statistically significant [F(2, 1256)= 40.85, p-value= 0.001].  
Dilutions are an important factor when determining sensitivity.  Based on the samples 
produced in this study there definitely needed to be balance between the amount of 
sample on the substrate and the amount of chemical used in order for the reaction to 
produce a quality profile.  x2 dilutions were the most successful of the dilutions used for 
this work.   
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Figure 6.54:  Average of the total PCR products for all of the chemicals used as 
enhancements for the substrates without regard to kit or specific chemical.  Error 
bars represent the standard deviations for each of the dilutions. 
 
 
6.3.4.3 Substrates 
Tile was the substrate which produced the highest total PCR concentration.  This was an 
expected result as tile is a smooth nonporous surface.  Lead produced the lowest 
numerical values of all substrates and was statistically different when compared to tile, 
gypsum, glass, plastic, and raw wood [F(7, 156)= 2.69, p-value= 0.012].   The two 
porous substrates, raw wood and gypsum, displayed higher total PCR concentrations than 
expected.  Since the surface was porous, it was hypothesized the blood would soak into 
the medium and would be difficult to remove via swabbing from the surface; however, 
this did not appear to be the issue based on the concentrations in Figure 6.55. 
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Figure 6.55:  The total PCR concentrations for all substrates: glass, gypsum, 
laminate, lead, plastic, raw wood, and tile without regard to kit or chemical.  Error 
bars represent the standard deviation.  
6.3.4.4 Human Identification Kits 
PowerPlex
®
 16HS and PowerPlex
® 
18D were compared across all substrates, chemicals, 
samples and dilutions.  A comparison between the two kits failed to show a statistically 
significant difference [F(1, 166)= 2.07, p-value=0.152).   This could be attributed to the 
small sample set and upon running more samples; the p-value should decrease. 
 
 
 
Figure 6.56:  Total PCR concentrations for both kits, PowerPlex
®
 16HS and 
PowerPlex
®
18D.  Error bars represent the standard deviations for the total PCR 
concentration. 
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6.4 Discussion 
PowerPlex
®
 18D performed better than PowerPlex
®
 16HS when analysing samples 
which have been exposed to chemical enhancement techniques.  The ability to 
compensate for haem inhibition could be attributed to the enhanced PCR master mix and 
the possible utilization of a new or mutant polymerase (Taq or other) as one of the 
components of the PowerPlex
®
 18D kit.   
The proposal of an alternate form of polymerase is not novel and has been studied from a 
biochemical perspective for many years (Eckert and Kunkel, 1991; Tindall and Kunkel, 
1988). In recent years, novel mutants of Taq polymerase have been proposed to 
compensate for various inhibitors which can be found in whole blood and other 
biological samples (Zhang et al., 2010).  OmniTaq (Taq-22), a double mutant of Taq 
polymerase, is an enzyme which is resistant to the inhibitory effects of blood, soil, crude 
soil extracts, and some food media (Zhange et al., 2010).  Omni Klentaq LA (Klen-taq-
10) is a triple mutant of the Klentaq polymerase which makes the enzyme resistant to the 
same inhibitory effects as OmniTaq with the inclusion of fluorescent dyes (Kermekchiev 
et al., 2009). Clontech Laboratories, part of Takara Biotech Company, has also released 
‘Terra™ PCR direct polymerase’ which is a novel enzyme developed for direct 
amplification from tissue samples and crude extracts (Lin et al., 2013).  The utility of 
these novel alterations to polymerase are especially notable in regards to whole blood 
samples which have often been a source of contention for the DNA analyst because of 
the inhibition displayed due to haemoglobin which can copurify with DNA (Akane et al., 
1994). This ultimately leads to the inactivation of the DNA polymerase, nonbinding 
primers, and/or degradation of the target DNA rendering these samples non-viable for 
development of a partial or full profile (Al-Soud and Radstrom, 2001).   
It should also be noted the optimization of the polymerase alone cannot avoid sample 
inhibition.  PCR enhancers may also aid in the robustness of the newly configured kits.  
Dimethyl sulfoxide, tetramethylxene, betaine, and homoectoine have all been 
documented as chemicals which can have positive effects on PCR (Bachman et al., 1990; 
Schnoor et al., 2004; Zhang et al., 2010).   Also, an increase in magnesium chloride and 
bovine serum albumin (BSA) concentration have been suggested as other alternatives for 
the increase in strong profiles generated from the new kits (vanOorschot et al., 2010).  
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It should also be noted in the validation of PowerPlex
®
 18D it has been optimized for 
direct PCR while PowerPlex
®
 16HS was developed for extracted samples (Ensenberger 
et al., 2010; Oostdik et al., 2013).  A validation which also confirms, that while 
optimized for direct amplification, whole blood samples were validated on FTA cards.  
This study did not use FTA cards for any whole blood samples.  Regardless of the 
individual components, PowerPlex
®
 18D was successful in developing full or partial 
profiles for samples for the majority of samples which have been exposed to chemical 
processing better than PowerPlex
®
 16HS. 
 
6.4.1 Substrates 
The deposit of the biological material is important to the development of the profiles but  
the substrates on which they are deposited are also of equal concern.  Different substrates 
have shown to have different effects on the generation of a DNA profile due to the 
physical properties of the surface which can affect the retention of the biological material 
deposited (Allen et al., 2008; Linacre et al., 2010; Templeton et al., 2015). Several 
surfaces were found to have very little data regarding the ability to obtain a DNA profile 
from their surface; this included gypsum board (drywall) and raw wood (Praska and 
Langenberg, 2013).  The results of this study concluded both surfaces were viable 
options for retrieving biological materials for subsequent DNA analaysis. 
Plastics, particularly those composed of polypropylene, are known to cause denaturation 
of DNA (Belotserkovskii and Johnson, 1997).  The plastic used in the course of this 
study was polypropylene based and decreased peak heights and reduced concentrations 
were to be expected.  These were only observed in the samples processed with LCV, 
however, not noted in any other chemical.  Therefore, it is theorized that the LCV was 
inhibiting the samples causing the samples to reflect decreased peak heights and reduced 
concentrations. 
The lead which was used in this study contained an oxide film which when exposed to 
sulfosalicylic acid (a strong oxidizing agent) contained in the LCV solution mix, caused 
a redox reaction which adversely affected the biological material (LabChem, 2012). This 
reaction was observed again with amido black presumably due to the acidic compound 
found within its solution.  Lead was the least successful substrate and was not successful 
when utilized with PowerPlex
®
 16HS as only partial profiles ranging from 1 locus to 13 
loci were able to be generated. 
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6.4.2 Chemicals 
Many experiments have been conducted on various paper products and the ability to 
develop a viable DNA profile post exposure to the chemical (Sewell et al., 2008; Thomas 
and Farrugia, 2013; Stein et al., 1996; Jelly et al., 2009; Bosser et al., 2011; Roux et al., 
1999; Frégeau et al., 2000; Moore et al., 2008).  To date, ninhydrin has shown little to no 
inhibition when trying to obtain a DNA profile from a surface which has been exposed to 
the enhancement techniques (Bhoelai et al., 2011; Schultz et al., 2004).  These data were 
reinforced with the results obtained within this chapter as the majority of the dilutions 
tested for ninhydrin yielded full profiles.  Its versatility to process latent fingerprints as 
well as being utilized as a blood enhancement technique has allowed laboratories to 
invest in a single chemical which has multiple purposes.  Ninhydrin has a limitation in 
crime-scene- based work in that it can only be utilized on porous surfaces. Several 
published articles mention paper as the substrate for development of DNA profiles with 
little to no mention of other porous surfaces such as raw wood or gypsum board. 
Therefore, during the course of this work, those two substrates were the primary focal 
point.  The data generated from those surfaces further displayed ninhydrin was a good 
option when selecting a chemical for enhancement on porous surfaces as the chemical 
did not appear to inhibit the samples and gave the highest average total PCR products 
when compared to all other chemicals processed in this study. 
Leucocrystal violet (LCV) is most commonly known for its ability to enhance shoe prints 
in blood which is how it was first reported from J. F. Fischer of the Federal Bureau of 
Investigations in the early 1990’s (Bodziak, 1995; Theeuwen et al., 1998; Cullen et al., 
2010).   It was chosen for this project for its haem- reactive qualities and while there is 
very little available documentation on the effects of LCV on DNA profiling, there is a 
need to explore all chemicals which could be used for blood enhancement (Spear et al., 
2002; Fox et al., 2014).  LCV was moderately successful in obtaining DNA profiles 
during this study; exceeding those which were chemically enhanced with Amido Black.  
This could be due to the highly acidic nature of the LCV formulation which does not 
require a de-staining step when processing the samples; therefore, high concentrations of 
hydrogen peroxide, sodium acetate and sulfosalicylic acid solution remain on the surface 
and are collected with the sample when swabbing (Fox et al., 2014).  More work is 
needed to explore the reactive nature of the chemical with other substrates as well as a 
possible improvement of the formulation of the chemical which would allow for greater 
success when DNA profiling is conducted. 
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Some research has been conducted on amido black, a diazo dye that stains proteins 
within blood samples (Fox et al., 2014; Gino and Omedei, 2011: Sears and Prizeman, 
2000).   Amido black can be found in two formulations, a water-based formula and a 
methanol-based formula.  The water-based formulation is good for general use at crime 
scenes and was used in this work in order to simulate what field technicians would most 
likely be using (Sears and Prizeman, 2000).  Amido black was the least successful of the 
chemicals tested which is consistent with one would anticipate as the protocol to use the 
chemical requires a de-staining step after the chemical exposure which would ultimately 
lead to sample loss.  Lead was the least successful substrate when examining the data and 
may be due to the substrate reacting with the acidic composition of the amido black. A 
review of the untreated data further supports this in that the untreated samples were more 
successful when generating profiles from samples that were placed on lead and not 
exposed to amido black (Figure 6.29(E)).    Further research should be conducted on the 
methanol-based formulation of amido black in order to determine if it exceeds the results 
of the water-based formula.  It would also be beneficial to see a direct comparison of the 
two formulations with comparable samples. 
The chemical processing methods evaluated in this experiment influenced the quality and 
robustness of the DNA profiles generated.  The process by which retrieval of the DNA 
occurred and the amplification process played a major role in determining how 
successful the DNA profile was generated.  The substrate on which the biological 
material is deposited is statistically significant in determining the quality of the profile 
across all chemicals reviewed.  The properties, both physical and chemical, of the 
substrate to be processed and the iteration of the chemical used to develop the stain on 
the DNA plays a critical role in determining the quality and quantity of the DNA 
recovered.  While PowerPlex
®
 18D was more successful in developing full and partial 
profiles, ultimately, more work needs to be conducted regarding the effects of chemical 
and substrate on the subsequent recovery of DNA. 
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CHAPTER 7. 
GENERAL DISCUSSION 
 
The studies carried out during this project showed that the ability to develop a DNA 
profile from samples which have been exposed to powder and chemical processing 
techniques can be produced with direct PCR. The project also concluded that in most 
cases the use of PowerPlex
®
 18D, PCR direct kit, was more successful in generating full 
profiles of a robust nature than its counterpart PowerPlex
®
 16HS, an extraction-based 
kit. 
7.1 Overview of the study and main outcomes  
The main aim of this project was to compare the effects an extraction-based human 
identification system, PowerPlex
®
 16HS, to a PCR direct kit, PowerPlex
®
 18D on 
forensic based samples.  In order to be cost effective, it was necessary to determine if 
lowering the reaction volume to 12.5 μl would be sufficient in producing the profiles 
from the two different kits.  The limit of detection for each kit with the two sample 
types, epithelial cells and whole blood, were also conducted in order to maximise the 
reagents allotted for this work.  In regards to the forensic-based samples, a set of of 
epithelial-cell-based samples were exposed to latent fingerprint powders (black, white 
and magnetic flake) on a nonporous substrate (laminate) at varying dilutions (x1, x2 and 
x10).  A second set of forensic-based samples comprised of whole blood were exposed 
to chemical enhancement liquids on a variety of substrates (glass, gypsum, metal, raw 
wood, plastic, tile, and laminate) at varying dilutions (x1, x2 and x10).  
The application of direct PCR to samples which have been exposed to techniques used 
for visualization was a concern when developing this project.  While publications reflect 
that profiles can be generated using extraction based processing methodologies, direct 
PCR does not remove inhibitors rather it relies on a more enhanced and robust reaction 
mix to compensate for the remaining inhibitors in the sample. Samples processed in this 
project were not subjected to FTA
®
 paper and were swabbed as evidentiary samples 
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collected in the field.  Taking a systematic approach, each sample was carefully 
prepared and analysed, assessing their profile qualities and evaluating their limitations.  
Chapter 3 evaluated lowering the volume of the PCR by half, 12.5 μl.  While published 
research indicates this would not affect the overall quality, a short study was conducted 
to confirm their results (Ensenberger et al., 2010; Oostdik et al., 2013).  During this 
study, it was found that reducing the volume of the reaction to 12.5 μl yielded an 
increase the sensitivity and amplification efficiency of the assay towards low amount of 
DNA. The stochastic effects usually related to reduce volume reactions were observed 
when using amounts lower than 0.5 ng/µl were evaluated. The results observed exceed 
those in the recommended publications for the standard PowerPlex
®
 16 (Hoffman and 
Fenger, 2010).  The half reactions were slightly more successful with PowerPlex
®
 16HS 
then were reflected in the PowerPlex
®
 16 as input DNA at 0.13 ng produced a full 
profile.  This could be due in part to the enhanced buffer system included in PowerPlex
®
 
16HS which is not part of the original PowerPlex
®
 16 kit (Ensenberger et al., 2010; 
Hoffman and Fenger, 2010).  The heterozygous peak balance (Hb) for samples 
generated with PowerPlex
®
 16HS proved to be almost equal when looking at full (45% 
below threshold) versus half reactions (50%) across all dilutions and heterozygous loci.  
This was slightly lower than values presented in the validation studies; however, 
decreasing amounts of DNA were not evaluated in this study (Ensenberger et al., 2010).  
Overall, the 12.5 μl reaction was not seen to negatively impact the profiles generated. 
For PowerPlex 18D, full profiles were obtained for DNA input at 2.0 ng and 1 ng with a 
12.5μl reaction.  Reaction volumes of 25μl produced full profiles only in samples with 
2.0 ng of DNA.  Partial profiles were generated at all other input DNA volumes, except 
for 0.06 ng where no profile was generated.  PCR product concentrations (RFU/μl) were 
higher when evaluating 12.5μl reactions than with 25μl.  While PowerPlex® 18D was 
not as successful as PowerPlex
®
 16HS in producing full profiles, the peak heights 
values were higher and more loci were present in the 12.5μl reactions than with the 
25μl.  This is possibly due to the direct amplification materials which are typically 
cruder than purified samples and often include inhibitors from the raw DNA sample 
(Oostdik et al., 2013).  It has been noted that adding the same amount of direct 
amplification material recommended for a full reaction into a reduced reaction volume 
can negatively impact performance; however, the developmental validation of 
PowerPlex
® 
18D showed reaction volumes ≥12.5 μl produced reliable full profiles 
186
  
 174  
(Oostdik et al., 2013).  For the purposes of this project, a half volume (12.5 μl)  reaction 
was used for all samples. 
Chapter 3 also determined the limit of detection for the epithelial-cell-based samples 
and the whole blood samples.  The x10 dilutions for both types of samples appeared to 
be the limit when evaluating both PowerPlex
®
 16HS and PowerPlex
®
 18D.  For the 
epithelial-cell samples this could be due to the low amount of DNA template present in 
the samples and for the PowerPlex
®
 16HS samples the additional loss of sample during 
the extraction process.  For the whole blood samples the low sample profiles could be 
due to the amount of inhibitors such as haem which are still present in the sample.  
Instead of an extraction step, PowerPlex
®
 18D relies on the ability of the reaction mix to 
compensate for the level of inhibition which is still in the sample throughout the 
profiling process.  Based on these results the samples in this project were processed at 
the x1, x2 and x10 dilution. 
Confirming concordance was also an area which was reviewed.  As discussed in 
Chapter 4, the primary focus was to determine that the two kits produced concordant 
results when amplifying the same sample. The two kits used were both from Promega
®
 
and contained the same primers.  The results obtained did demonstrate the ability of the 
two kits to produce profiles with concordant results.  It was also noted that micro 
variants which were observed in a small number of the samples were also identified in 
both kit.  For all alleles which were produced, all were the same.  It should be noted; 
however, that PowerPlex
®
 16HS failed to produce full profiles for several of the 
samples.  This could be attributed to donor deposit and variability between individuals. 
Epithelial cell samples exposed to powder processing techniques were the first of the 
forensic-based samples to be analysed.  In chapter 5, black powder and white powder 
achieve the highest total PCR and total PCR concentrations while magnetic powder was 
the weakest of those processed.  Earlier publications have indicated that both white 
powder and black powder do not inhibit the STR profiling process and the data 
generated in this study agreed with these findings (Raymond et al., 2004; Roux et al., 
1999; Stein et al., 1996; vanOorschot et al., 2003; vanOorschot et al., 2005).  Magnetic 
powder has been problematic for DNA analysts and while it has been shown to develop 
profiles they are much weaker than their standard powder counterparts (Tozzo, 2014).  
However, in this study PowerPlex
®
 18D was more successful when attempting to 
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produce profiles from samples exposed to magnetic flake than with PowerPlex
®
 16HS.  
This is an important finding in this study given the low amount of starting template with 
epithelial-cell-based samples and the crude nature of the sample being placed into the 
thermal cycler.   
Chapter 6 outlines the whole blood samples which were the second set of samples to be 
processed and analysed.  These samples were exposed to three different chemicals 
(leucocrystal violet, amido black and ninhydrin) on multiple substrates (glass, gypsum, 
metal, raw wood, plastic, tile, and laminate).  As haem is a known inhibitor, it was 
hypothesized that these samples would only work in a minimal capacity (Akane et al., 
1994; Al-Soud and Radstrom 2001).  However, the majority of the samples worked 
across a variable of substrates and dilutions.  Direct PCR produced more full profiles 
than the extraction-based PCR and in the majority of samples provided higher RFU 
values.  One consideration for this result is utilization of an alternative polymerase 
(improved taq or other polymerase) and enhanced PCR buffers which overcome the 
inhibition in the samples (Zhang et al., 2010). 
Overall the work clearly shows the potential of implementing direct PCR into forensic 
casework samples.  The majority of casework samples obtained from crime laboratories 
contain blood or latent material; however, it will be important to continue to evaluate 
other types of biological evidence such as semen, urine, saliva and evaluate if 
comparable results are obtained. 
7.4 Application of Direct Amplification for Forensic 
Casework   
The possibility of implementing direct amplification into forensic casework can have a 
major positive impact on backlog reduction and lower operating costs for laboratories.  
Direct amplification uses samples which skip the extraction step and use faster cycling 
times than standard DNA methods.  Overall these factors will help reduce the amount of 
time it takes to generate a profile for analysis. 
Financial implications are also at the forefront of the discussions regarding direct 
amplification.  With the elimination of robotics made for automated extraction, 
consumables and general maintenance contracts, monies could be saved thus improving 
the efficiency of the lab.   
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A reduction in the laboratory work conducted by analysts would also be reduced.  This 
would allow for more time to analyse data and generate reports for submitting agencies.  
With reports generated in a faster manner, law enforcement could be more proactive in 
prosecuting crimes in a timely manner.    
7.3  Crime Scene Personnel   
Crime scene technicians are at the forefront of evidence collection.  Continuing 
education and training of proper processing techniques via surface encountered could 
help to increase the chance of obtaining a profile for use in developing a DNA profile.  
To date, there are no general quick reference resources for technicians.  A failure to 
collect the stain encountered at a crime scene with the proper chemical could be 
detrimental to a case. 
7.4 Future work 
This study was intended to be an evaluation of a direct amplification system on 
epithelial cells and blood samples using common enhancement techniques which are 
used on crime-scene-based samples.  Further studies should be carried out to explore 
other chemicals, surfaces and types of biological material which may also need to be 
processed using direct amplification should this method be implemented into casework 
laboratories. 
The chemicals selected for this work were chosen based on their reactivity to various 
components within blood.  There are an abundance of other chemicals which are 
currently on the market and used for forensic samples.  These chemicals use a variety of 
techniques to expose the substrates to the chemical some by staining and washing or 
staining alone.  Each of these techniques could affect the yield of DNA obtained and 
best practices should be evaluated along with their ability to produce a DNA profile 
with direct amplification.   
Fluorescence has also become a useful tool when looking for valuable biological 
evidence and latent prints which may be deposited on surfaces and difficult to visualize 
in ambient light.   The use of an alternative light source to locate such evidence has 
become common practice when processing a crime scene.  The use of fluorescent dyes 
and powders has also become a popular form of enhancement. Dyes such as Basic 
Yellow and 1,8-diaza-9-fluorenone (DFO) are frequently used to process items of 
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evidence (Schwarz and Klenke, 2007).  Deriving a DNA profile from samples with a 
fluorescent component could be problematic as it may interfere with capillary 
electrophoresis. A new mutant Omni Klentaq LA is marketed as an enzyme which is 
resistant to the inhibitory effects of fluorescent dyes.  It would be beneficial to evaluate 
samples with this new form of taq polymerase to monitor the effects, if any; fluorescent 
powders and dyes may have on a profile. 
Substrates in this work were limited due to amount of available resources.  More work 
should be conducted to explore the effects of direct amplification on more common 
porous substrates.  This is especially important in regards to the different types of paper 
which can be located within crime scenes.  For example, thermal paper can be 
extremely problematic when determining what process to use for visualization of 
fingerprints and subsequent DNA analysis.  Most thermal paper is composed of a solid-
state mixture dye such as Yamamoto Blue (or other leuco dye) and needs an acid in 
order to change have a colour change reaction (Yamamoto et al., 2008).  This type of 
paper can have an adverse reaction when exposed to Ninhydrin causing the paper to turn 
black thus destroying any type of fingerprint analysis and possible jeopardizing the 
chance of developing a DNA profile (Jasuja and Singh, 2009; Schwarz and Klenke, 
2007).   
Sequential processing is a technique often utilized to maximize the material left behind 
on a surface.  Sequential processing involves using multiple viewing techniques and 
chemicals to optimize the chance of obtaining individualizing information from a piece 
of evidence (Bleay et al., 2012)  Using multiple chemicals on a surface prior to 
swabbing for DNA analysis may complicate the ability to obtain a profile, even if the 
chemicals tested independently show no inhibition.   
7.2 Conclusion  
The PowerPlex
®
 18D system should be seriously considered for implementation into 
laboratory protocols. With reduced processing times, cost efficiency and providing 
results that supersede extraction-based methods, there is no reason not to consider the 
process.  
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PowerPlex
®
 18D has the ability to provide full and/or partial profiles of a good quality 
using reduced volume reactions for epithelial-cell-based samples which are exposed to 
latent fingerprint powders as well as single source blood samples which have been 
chemically enhanced on different substrates using leucocrystal violet, amido black and 
ninhydrin.   
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The following Appendices are found in this section: 
 
Appendix 1: Materials and Equipment Used 
Appendix 2:  Reagent Preparation  
Appendix 3: Raw Data/ Statistical Analysis Information 
Appendix 4: Human DNA Profiles 
Appendix 5: Partial Profiles Generated using PowerPlex
®
 16HS 
Appendix 6: Consent Forms 
Appendix 7: Quantitation (Concordance Study Samples) 
Appendix 8: Summary of Loci 
Appendix 9: Allele Frequency and Comparison Charts 
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Appendix 1:  Material and Equipment Used 
 
The following is a list of materials and equipment that were used during the project and their 
respective supplier. (A1.1)  
 
Materials  Supplier 
  
 3500 Running Buffer, 10X Applied Biosystems 
 3130 Running Buffer, 10X Applied Biosystems 
 Omni swabs Whatman 
 Laminate tile flooring (black and white) Hampton Bay 
 Fingerprint Powder 
- Standard black powder 
- Magnetic flake powder 
- Standard white powder 
 
K9 Forensics, UK 
 Bleach Domestos 
  Raw Wood Home Base 
 Lead Home Base 
 Gypsum Board Home Base 
 Decon® 90 Appleton Woods  
 DNA 2800M Promega 
  Acetate sheets Grafix 
 Wooden handle sterile swabs  
  Leucocrystal Violet Evident, USA 
  Ethanol (absolute) Sigma Aldrich 
  Ninhydrin Sigma Aldrich 
  Formamide Applied Biosystem 
 Microscope slides Fisherbrand  
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Materials  Supplier 
  
 Promega® PowerPlex®16hsTM kit, containing: 
- Promega
®
 PowerPlex
®
16hs
TM
 Reaction Mix 
- Promega
®
 PowerPlex
®
16hs
TM
 Primer Mix 
- Promega
®
 PowerPlex
®
16hs
TM
 Control DNA 2800M 
- Promega
®
 PowerPlex
®
16hs
TM
 Allelic Ladder  
Promega 
  Promega® PowerPlex® 18d kit, containing: 
- Promega
®
 PowerPlex
®
 18d Reaction Mix 
- Promega
®
 PowerPlex
®
 18d
 
Primer Mix 
- Promega
®
 PowerPlex
®
 18d
 
Control DNA 2800M 
- Promega
®
 PowerPlex
®
 18d
 
Allelic Ladder  
Promega 
 Hi-Di Formamide  Applied Biosystems  
 Isopropanol Sigma Aldrich 
 POP-6™ Polymer Applied Biosystems 
 Amido Black 2x Solution Sigma Aldrich 
 QIAamp® DNA Mini Kit, containing:  
- QIAamp Mini Spin Columns 
- Buffer AL 
- Buffer AW 1 
- Buffer AW 2 
- Buffer AE 
 
 
 
 
 
 
 
 
Qiagen 
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Equipment  Supplier 
  
 ABI 3500 Genetic Analyzer set up with Data Collection and 
GeneMapper
®
 ID-X. 
Applied Biosystems 
 ABI 3130 Genetic Analyzer setup with Data Collection and 
GeneMapper
® 
v2.0. 
Applied Biosystems 
 Centrifuge Eppendorf 
 9700 Thermocycler Applied Biosystems  
 Incubator Gallenkamp 
 Microcentrifuge tubes (1.5 ml) ABgene 
 Eclipse E200 Microscope Nikon 
 PCR tubes (300µl) ABgene 
 Pipettes (0.1-2 μl, 2-20 μl, 20-200 μl, 200-1000 μl) Nichipet EX 
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Appendix 2:  Reagent Preparation 
 
 
The following section describes the preparation of the reagents used during this project.  
 
Preparation of Amido Black Solution 
Amido Black Staining Solution 2X (Sigma-Aldrich
®
) was combined with deionized 
water to a final volume of 500 ml per the manufacturer’s instructions.  At the final 
volume the solution contained 0.1% (w/v) Amido Black, 25% (v/v) isopropanol, and 
10% (v/v) acetic acid. 
 
Phosphate-buffered Saline 
A 10X solution of PBS was made by dissolving 80g of NaCl, 2.0g of KCl, 14.4g of 
Na2HPO4, 2.4g of KH2PO4 with 800ml distilled H2O.  The pH was then adjusted to 
7.4 and the volume increased to 1L with additional distilled H2O. For each experiment 
bottle of PBS 1X was made by diluting the 10X solution to 1:10. 
 
Haematoxylin and Eosin Staining Reagents 
Ehrlich’s haematoxylin:  Haematoxylin 6g; Absolute alcohol 300ml; Distilled 
water 300ml; Glycerol 300ml; Glacial acetic acid 30ml; Potassium alum- in excess 
 
Dissolve haematoxylin in alcohol, and then add components in order.  Add potash alum 
until a few crystals remain undissolved. 
 
Acid Alcohol:  1ml conc HCl in 99ml 70% alcohol. 
Alcoholic eosin: 0.5% eosin in 90% ethanol. 
Scott’s tap water: Sodium bicarbonate  3.5g;  Magnesium sulphate  20g;  Tap water 
1000ml;  Thymol crystal (preservative). 
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Appendix 3:  Raw Data 
 
This section addresses the information and outline of the data contained on the additional digital 
drive.  It should be noted for the purposes of the data analysis ‘saliva’ refers to the epithelial cell 
samples and ‘stock’/’neat’ refers to the x1 dilutions as reported in the write-up.  
 
All Chapters: Quantitation Data 
Chapter 3:   Sensitivity Study 
 Minitab Project  
o Data Sensitivity 
 Excel Spread sheets: 
o Blood Dilutions_16HS & Blood Dilutions_18D 
o Full vs. Half Reactions_16HS & Full vs. Half Reactions_18D 
o Saliva Dilutions_16HS & Saliva Dilutions_18D 
 
Chapter 5:   Evaluation of Epithelial Cell Samples Processed with Powder 
 Minitab Project 
o  Data Powder 
 Excel Spread sheets: 
o Powder_16HS & Powder_18D 
 
Chapter 6:   Evaluation of Blood Samples Enhanced with Chemicals  
 Minitab Projects 
o Data Amido Black 
o Data LCV 
o Data Ninhydrin 
o Data Combined 
 Excel Spread sheets: 
o Amido Black_16HS & Amido Black_18D 
o LCV_16HS & LCV_18D 
o Ninhydrin_16HS & Ninhydrin_18D 
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Appendix 4:  Genotypes of Human DNA 
 
 
This section lists the known genotypes for profiles used in this project.   
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Table A4.1: Known genetic profiles used throughout the project. 
 
D 
3 
S 
1 
3 
5 
8 
T 
H 
0 
1 
D 
2 
1 
S 
1 
1 
D 
1 
8 
S 
5 
1 
P 
E 
N 
T 
A 
 
E 
D 
5 
S 
8 
1 
8 
D 
1 
3 
S 
3 
1 
7 
D 
7 
S 
8 
2 
0 
D 
1 
6 
S 
5 
3 
9 
C 
S 
F 
1 
P 
O 
P 
E 
N 
T 
A 
 
D 
A 
M 
E 
L 
V 
W 
A 
D 
8 
S 
1 
1 
7 
9 
T 
P 
O 
X 
F 
G 
A 
D 
1 
9 
S 
4 
3 
3 
D 
2 
S 
1 
3 
3 
8 
Sample                   
2800M 17,18 6,9.3 29,31.2 16,18 7,14 12 9,11 8,11 9,13 12 12,13 X,Y 16,19 14,15 11 20,23 13,14 22,25 
A 15,18 9.3 30,32.2 15,19 11,13 10,13 8,11 9,10 11 9,12 9,10 X 17,18 11,16 11 22,24 13,14 19,21 
B 17,18 7 30.2,32.2 14,19 7,17 11 11,13 8,10 11 10,11 12 X 14 12 11 22,24 15 17,25 
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Appendix 5: Partial Profiles Generated using Promega
®
 
PowerPlex
®
 16HS
 
 
 
The following section represents the status of the partial profiles generated by PowerPlex
®
 
16HS for the Concordance Study (Chapter 4). (PP#= Partial profile# loci present). (A5.1) 
Sample 
Status of 
Profile 
1 of 2 Alleles No Alleles 
23M PP#12 D5, FGA D18, CSF 
26M PP#12  D18, CSF, Penta E, D16 
28M PP#13 FGA D18, CSF 
29M PP#7 D21, D16, D13, Penta D D18, CSF, Penta E, FGA, TPOX 
30M PP#3  
D18, D21, Penta E, CSF, D5, D13, 
D7, D16, Penta D, vWA, D8, FGA 
32M PP#2 D3, TH01, D5, D7 
D18, D21, Penta E, CSF, D16, Penta 
D, vWA, D8, FGA 
33M PP#7 Penta E, Penta D, D16 D18, D21, D7, CSF, D8, FGA 
35M PP#8 D13, D16, Penta D D18, CSF, FGA, Penta E 
36M PP#11 D18, Penta E, Penta D, FGA CSF 
37M PP#8 D13, Penta D, TPOX, FGA D18, Penta E, CSF, D16 
39B PP#12 D16, Penta E D18, CSF 
40B PP#15 CSF  
41B PP#5 
Penta E, D13, Penta D, 
vWA, D8 
D18, D5, D16, CSF, Amel, FGA 
42B PP#5 vWA, D13, Penta D, FGA 
TH01, D18, Penta E, D16, CSF, 
TPOX, Amel 
43B PP#15 CSF  
44B PP#15 CSF  
46B PP#12 D16 D18, CSF, FGA 
50B PP#15 CSF  
5W PP#14  D18, CSF 
10W PP#15  D18 
11W PP#13 Penta E D18, CSF, D8 
12W PP#14  D18, CSF 
14W PP#14  D18, CSF 
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15W PP#14  D18, CSF 
17W PP#14 D18, Penta E  
19W PP#15 D18  
20W PP#15  D18 
28W PP#14  D18, CSF 
29W PP#15 CSF  
31W PP#14  D18, CSF 
33W PP#14  D18, CSF 
35W PP#14  D18, CSF 
36W PP#14 D18, CSF  
40W PP#14 D18, CSF  
41W PP#14 CSF D18 
42W PP#15  CSF 
48W PP#14 D18, CSF  
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Appendix 6:  Consent Forms 
 
As discussed in Chapter 2, prior to collecting any samples this project was approved through 
the Institutional Review Board at St. Edward’s University and received ethical approval through 
the University of Central Lancashire.  A risk assessment is also on file at the University of 
Central Lancashire.  All samples obtained from individuals during the course of this research 
were collected following a written consent which was approved by both universities.  Copies of 
both consent forms are located in this section:  BUCCAL CONSENT, BLOOD CONSENT. 
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Appendix 7:  NanoDrop® Results of Extracted Samples for the 
Concordance Study 
 
 
The following section lists in table form the quantification values of each of the buccal swabs used 
during the concordance study (A7.1). These samples were extracted using PureLink™ Genomic 
DNA Purification kit (Invitrogen by Life Technologies) and were quantified on the NanoDrop 
2000.   
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Mexican Sample ID# Nucleic Acid Concentration (ng/µl) 260/280 Ratio 
1M 8.8 1.76 
2M 3.3 1.66 
3M 8.5 1.62 
4M 4.6 1.61 
5M 7.8 1.85 
6M 6.7 1.83 
7M 2.3 1.61 
8M 4.2 1.3 
9M 2.8 1.76 
10M 7.4 1.45 
11M 5.6 1.64 
12M 4.2 1.83 
13M 4.1 1.44 
14M 3 1.62 
15M 4.6 1.58 
16M 3.3 1.66 
17M 3.8 1.79 
18M 6.2 1.69 
19M 4 1.52 
20M 4.3 1.71 
21M 5.1 1.42 
22M 2.9 1.59 
23M 1.8 1.86 
24M 2.3 1.62 
25M 4.3 1.42 
26M 1.6 6.66 
27M 1.1 1.98 
28M 1.5 2.34 
29M 1.0 4.61 
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30M 0.5 1.93 
31M 1.0 1.76 
32M 1.0 4.67 
33M 1.7 1.69 
34M 1.1 1.3 
35M 1.5 1.56 
36M 1.6 1.43 
37M 1.5 1.55 
38M 2.0 1.98 
39M 2.5 1.87 
40M 1.3 1.76 
41M 3.1 1.8 
42M 5.7 1.78 
43M 1.2 5.87 
44M 1.6 3.45 
45M 2.0 4.88 
46M 0.6 4.76 
47M 1.6 2.0 
48M 1.1 3.42 
49M 1.2 1.89 
50M 11.8 2.84 
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Black Sample ID# Nucleic Acid Concentration (ng/µl) 260/280 Ratio 
1B -2.8 1.93 
2B 7.7 1.82 
3B -1.2 0.96 
4B 7 1.54 
5B 1.5 1.25 
6B 6.9 1.73 
7B 9.5 1.76 
8B 2.7 2.03 
9B 5 1.7 
10B 1.1 2.54 
11B 1.6 1.56 
12B 5.5 1.59 
13B 5.7 1.55 
14B 7.6 1.54 
15B 4.9 1.78 
16B 4.5 1.3 
17B 9.7 1.52 
18B 7 1.78 
19B 5.5 1.7 
20B 19.2 1.55 
21B 13.1 1.65 
22B 36 1.46 
23B 4.7 2.0 
24B 7.2 1.85 
25B 8.6 2.25 
26B 1.6 1.46 
27B 1.8 1.99 
28B 1 0.94 
29B 1.2 1.87 
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30B 0.6 3.65 
31B 1.4 1.44 
32B 1.3 2.0 
33B 0.9 1.54 
34B 3 4.33 
35B 4.9 2.52 
36B 3.4 1.90 
37B 0.6 1.81 
38B 0.4 2.01 
39B 1.1 2.11 
40B 2.5 2.37 
41B 1.5 2.89 
42B 2.3 1.96 
43B 1.3 1.45 
44B 1.8 1.88 
45B 0.8 1.23 
46B 2.3 2.1 
47B 1.4 1.34 
48B 1.9 2.03 
49B 3.9 4.87 
50B 1.2 1.81 
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Caucasian Sample ID# Nucleic Acid Concentration (ng/µl) 260/280 Ratio 
1W 1.2 1.36 
2W 1.8 2.35 
3W 1.7 2.52 
4W 2.2 1.90 
5W 1.5 1.81 
6W 1.8 2.21 
7W 1.9 1.14 
8W 5.9 4.37 
9W 1.6 2.73 
10W 2 1.81 
11W 1.6 1.25 
12W 2.2 1.85 
13W 1.3 1.29 
14W 1.2 2.33 
15W 4.5 1.32 
16W 1.3 1.26 
17W 1.4 1.03 
18W 2 1.62 
19W 1.4 1.65 
20W 1.2 1.89 
21W 1.7 1.76 
22W 2.1 1.81 
23W 1.2 1.68 
24W 3.2 5.87 
25W 2.8 3.45 
26W 0.6 1.37 
27W 1.2 1.84 
28W 1.8 1.45 
29W 0.6 1.52 
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30W 1.8 1.88 
31W 1 1.95 
32W 1.6 2.11 
33W 1.7 1.8 
34W 2.2 1.74 
35W 1.5 2.54 
36W 0.7 2.56 
37W 1.1 1.39 
38W 1.9 1.75 
39W 1.8 1.52 
40W 0.8 1.71 
41W 1.9 1.77 
42W 4.9 1.81 
43W 3.1 1.61 
44W 1.1 1.25 
45W 3.8 4.78 
46W 0.5 3.22 
47W 2.7 2.61 
48W 0.5 2.81 
49W 0.5 1.44 
50W 2.7 3.97 
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Appendix 8:  Summary of Loci in PowerPlex 16HS
®
 and 
PowerPlex
®
 18D 
A short summary of all the loci used in both kits for the course of this project (A8.1). 
                                                          
1
 D2S1338 and D19S433 are in bold to represent the 2 additional loci in PowerPlex® 18D. 
STR Loci
1
 Alleles Chromosomal Location Category; Repeat Motif Description 
D2S1338 10 to 31 2q35 Compound; TGCC/TTCC 
Long arm of 
chromosome 2 
D3S1358 6 to 26 3p21.31 Compound; TCTA/TCTG 
Sort arm of 
chromosome 3 
D5S818 4 to 29 5q23.2 Simple; AGAT 
Long arm of 
chromosome 5 
D7S820 5 to 16 7q21.11 Simple; GATA 
Long arm of 
chromosome 7 
D8S1179 6 to 20 8q24.13 Compound; TCTA/TCTG 
Chromosome 8, 
primarily TCTA, 
TCTG enters for alleles 
larger than 13 repeats 
D13S317 5 to 17 13q31.1 Simple; TATC 
Long arm of 
chromosome 13 
D16S539 4 to 17 16q24.1 Simple; GATA 
Long arm of 
chromosome 16, 
D18S51 5.3 to 40 18q21.33 Simple; AGAA  
D19S433 5.2 to 20 19q12 Compound; AAGG/TAGG  
D21S11 12 to 43.2 21q21.1 Complex; TCTA/TCTG  
FGA 
12.2 to 
51.2 
4q31.3 
 
Compound; CTTT/TTCC 
Alpha fibrinogen, 
3
rd
 Intron, long arm of 
chromosome 4 
TH01 3 to 14 11p15.5; 
 
Simple; TCAT 
Tyrosine Hydroxylase, 
1
st
 Intron, short arm of 
chromosome 11 
vWA 10 to 25 
12p13.31; 
 
Compound; TCTA/TCTG 
vonWillebrand Factor, 
40
th
 Intron, short arm 
of chromosome 12 
Penta E 5 to 32 15q26.2 Simple; AAAGA 
Long arm of 
chromosome 15; 
polymorphic 
Penta D 1.1 to 19 21q22.3 Simple; AAAGA 25 Mb from D21S11 
TPOX 4 to 16 2p25.3 
 
Simple; AATG 
Thyroid peroxidase, 
10
th
 Intron, short end 
on chromosome 2 
CSF1PO 5 to 17 5q33.1 Simple; AGAT 
c-fms proto-oncogene, 
long arm of 
chromosome 5, 6
th
 
Intron 
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Appendix 9:  Allele Frequency and Comparison Charts 
 
 
Although the population study could not be conducted due to low sample numbers and limited 
resources every effort was made to evaluate the data from a population perspective. 
Tables A9.1 detail the allelic frequencies for each of the populations as described in Chapter 2.   
Tables A9.2 look comparatively at the frequencies generated from the samples in this study and 
compare them to published allelic frequency data (Hill et al., 2013).   The standard deviation 
between the data obtained in this study and published data are also noted for each allele and all loci. 
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TableA9.1: Caucasian Samples Allele Frequency Chart 
Allele CSF1PO D2S1338 D3S1358 D5S818 D7S820 D8S1179 D13S317 D16S539 
2 
        
3 
        
4 
        
5 
        
6 
        
7 
   
0.010 
   
0.010 
8 
    
0.130 0.030 0.100 0.020 
9 
   
0.040 0.250 0.010 0.070 0.080 
9.3 
        
10 0.280 
  
0.040 0.250 0.080 0.060 0.060 
11 0.330 
  
0.440 0.200 0.020 0.290 0.400 
12 0.330 
  
0.320 0.120 0.150 0.290 0.270 
13 0.040 
 
0.010 0.140 0.040 0.380 0.130 0.110 
14 0.020 0.010 0.090 0.010 0.010 0.160 0.060 0.050 
14.2 
        
15 
  
0.230 
  
0.110 
  
15.2 
        
16 
 
0.030 0.320 
  
0.050 
  
16.2 
        
17 
 
0.220 0.190 
  
0.010 
  
18 
 
0.080 0.140 
     
19 
 
0.160 0.020 
     
20 
 
0.060 
      
21 
 
0.030 
      
22 
 
0.030 
      
23 
 
0.130 
      
23.2 
        
24 
 
0.130 
      
25 
 
0.110 
      
25.2 
        
26 
 
0.010 
      
         
H(ob) 0.680 0.820 0.840 0.700 0.800 0.780 0.740 0.780 
H(ex) 0.724 0.885 0.789 0.888 0.816 0.816 0.786 0.754 
PD 0.857 0.945 0.900 0.841 0.907 0.922 0.920 0.885 
PE 0.398 0.637 0.675 0.428 0.599 0.562 0.493 0.562 
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TableA9.1: Caucasian Samples Allele Frequency Chart continued 
Allele D18S51 D19S433 D21S11 FGA Penta D Penta E TH01 TPOX vWA 
7 
    
0.010 0.190 0.160 
  
8 
     
0.010 0.140 0.490 
 
9 
    
0.290 
 
0.200 0.140 
 
10 0.010 
   
0.080 0.070 
 
0.100 
 
11 0.010 
   
0.130 0.130 
 
0.220 
 
12 0.140 0.110 
  
0.180 0.170 
 
0.040 
 
13 0.180 0.210 
  
0.210 0.100 
 
0.010 
 
14 0.120 0.350 
  
0.060 0.060 
  
0.100 
14.2 
 
0.020 
       
15 0.160 0.190 
  
0.040 0.070 
  
0.130 
15.2 
 
0.090 
       
16 0.130 0.010 
   
0.060 
  
0.190 
17 0.110 
    
0.020 
  
0.310 
18 0.100 
  
0.050 
 
0.060 
  
0.170 
19 0.010 
  
0.060 
    
0.080 
20 0.020 
  
0.120 
 
0.010 
  
0.020 
21 
   
0.190 
 
0.010 
   
22 
   
0.200 
     
24 0.010 
  
0.150 
     
25 
   
0.050 
     
25.2 
  
0.010 
      
26 
   
0.020 
     
27 
  
0.020 
      
28 
  
0.090 
      
29 
  
0.250 
      
30 
  
0.260 
      
30.2 
  
0.020 
      
31 
  
0.040 
      
31.2 
  
0.130 
      
32.2 
  
0.130 
      
33.2 
  
0.040 
      
34.2 
  
0.010 
      
 
         
H(ob) 0.900 0.660 0.880 0.840 0.840 0.860 0.820 0.660 0.780 
H(ex) 0.880 0.767 0.835 0.857 0.852 0.796 0.755 0.637 0.810 
PD 0.950 0.914 0.931 0.946 0.910 0.946 0.905 0.851 0.929 
PE 0.795 0.369 0.755 0.675 0.675 0.715 0.637 0.369 0.562 
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TableA9.1: African American Samples Allele Frequency Chart 
Allele CSF1PO D2S1338 D3S1358 D5S818 D7S820 D8S1179 D13S317 D16S539 
7 0.082 
       
8 0.051 
  
0.060 0.210 
 
0.031 0.020 
9 0.051 
  
0.010 0.130 
 
0.020 0.224 
9.3 
        
10 0.235 
  
0.130 0.340 
 
0.031 0.102 
11 0.194 
  
0.190 0.190 0.060 0.347 0.357 
12 0.327 
  
0.380 0.080 0.090 0.429 0.173 
12.2 
        
13 0.041 
 
0.020 0.190 0.020 0.220 0.122 0.102 
13.2 
        
14 0.020 0.010 0.122 0.020 0.010 0.320 0.020 0.020 
14.2 
        
15 
  
0.276 0.010 0.010 0.220 
  
15.2 
        
16 
 
0.041 0.286 
  
0.060 
  
16.1 
        
16.2 
        
17 
 
0.143 0.214 0.010 0.010 0.030 
  
18 
 
0.071 0.061 
     
18.2 
        
19 
 
0.143 0.020 
     
20 
 
0.071 
      
21 
 
0.092 
      
22 
 
0.122 
      
23 
 
0.143 
      
24 
 
0.061 
      
25 
 
0.051 
      
26 
 
0.051 
      
         
H(ob) 0.857 0.837 0.735 0.780 0.780 0.880 0.653 0.796 
H(ex) 0.776 0.893 0.744 0.757 0.775 0.803 0.702 0.795 
PD 0.908 0.965 0.914 0.899 0.908 0.898 0.858 0.888 
PE 0.709 0.669 0.484 0.562 0.562 0.755 0.359 0.591 
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TableA9.1: African American Samples Allele Frequency Chart continued 
Allele D18S51 D19S433 D21S11 FGA Penta D Penta E TH01 TPOX vWA 
5 
    
0.030 0.080 0.010 
  
6 
    
0.010 
 
0.120 0.080 
 
7 
    
0.030 0.100 0.380 0.010 
 
8 
    
0.100 0.180 0.260 0.410 
 
9 
    
0.080 0.050 0.110 0.190 
 
10 
 
0.020 
  
0.100 0.050 0.010 0.070 
 
11 0.010 0.082 
  
0.190 0.080 
 
0.180 
 
12 0.061 0.153 
  
0.200 0.080 
 
0.040 
 
12.2 
 
0.031 
       
13 0.061 0.224 
  
0.100 0.090 
  
0.030 
13.2 
 
0.071 
       
14 0.102 0.235 
   
0.110 
  
0.040 
14.2 
 
0.071 
       
15 0.143 0.020 
 
0.010 0.010 0.080 0.010 0.010 0.230 
15.2 0.010 0.051 
       
16 0.194 0.020 
   
0.070 
  
0.240 
16.2 
 
0.020 
       
17 0.143 
  
0.020 0.010 0.030 0.010 0.010 0.150 
18 0.122 
       
0.170 
19 0.051 
  
0.060 
    
0.100 
20 0.071 
  
0.070 
    
0.020 
21 0.031 
  
0.140 
    
0.010 
24 
   
0.170 
     
25 
   
0.050 
     
26 
   
0.060 
     
27 
  
0.051 0.020 
     
28 
  
0.184 0.030 
     
29 
  
0.235 0.010 
     
30 
  
0.194 
      
32 
  
0.020 
      
36 
  
0.010 
      
47.2 
   
0.010 
     
 
         
H(ob) 0.837 0.918 0.776 0.880 0.920 0.900 0.720 0.740 0.820 
H(ex) 0.885 0.854 0.845 0.876 
  
0.736 0.764 0.813 
PD 0.960 0.942 0.949 0.959 0.954 0.966 0.895 0.889 0.940 
PE 0.669 0.833 0.554 0.755 0.836 0.795 0.460 0.493 0.637 
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TableA9.1: Mexican Samples Allele Frequency Chart 
Allele CSF1PO D2S1338 D3S1358 D5S818 D7S820 D8S1179 D13S317 D16S539 
7 
   
0.040 0.010 
   
8 
    
0.110 0.010 0.102 0.010 
9 0.020 
  
0.020 0.050 0.010 0.265 0.102 
9.3 
        
10 0.224 
  
0.080 0.340 0.100 0.112 0.153 
10.2 
        
10.3 
    
0.010 
   
11 0.378 
  
0.500 0.230 0.030 0.214 0.235 
12 0.316 
  
0.180 0.190 0.140 0.235 0.276 
12.2 
        
13 0.051 
  
0.170 0.060 0.360 0.051 0.214 
13.2 
        
14 0.010 0.020 0.120 0.010 
 
0.240 0.020 0.010 
14.2 
        
15 
 
0.010 0.350 
  
0.110 
  
15.2 
        
16 
 
0.040 0.190 
     
16.1 
        
16.2 
        
17 
 
0.150 0.240 
     
18 
 
0.030 0.090 
     
19 
 
0.110 0.010 
     
20 
 
0.180 
      
21 
 
0.010 
      
22 
 
0.080 
      
23 
 
0.240 
      
24 
 
0.080 
      
25 
 
0.050 
      
26 
        
27 
        
28 
        
35.2 
        
         
H(ob) 0.735 0.940 0.780 0.720 0.680 0.760 0.796 0.837 
H(ex) 0.731 0.878 0.772 0.734 0.796 0.818 0.834 0.802 
PD 0.842 0.938 0.897 0.859 0.906 0.897 0.921 0.905 
PE 0.484 0.878 0.562 0.460 0.398 0.527 0.591 0.669 
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 TableA9.1: Mexican Samples Allele Frequency Chart continued 
Allele D19S433 D21S11 FGA Penta D Penta E TH01 TPOX vWA 
6 
   
0.010 0.050 
   
8 
   
0.010 0.100 0.340 
  
9 
   
0.010 0.010 0.050 0.480 
 
9.3 
   
0.180 
 
0.130 0.100 
 
10 
     
0.230 0.010 
 
10.2 
   
0.230 0.060 0.030 0.040 
 
12 
  
0.010 0.120 0.080 
 
0.270 
 
12.2 0.100 0.010 
 
0.120 0.190 
 
0.100 
 
13 0.010 0.010 
      
13.2 0.230 
 
0.010 0.240 0.090 
   
14 0.050 
       
14.2 0.290 
  
0.080 0.060 
  
0.120 
15 0.030 
       
15.2 0.140 
   
0.090 
  
0.070 
16 0.050 
       
16.1 0.050 
   
0.040 
  
0.350 
18 
    
0.050 
  
0.270 
19 
    
0.040 
  
0.160 
20 
  
0.070 
 
0.030 
  
0.030 
21 
  
0.080 
 
0.040 
   
22 
  
0.130 
 
0.030 
   
23 
  
0.130 
 
0.030 
   
25 
  
0.180 
 
0.010 
   
26 
  
0.120 
     
27 
 
0.010 0.090 
     
28 
 
0.050 0.020 
     
30 
 
0.170 
      
30.2 
 
0.220 
      
31 
 
0.010 
      
31.2 
 
0.030 
      
32 
 
0.110 
      
35.2 
 
0.040 
      
  
0.010 
      
H(ob) 0.709 0.637 0.715 0.878 0.675 0.919 0.637 0.493 
H(ex) 0.820 0.860 0.940 0.840 0.960 0.820 0.740 0.780 
PD 0.775 0.847 0.880 .0709 .0637 0.787 0.881 0.814 
PE 0.920 0.943 0.948 0.938 0.969 0.889 0.830 0.895 
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Allele 
CSF1PO D13S317 D16S539 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2                
3.2                
4.0                
4.2                
5.0                
6.0                
6.3                
7.0             0.0100  
8.0 0.0055    0.1205 0.1000 0.0145 0.0180 0.0200 0.0014 
8.1                
9.0 0.0139    0.0776 0.0700 0.0054 0.1066 0.0800 0.0188 
9.1                
9.3                
10.0 0.2202 0.2800 0.0423 0.0471 0.0600 0.0091 0.0568 0.0600 0.0023 
10.1                
10.2                
10.3                
11.0 0.3089 0.3300 0.0149 0.3255 0.2900 0.0251 0.3144 0.4000 0.0605 
11.2                
11.3                
12.0 0.3601 0.3300 0.0213 0.2687 0.2900 0.0151 0.3144 0.2700 0.0314 
12.2                
12.3                
13.0 0.0817 0.0400 0.0295 0.1163 0.1300 0.0097 0.1634 0.1100 0.0378 
13.2                
13.3                
13.4                
14.0 0.0097 0.0200 0.0073 0.0429 0.0600 0.0121 0.0263 0.0500 0.0168 
14.2                
14.3                
15.0      0.0014         
15.2                
15.3                
15.4                
16.0                
16.1                
16.2                
16.3                
17.0                
17.1                
17.2                
Table A9.2: Caucasian comparison chart.  
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Allele 
D18S51 D2S1338 Penta_E 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
5.0           0.0762 0.0400 0.0256 
6.0          
7.0           0.1690 0.1900 0.0148 
8.0           0.0139 0.0100 0.0028 
9.0           0.0125    
9.3 0.0083              
10.0   0.0100       0.0859 0.0700 0.0112 
10.3 0.0097              
11.0   0.0100       0.0873 0.1300 0.0302 
11.2                
11.3 0.1136              
12.0   0.1400       0.1994 0.1700 0.0208 
12.2                
12.3 0.1233              
13.0   0.1800       0.0859 0.1000 0.0100 
13.4 0.1343              
14.0 0.0014 0.1200 0.0839   0.0100  0.0623 0.0600 0.0016 
14.2                
14.3 0.1704              
15.0   0.1600  0.0014    0.0429 0.0700 0.0192 
15.4 0.1468         0.0014    
16.0   0.1300  0.0374 0.0300 0.0052 0.0512 0.0600 0.0062 
16.1 0.0014              
16.2                
16.3 0.1385              
17.0   0.1100  0.1856 0.2200 0.0243 0.0485 0.0200 0.0202 
17.3 0.0776              
18.0   0.1000  0.0734 0.0800 0.0047 0.0332 0.0600 0.0190 
18.3 0.0402              
19.0   0.0100  0.1205 0.1600 0.0279 0.0152    
19.4 0.0180              
20.0   0.0200  0.1565 0.0600 0.0682 0.0097 0.0100 0.0002 
20.3 0.0097              
21.0      0.0374 0.0300 0.0052 0.0028 0.0100 0.0051 
21.3 0.0069              
22.0      0.0346 0.0300 0.0033 0.0014    
23.0      0.1053 0.1300 0.0175      
24.0   0.0100  0.1150 0.1300 0.0106 0.0014    
25.0   
 0.1025 0.1100 0.0053 
  
 
25.2   
      
  
 
26.0   
 0.0305 0.0100 0.0145 
  
 
Table A9.2: Caucasian comparison chart. continued 
252
 Allele 
D19S433 D22S1045 D8S1179 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
5.0          
6.0 
  
 
  
 
  
 
6.3 
  
 
  
 
  
 
7.0 
  
 
  
 
  
 
8.0 
  
 
  
 0.0139 0.0300 0.0114 
8.1 
  
 
  
 
  
 
9.0 
  
 
  
 0.0055 0.0100 0.0032 
9.1 
  
 
  
 
  
 
9.3 
  
 
  
 
  
 
10.0 0.0014 
 
 
  
 0.1025 0.0800 0.0159 
10.1 
  
 
  
 
  
 
10.2 
  
 
  
 
  
 
10.3 
  
 
  
 
  
 
11.0 0.0055 
 
 0.1399 
 
 0.0762 0.0200 0.0397 
11.2 
  
 
  
 
  
 
11.3 
  
 
  
 
  
 
12.0 0.0706 0.1100 0.0279 0.0125 
 
 0.1676 0.1500 0.0124 
12.2 0.0014 
 
 
  
 
  
 
12.3 
  
 
  
 
  
 
13.0 0.2548 0.2100 0.0317 0.0069 
 
 0.3296 0.3800 0.0356 
13.2 0.0069 
 
 
  
 
  
 
13.3 
  
 
  
 
  
 
13.4 
  
 
  
 
  
 
14.0 0.3615 0.3500 0.0081 0.0568 
 
 0.1662 0.1600 0.0044 
14.2 0.0235 0.0200 0.0025 
  
 
  
 
14.3 
  
 
  
 
  
 
15.0 0.1565 0.1900 0.0237 0.3213 
 
 0.1039 0.1100 0.0043 
15.2 0.0360 0.0900 0.0382 
  
 
  
 
15.3 
  
 
  
 
  
 
15.4 
  
 
  
 
  
 
16.0 0.0568 0.0100 0.0331 0.3823 
 
 0.0332 0.0500 0.0119 
16.1 
  
 
  
 
  
 
16.2 0.0152 0.0200 0.0034 
  
 
  
 
16.3 
  
 
  
 
  
 
17.0 0.0069 
 
 0.0748 
 
 0.0014 0.0100 0.0061 
17.1 
  
 
  
 
  
 
17.2 0.0014 
 
 
  
 
  
 
17.3 
  
 
  
 
  
 
18.0 
  
 0.0055 
 
 
  
 
18.1 
  
 
  
 
  
 
18.2 0.0014 
 
 
  
 
  
 
18.3 
  
 
  
 
  
 
Table A9.2: Caucasian comparison chart. continued 
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Allele 
D21S11 FGA 
Promega Parish STDEV Promega Parish STDEV 
18.0 
  
 0.0249 0.0500 0.0177 
19.0 
  
 0.0499 0.0600 0.0071 
20.0 
  
 0.1233 0.1200 0.0023 
21.0 
  
 0.1787 0.1900 0.0080 
21.2 
  
 0.0055 
 
 
21.3 
  
 
  
 
22.0 
  
 0.2050 0.2000 0.0035 
22.2 
  
 0.0125 
 
 
22.3 
  
 
  
 
23.0 
  
 0.1524 0.1400 0.0088 
23.2 
  
 0.0028 0.0200 0.0122 
23.3 
  
 
  
 
24.0 
  
 0.1343 0.1500 0.0111 
24.2 
  
 0.0014 
 
 
24.3 
  
 
  
 
25.0 
  
 0.0789 0.0500 0.0204 
25.2 0.0014 0.0100 0.0061 
  
 
26.0 
  
 0.0263 0.0200 0.0045 
26.2 
  
 
  
 
27.0 0.0222 0.0200 0.0016 0.0042 
 
 
27.2 
  
 
  
 
27.3 
  
 
  
 
28.0 0.1593 0.0900 0.0490 
  
 
28.2 
  
 
  
 
28.3 
  
 
  
 
29.0 0.2022 0.2500 0.0338 
  
 
29.2 0.0028 
 
 
  
 
29.3 
  
 
  
 
30.0 0.2825 0.2600 0.0159 
  
 
30.2 0.0291 0.0200 0.0064 
  
 
30.3 
  
 
  
 
31.0 0.0720 0.0400 0.0226 
  
 
31.2 0.0983 0.1300 0.0224 
  
 
32.0 0.0055 
 
 
  
 
32.2 0.0900 0.1300 0.0283 
  
 
33.0 0.0014 
 
 
  
 
33.1 
  
 
  
 
33.2 0.0263 0.0400 0.0097 
  
 
34.0 
  
 
  
 
34.2 0.0042 0.0100 0.0041 
  
 
35.0 0.0014 
 
 
  
 
35.2 0.0014 
 
 
  
 
 
Table A9.2: Caucasian comparison chart. continued 
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Allele 
D3S1358 vWA 
Promega Parish STDEV Promega Parish STDEV 
11.0 0.0014         
11.2           
11.3           
12.0      0.0014    
12.2           
12.3           
13.0 0.0014 0.0100 0.0061 0.0014    
13.2           
13.3           
13.4           
14.0 0.1066 0.0900 0.0117 0.0928 0.1000 0.0051 
14.2           
14.3           
15.0 0.2729 0.2300 0.0303 0.1053 0.1300 0.0175 
15.2           
15.3           
15.4           
16.0 0.2382 0.3200 0.0578 0.2008 0.1900 0.0076 
16.1           
16.2           
16.3           
17.0 0.2105 0.1900 0.0145 0.2839 0.3100 0.0185 
17.1           
17.2           
17.3           
18.0 0.1510 0.1400 0.0078 0.2022 0.1700 0.0228 
18.1           
18.2           
18.3           
19.0 0.0166 0.0200 0.0024 0.1039 0.0800 0.0169 
19.1           
19.2           
19.3           
19.4           
20.0 0.0014    0.0069 0.0200 0.0093 
20.1           
20.2 
  
      
20.3 
  
      
21.0 
  
 0.0014    
22.2 
  
 
  
 
22.3 
  
 
  
 
24.0       
 
Table A9.2: Caucasian comparison chart. continued 
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 Allele 
D5S818 D7S820 Penta_D 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2           0.0042    
3.2                
4.0                
4.2                
5.0                
6.0           0.0042    
6.3                
7.0 0.0028 0.0100 0.0051 0.0277    0.0042 0.0100 0.0041 
8.0 0.0055    0.1440 0.1300 0.0099 0.0208    
8.1      0.0014         
9.0 0.0416 0.0400 0.0011 0.1676 0.2500 0.0583 0.2216 0.2900 0.0484 
9.1                
9.3                
10.0 0.0554 0.0400 0.0109 0.2562 0.2500 0.0044 0.1150 0.0800 0.0247 
10.1                
10.2                
10.3                
11.0 0.3560 0.4400 0.0594 0.2050 0.2000 0.0035 0.1260 0.1300 0.0028 
11.2                
11.3                
12.0 0.3878 0.3200 0.0479 0.1593 0.1200 0.0278 0.2327 0.1800 0.0373 
12.2                
12.3                
13.0 0.1427 0.1400 0.0019 0.0346 0.0400 0.0038 0.1967 0.2100 0.0094 
13.2                
13.3                
13.4                
14.0 0.0069 0.0100 0.0022 0.0042 0.0100 0.0041 0.0609 0.0600 0.0006 
14.2                
14.3                
15.0 0.0014         0.0097 0.0400 0.0214 
15.2                
15.3                
15.4                
16.0           0.0028    
16.1                
16.2                
16.3                
17.0           0.0014    
17.1                
17.2 
  
 
  
 
  
 
17.3          
Table A9.2: Caucasian comparison chart. continued 
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Allele 
TH01 TPOX 
Promega Parish STDEV Promega Parish STDEV 
2.2           
3.2           
4.0           
4.2           
5.0 0.0014    0.0014    
6.0 0.2355 0.2400 0.0032 0.0014    
6.3           
7.0 0.1939 0.1600 0.0240      
8.0 0.0956 0.1400 0.0314 0.5249 0.4900 0.0247 
8.1           
9.0 0.1191 0.2000 0.0572 0.1274 0.1400 0.0089 
9.1           
9.3 0.3449 0.2600 0.0600      
10.0 0.0083    0.0499 0.1000 0.0354 
10.1           
10.2           
10.3           
11.0 0.0014    0.2521 0.2200 0.0227 
11.2           
11.3           
12.0      0.0416 0.0400 0.0011 
12.2           
12.3           
13.0      0.0014 0.0100 0.0061 
13.2           
13.3           
13.4           
14.0 
  
 
  
 
14.2 
  
 
  
 
14.3 
  
 
  
 
15.0 
  
 
  
 
15.2 
  
 
  
 
15.3 
  
 
  
 
15.4 
  
 
  
 
16.0 
  
 
  
 
16.1 
  
 
  
 
16.2 
  
 
  
 
16.3 
  
 
  
 
17.0 
  
 
  
 
17.1 
  
 
  
 
17.2 
  
 
  
 
17.3 
  
 
  
 
 
Table A9.2: Caucasian comparison chart. continued 
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Allele 
CSF1PO D13S317 D16S539 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2                
3.2                
4.0                
4.2                
5.0           0.0015    
6.0                
6.3                
7.0 0.0556 0.0820 0.0187           
8.0 0.0556 0.0510 0.0033 0.0278 0.0310 0.0023 0.0322 0.0200 0.0086 
8.1                
9.0 0.0395 0.0510 0.0081 0.0336 0.0200 0.0096 0.1827 0.2240 0.0292 
9.1                
9.3                
10.0 0.2500 0.2350 0.0106 0.0307 0.0310 0.0002 0.1170 0.1020 0.0106 
10.1                
10.2                
10.3                
11.0 0.2485 0.1940 0.0385 0.3099 0.2470 0.0445 0.3143 0.3570 0.0302 
11.2                
11.3                
12.0 0.2953    0.4181 0.4290 0.0077 0.2047 0.1730 0.0224 
12.2                
12.3                
13.0 0.0468 0.0310 0.0112 0.1404 0.1220 0.0130 0.1228 0.1020 0.0147 
13.2                
13.3                
13.4                
14.0 0.0088 0.0200 0.0079 0.0395 0.0200 0.0138 0.0249 0.0200 0.0335 
14.2                
14.3                
15.0 
  
 
  
 
  
 
15.2 
  
 
  
 
  
 
15.3 
  
 
  
 
  
 
15.4 
  
 
  
 
  
 
16.0 
  
 
  
 
  
 
16.1 
  
 
  
 
  
 
16.2 
  
 
  
 
  
 
16.3 
  
 
  
 
  
 
17.0 
  
 
  
 
  
 
17.1 
  
 
  
 
  
 
17.2 
  
 
  
 
  
 
17.3 
  
 
  
 
  
 
 
Table A9.2: African American comparison chart.  
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Allele 
D18S51 D2S1338 Penta_E 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
4.2          
5.0           0.0950 0.0800 0.0106 
6.0           0.0015    
6.3                
7.0           0.1038 0.1000 0.0027 
8.0           0.1667 0.1800 0.0094 
8.1                
9.0 0.0029         0.0512 0.0500 0.0008 
10.0 0.0044         0.0468 0.0500 0.0023 
11.0 0.0015 0.0100 0.006      0.0643 0.0800 0.0111 
11.2                
11.3                
12.0 0.0760 0.0610 0.0106      0.1287 0.0800 0.0344 
12.2                
12.3                
13.0 0.0409 0.0610 0.0142      0.1038 0.0900 0.0098 
13.2 0.0044              
14.0 0.0716 0.1020 0.0215   0.0100  0.0687 0.1100 0.0292 
14.2                
14.3                
15.0 0.1652 0.1430 0.0157 0.0015    0.0556 0.0800 0.0173 
15.2 0.0015 0.0100 0.006           
15.3                
15.4                
16.0 0.1711 0.1940 0.0162 0.0556 0.0410 0.0103 0.0409 0.0700 0.0206 
17.0 0.1520 0.1430 0.0064 0.1009 0.1430 0.0298 0.0439 0.0300 0.0098 
18.0 0.1213 0.1220 0.0005 0.0424 0.0710 0.0202 0.0161    
19.0 0.0994 0.0510 0.0342 0.1389 0.1430 0.0029 0.0073    
20.0 0.0629 0.0710 0.0057 0.1038 0.0710 0.0232 0.0044    
21.0 0.0102 0.0310 0.0147 0.1360 0.0920 0.0311 
  
 
21.2 0.0015         
  
 
21.3           
  
 
22.0 0.0073    0.1374 0.1220 0.0109 
  
 
22.2           
  
 
22.3           
  
 
23.0 0.0044    0.1038 0.1430 0.0277 
  
 
24.0 0.0015    0.0833 0.0610 0.0158 
  
 
25.0      0.0775 0.0510 0.0187 
  
 
25.2           
  
 
26.0 
  
 0.0146 0.0510 0.0257 
  
 
26.2 
  
      
  
 
27.0 
  
 0.0044    
  
 
 
Table A9.2: African American comparison chart. continued 
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 Allele 
D19S433 D8S1179 
Promega Parish STDEV Promega Parish STDEV 
4.2           
5.0           
6.0           
6.3           
7.0           
8.0      0.0073    
8.1           
9.0      0.0044    
9.1           
9.3           
10.0 0.0102 0.0200 0.0069 0.0307    
10.1           
10.2           
10.3           
11.0 0.0629 0.0820 0.0135 0.0526 0.0600 0.0052 
11.2           
11.3           
12.0 0.1228 0.1530 0.0214 0.1301 0.0900 0.0284 
12.2 0.0365 0.0310 0.0039      
12.3           
13.0 0.2456 0.2240 0.0153 0.2193 0.2200 0.0005 
13.2 0.0526 0.0710 0.0130      
13.3           
13.4           
14.0 0.2105 0.2350 0.0173 0.2939 0.3200 0.0185 
14.2 0.0746 0.0710 0.0025      
14.3           
15.0 0.0804 0.0200 0.0427 0.1901 0.2200 0.0211 
15.2 0.0614 0.0510 0.0074      
15.3           
15.4           
16.0 0.0044 0.0200 0.0110 0.0643 0.0600 0.0030 
16.1           
16.2 0.0263 0.0200 0.0045      
16.3           
17.0      0.0044 0.0300 0.0181 
17.1           
17.2 0.0088         
17.3           
18.0      0.0029    
18.1           
18.2 0.0029    
  
 
Table A9.2: African American comparison chart. continued 
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Allele 
D21S11 FGA 
Promega Parish STDEV Promega Parish STDEV 
16.2      0.0015    
17.0        0.0200  
17.2      0.0015    
18.0      0.0015    
18.2      0.0175 0.0200 0.0018 
19.0      0.0512 0.0600 0.0062 
19.2      0.0029    
20.0      0.0541 0.0700 0.0112 
20.3           
21.0      0.1228 0.1400 0.0122 
22.0      0.1988 0.2100 0.0079 
22.2      0.0044    
22.3      0.0015    
23.0      0.1696 0.1200 0.0351 
23.2      0.0015    
24.0      0.1330 0.1700 0.0262 
25.0      0.1184 0.0500 0.0484 
25.2      0.0015    
26.0 0.0015    0.0702 0.0600 0.0072 
26.2           
27.0 0.0746 0.0510 0.0167 0.0234 0.0200 0.0024 
27.2           
27.3           
28.0 0.2456 0.1840 0.0436 0.0146 0.0300 0.0109 
29.0 0.2047 0.2350 0.0214 0.0058    
29.3 0.0015         
30.0 0.1696 0.1940 0.0173 0.0015    
30.2 0.0175 0.0200 0.0018 0.0015    
31.0 0.0789 0.1120 0.0234      
31.2 0.0512 0.1020 0.0359 0.0015    
32.0 0.0088 0.0200 0.0079      
32.2 0.0614 0.0200 0.0293 
  
 
33.0 0.0044    
  
 
33.1 0.0029    
  
 
33.2 0.0351    
  
 
34.0 0.0058    
  
 
35.0 0.0219 0.0510 0.0206 
  
 
35.2 0.0088 0.0100 0.0008 
  
 
36.0 0.0029    
  
 
37.0 0.0015    
  
 
38.0 0.0015    
  
 
 
 
Table A9.2: African American comparison chart. continued 
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Allele 
D3S1358 vWA 
Promega Parish STDEV Promega Parish STDEV 
10.3       
11.0      0.0029    
11.2           
11.3           
12.0 0.0044    0.0015    
12.2           
12.3           
13.0 0.0029 0.0200 0.0121 0.0088 0.0300 0.0150 
13.2           
13.3           
13.4           
14.0 0.0906 0.1120 0.0151 0.0804 0.0400 0.0286 
14.2           
14.3           
15.0 0.3085 0.2760 0.0230 0.1915 0.2300 0.0272 
15.2 0.0015         
15.3           
15.4           
16.0 0.3187 0.2860 0.0231 0.2500 0.2400 0.0071 
16.1           
16.2           
16.3           
17.0 0.2120 0.2140 0.0014 0.2354 0.1500 0.0604 
17.1           
17.2           
17.3           
18.0 0.0570 0.0610 0.0028 0.1491 0.1700 0.0148 
18.1           
18.2           
18.3           
19.0 0.0044 0.0200 0.0110 0.0629 0.1000 0.0262 
19.3 
  
      
19.4 
  
      
20.0 
  
 0.0161 0.0200 0.0028 
20.1 
  
      
20.2 
  
      
20.3 
  
      
21.0 
  
 0.0015 0.0100 0.0060 
21.2 
  
      
21.3 
  
      
22.0 
  
   0.0100  
22.2 
  
      
 
Table A9.2: African American comparison chart. continued 
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Allele 
D5S818 D7S820 Penta_D 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2           0.1140 0.1100 0.0028 
3.2           0.0088 0.0300 0.0150 
5.0           0.0439 0.0300 0.0098 
6.0      0.0015    0.0102 0.0100 0.0001 
6.3                
7.0 0.0015    0.0117    0.0439 0.0300 0.0098 
8.0 0.0468 0.0600 0.0093 0.2281 0.2100 0.0128 0.1082 0.1000 0.0058 
8.1                
9.0 0.0322 0.0100 0.0157 0.1155 0.1300 0.0103 0.1681 0.0800 0.0623 
9.1                
9.3                
10.0 0.0731 0.1300 0.0402 0.3363 0.3400 0.0026 0.0994 0.1000 0.0004 
10.1                
10.2                
10.3                
11.0 0.2339 0.1900 0.0310 0.2032 0.1900 0.0093 0.1798    
11.2                
11.3                
12.0 0.3699 0.3800 0.0071 0.0877 0.0800 0.0054 0.1082    
12.2                
12.3                
13.0 0.2237 0.1900 0.0238 0.0146 0.0200 0.0038 0.0833 0.1000 0.0118 
13.2                
13.3                
13.4           0.0015    
14.0 0.0161 0.0020 0.0100 0.0015 0.0100 0.0060 0.0249    
14.2                
14.3                
15.0 0.0029 0.0100 0.0050   0.0100  0.0044 0.0100 0.0040 
15.2                
15.3                
15.4                
16.0                
16.1                
16.2                
16.3                
17.0   0.0100    0.0100  0.0015 0.0100 0.0060 
17.1           
  
 
17.2           
  
 
17.3           
  
 
18.0           
  
 
18.1 
  
 
  
 
  
 
 
Table A9.2: African American comparison chart. continued 
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Allele 
TH01 TPOX 
Promega Parish STDEV Promega Parish STDEV 
2.2           
3.2           
4.0           
4.2           
5.0 0.0044 0.0100 0.0040      
6.0 0.1316 0.1200 0.0082 0.0892 0.0800 0.0065 
6.3           
7.0 0.4079 0.3800 0.0197 0.0175 0.0100 0.0053 
8.0 0.1959 0.2600 0.0453 0.3670 0.4100 0.0304 
8.1           
9.0 0.1594 0.1100 0.0349 0.1959 0.1900 0.0042 
9.1           
9.3 0.0965 0.0900 0.0046      
10.0 0.0044 0.0100 0.0040 0.0863 0.0700 0.0115 
10.1           
10.2           
10.3           
11.0      0.2164 0.1900 0.0187 
11.2           
11.3           
12.0      0.0263 0.0400 0.0097 
12.2           
12.3           
13.0      0.0015    
13.2           
13.3           
13.4           
14.0           
14.2           
14.3           
15.0   0.0100    0.0100  
15.2           
15.3           
15.4           
16.0           
16.1           
16.2           
16.3           
17.0   0.0100    0.0100  
17.1           
17.2           
17.3           
 
Table A9.2: African American comparison chart. continued 
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Allele 
CSF1PO D13S317 D16S539 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2                
3.2                
4.0                
4.2                
5.0                
6.0                
6.3                
7.0 0.0127              
8.0 0.0042    0.1102 0.1020 0.0058 0.0191 0.0100 0.0064 
8.1                
9.0 0.0233 0.0200 0.0023 0.1653 0.2650 0.0705 0.1398 0.1020 0.0267 
9.1                
9.3                
10.0 0.2373 0.2240 0.0094 0.0996 0.1120 0.0088 0.1504 0.1530 0.0018 
10.1                
10.2                
10.3                
11.0 0.2797 0.3780 0.0695 0.2182 0.2140 0.0030 0.2648 0.2350 0.0211 
11.2                
11.3                
12.0 0.3750 0.3160 0.0417 0.2352 0.2350 0.0001 0.2775 0.2760 0.0011 
12.2                
12.3                
13.0 0.0593 0.0510 0.0059 0.1059 0.0510 0.0388 0.1335 0.2140 0.0569 
13.2                
13.3                
13.4                
14.0 0.0064 0.0100 0.0025 0.0614 0.0200 0.0293 0.0127 0.0100 0.0019 
14.2                
14.3                
15.0 0.0021    0.0042    0.0021    
15.2                
15.3                
15.4                
16.0                
16.1                
16.2                
16.3                
17.0                
17.1                
17.2                
17.3                
 
Table A9.2: Mexican comparison chart.  
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Allele 
D18S51 D2S1338 Penta_E 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
5.0           0.0360 0.0500 0.0099 
6.0                
6.3                
7.0           0.1186 0.1000 0.0132 
8.0           0.0254 0.0100 0.0109 
8.1                
9.0           0.0169    
9.1                
9.3                
10.0 0.0021         0.0847 0.0600 0.0175 
10.1                
10.2                
10.3                
11.0 0.0148 0.0200 0.0037      0.0742 0.0800 0.0041 
11.2                
11.3                
12.0 0.1144 0.0510 0.0448      0.1737 0.1900 0.0115 
12.2                
12.3                
13.0 0.1229 0.1730 0.0354      0.0932 0.0900 0.0023 
14.0 0.1610 0.1020 0.0417   0.0200  0.0720 0.0600 0.0085 
14.2 0.0021              
14.3                
15.0 0.1589 0.1730 0.0100   0.0100  0.0911 0.0900 0.0008 
15.2                
15.4           0.0021    
16.0 0.1250 0.2140 0.0629 0.0297 0.0400 0.0073 0.0614 0.0400 0.0151 
16.1   0.0100            
17.0 0.1250 0.0920 0.0233 0.1695 0.1500 0.0138 0.0551 0.0500 0.0036 
18.0 0.0784 0.0410 0.0264 0.0805 0.0300 0.0357 0.0339 0.0400 0.0043 
19.0 0.0466 0.0610 0.0102 0.1928 0.1100 0.0585 0.0212 0.0300 0.0062 
20.0 0.0275 0.0100 0.0124 0.1271 0.1800 0.0374 0.0212 0.0400 0.0133 
21.0 0.0085 0.0310 0.0159 0.0318 0.0100 0.0154 0.0064 0.0300 0.0167 
22.0 0.0106 0.0100 0.0004 0.0572 0.0800 0.0161 0.0021 0.0300 0.0197 
23.0      0.1398 0.2400 0.0709 0.0064    
24.0 0.0021    0.0763 0.0800 0.0026   0.0100  
24.2                
24.3                
25.0   0.0100  0.0784 0.0500 0.0201 0.0042    
25.2 
  
      
  
 
26.0 
  
 0.0169    
  
 
26.2 
  
 
  
 
  
 
 
Table A9.2: Mexican comparison chart. continued 
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Allele 
D19S433 D22S1045 D8S1179 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
6.3          
7.0                
8.0           0.0148 0.0100 0.0034 
8.1                
9.0 0.0021         0.0064 0.0100 0.0025 
9.1                
9.3                
10.0 0.0021    0.0148    0.0932 0.1000 0.0048 
10.1                
10.2   0.0100            
10.3                
11.0 0.0148    0.0636    0.0530 0.0300 0.0163 
11.2                
11.3                
12.0 0.0657 0.1000 0.0243 0.0127    0.1292 0.1400 0.0076 
12.2 0.0127 0.0100 0.0019           
12.3                
13.0 0.2225 0.2300 0.0053 0.0085    0.2733 0.3600 0.0613 
13.2 0.0445 0.0500 0.0039           
13.3                
13.4                
14.0 0.3538 0.2900 0.0451 0.0275    0.2627 0.2400 0.0161 
14.2 0.0381 0.0300 0.0057           
14.3                
15.0 0.1356 0.1400 0.0031 0.4258    0.1292 0.1100 0.0136 
15.2 0.0551 0.0500 0.0036           
15.3                
15.4                
16.0 0.0254 0.0500 0.0174 0.3496    0.0318    
16.1                
16.2 0.0275 0.0400 0.0088           
16.3                
17.0      0.0911    0.0042    
17.1                
17.2                
17.3                
18.0 
  
 0.0064    0.0021    
18.1 
  
 
  
 
  
 
18.2 
  
 
  
 
  
 
18.3 
  
 
  
 
  
 
19.0 
  
 
  
 
  
 
19.1 
  
 
  
 
  
 
 
Table A9.2: Mexican comparison chart. continued 
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Allele 
D21S11 FGA 
Promega Parish STDEV Promega Parish STDEV 
10.3       
11.0        0.0100  
12.0   0.0100       
12.2   0.0100       
13.0        0.0100  
17.0      0.0021    
18.0      0.0127    
19.0      0.0805 0.0700 0.0074 
20.0      0.0847 0.0800 0.0033 
21.0      0.1525 0.1300 0.0159 
22.0      0.1653 0.1300 0.0250 
22.2      0.0042    
22.3           
23.0      0.1208 0.1600 0.0277 
23.2      0.0042    
23.3           
24.0      0.1419 0.1800 0.0269 
24.2 0.0021         
24.3           
25.0      0.1186 0.1200 0.0010 
25.2           
26.0   0.0100  0.0614 0.0200 0.0293 
26.2 0.0021         
27.0 0.0275 0.0500 0.0159 0.0445    
28.0 0.0996 0.1500 0.0356 0.0021    
29.0 0.2076 0.1700 0.0266 0.0021    
29.2 0.0021         
29.3           
30.0 0.2733 0.2200 0.0377 0.0021    
30.2 0.0233 0.0100 0.0094      
30.3           
31.0 0.0763 0.0300 0.0327      
31.2 0.0996 0.1100 0.0074      
32.0 0.0169 0.0300 0.0093      
32.2 0.1271 0.1500 0.0162      
33.0 0.0042         
33.1 0.0021 0.0400 0.0268      
33.2 0.0339         
34.0 0.0021         
35.2   0.0100       
39.0 0.0005         
43.2      0.0005    
 
Table A9.2: Mexican comparison chart. continued 
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Allele 
D3S1358 vWA 
Promega Parish STDEV Promega Parish STDEV 
10.3       
11.0      0.0021    
13.0 0.0064         
13.2           
13.3           
13.4           
14.0 0.0784 0.1200 0.0294 0.0805 0.1200 0.0279 
14.2           
14.3           
15.0 0.3220 0.3500 0.0198 0.1441 0.0700 0.0524 
15.2           
15.3           
15.4           
16.0 0.2797 0.1900 0.0634 0.2839 0.3500 0.0467 
16.1           
16.2           
16.3           
17.0 0.1843 0.2400 0.0394 0.2458 0.2700 0.0171 
17.1           
17.2           
17.3           
18.0 0.1229 0.0900 0.0233 0.1801 0.1600 0.0142 
18.1           
18.2           
18.3           
19.0 0.0042 0.0100 0.0041 0.0508 0.0300 0.0147 
19.1           
19.2           
19.3           
19.4           
20.0 0.0021    0.0106    
20.1 
  
      
20.2 
  
      
20.3 
  
      
21.0 
  
 0.0021    
21.2 
  
      
21.3 
  
 
  
 
22.0 
  
 
  
 
22.2 
  
 
  
 
22.3 
  
 
  
 
23.0 
  
 
  
 
23.2 
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Allele 
D5S818 D7S820 Penta_D 
Promega Parish STDEV Promega Parish STDEV Promega Parish STDEV 
2.2           0.0169    
3.2           0.0021    
4.0                
4.2                
5.0           0.0064 0.0100 0.0025 
6.0           0.0021    
6.3                
7.0 0.0339 0.0400 0.0043 0.0106 0.0100 0.0004 0.0021 0.0100 0.0056 
8.0 0.0085    0.1208 0.1100 0.0076 0.0191 0.0100 0.0064 
8.1                
9.0 0.0530 0.0200 0.0233 0.0911 0.0500 0.0291 0.2415 0.1800 0.0435 
9.1                
9.3                
10.0 0.0572 0.0800 0.0161 0.3072 0.3400 0.0232 0.1568 0.2300 0.0518 
10.1                
10.2                
10.3      0.0021 0.0100 0.0056      
11.0 0.3898 0.5000 0.0779 0.2775 0.2300 0.0336 0.1568 0.1200 0.0260 
11.2                
11.3                
12.0 0.3390 0.1800 0.1124 0.1547 0.1900 0.0250 0.1631 0.1200 0.0305 
12.2                
12.3                
13.0 0.1081 0.1700 0.0438 0.0360 0.0600 0.0170 0.1441 0.2400 0.0678 
13.2                
13.3                
13.4                
14.0 0.0085 0.0100 0.0011      0.0720 0.0800 0.0057 
14.2                
14.3                
15.0 0.0021         0.0106    
15.2 
  
 
  
      
15.3 
  
 
  
      
15.4 
  
 
  
      
16.0 
  
 
  
 0.0042    
16.1 
  
 
  
      
16.2 
  
 
  
      
16.3 
  
 
  
      
17.0 
  
 
  
 0.0021    
17.1 
  
 
  
 
  
 
17.2 
  
 
  
 
  
 
17.3 
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Allele 
TH01 TPOX 
Promega Parish STDEV Promega Parish STDEV 
2.2           
3.2           
4.0           
4.2           
5.0           
6.0 0.2394 0.2200 0.0137 0.0085    
6.3           
7.0 0.2966 0.3400 0.0307 0.0064    
8.0 0.0911 0.0500 0.0291 0.4852 0.4800 0.0037 
8.1           
9.0 0.1462 0.1300 0.0115 0.0932 0.1000 0.0048 
9.1           
9.3 0.2182 0.2300 0.0083   0.0100  
10.0 0.0085 0.0300 0.0152 0.0487 0.0400 0.0062 
10.1           
10.2           
10.3           
11.0      0.2542 0.2700 0.0112 
11.2           
11.3           
12.0      0.1038 0.1000 0.0027 
12.2 
  
 
  
 
12.3 
  
 
  
 
13.0 
  
 
  
 
13.2 
  
 
  
 
13.3 
  
 
  
 
13.4 
  
 
  
 
14.0 
  
 
  
 
14.2 
  
 
  
 
14.3 
  
 
  
 
15.0 
  
 
  
 
15.2 
  
 
  
 
15.3 
  
 
  
 
15.4 
  
 
  
 
16.0 
  
 
  
 
16.1 
  
 
  
 
16.2 
  
 
  
 
16.3 
  
 
  
 
17.0 
  
 
  
 
17.1 
  
 
  
 
17.2 
  
 
  
 
17.3 
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